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Summary 
 
Prostate cancer is the second leading cause of cancer death in men in the UK. Around 30% 
of patients with apparently localized disease at diagnosis and who receive radical surgery to 
remove the primary tumour, will present with skeletal metastasis, in many cases >5 years 
after initial treatment. This suggests that prostate cancer cells can persist in a dormant or 
indolent state, undetected in patients for many years. To investigate states of dormancy in 
prostate cancer cells, the growth of human prostate cancer cell lines in vitro was examined to 
test the hypothesis that there are sub-populations of dormant cells present even within widely 
used, rapidly proliferating cell lines. My studies successfully identified these cells, which 
were then extensively characterised. Parallel studies in our laboratory indicated that these 
cells had greater potency than other cells in the initiation of metastatic lesions in xenograft 
models.  
 
To identify dormant cells in three prostate cancer cell lines: PC-3NW1, LNCaP and C42B4, 
were stained with the lipophilic membrane dye Vybrant DiD. The retention of this dye was 
used as a marker of dormant or slow-cycling cells. Flow cytometry analysis and fluorescent 
microscopy identified a dormant cell sub-population in all three prostate cancer cell lines at a 
frequency of <2% after 14 days in culture. Dormancy was not an intrinsic characteristic of 
this sub-population, as this phenotype could re-emerge in cultures of separated re-cultured 
non-dormant cells. The frequency of dormant cells in cultures could be altered by changes in 
culture conditions and when isolated these cells could be released from dormancy to form 
colonies. Gene expression profiles for the non-dormant and  dormant sub-population were 
compared by RT-qPCR and a set of differentially expressed, dormancy specific genes 
identified. Immunofluorescence microscopy was used to assess whether the observed 
differences in gene expression between populations were reflected in altered specific protein 
levels. The presence of a specific marker of dormancy, CXCR4, identified by these 
experiments, was then evaluated in 75 primary patient samples by immunohistochemistry. 
Elevated CXCR4, as measure by immunohistochemistry, in patient samples correlated to 
other indicators of poor prognosis but did not independently predict the presence of 
metastases.  
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1.1 Background: Prostate cancer 
 
Prostate cancer is the most commonly diagnosed cancer in men in the United Kingdom 
and is the second most common cause of cancer death (CancerResearchUK, 2011). 
With effective treatment, the disease has an average 5 year survival rate of around 95% 
in patients with clinically localized or regionally advanced disease, yet the survival rate 
of men with distant metastases remains low (Jemal et al., 2008).  Prostate cancer 
commonly metastasizes to bone, most frequently the lower spine, pelvis, and femur. 
Once established in the bone, disease management is mainly palliative. Metastases to 
the skeleton cause symptoms such as spinal-cord compression, pathological fracture, 
bone pain, and anaemia (Logothetis and Lin, 2005). 
 
The prostate itself is a walnut sized gland, which surrounds the upper part of the urethra, 
below the bladder in men. As a male accessory sex gland, the prostate contributes to 
seminal   fluid   with   secretions   that   include   a   protein   called   ‘prostate   specific   antigen’  
(PSA).  This  protein  ‘leaks’  into  the  circulation  if  the  prostate  is  damaged  by  infection  or  
infarcts, but can also be used as a marker for prostate cancer (Barry, 2001). This is due 
to the development of cancerous lesions causing damage within the prostate or the 
presence of PSA producing tumour cells in the circulation (Barry, 2001). A PSA score 
of between 3-10ng/ml would raise suspicion of prostate cancer potentially confined to 
the prostate, while a score >10ng/ml carries a 26% chance of a patient having metastatic 
disease (James Buchanan Brady Urological Institute, 2012). Serum PSA is however a 
prostate specific rather than tumour specific marker so, when used in prostate cancer 
diagnosis, it is considered in conjunction with a digital rectal examination followed by a 
biopsy of prostate tissue to confirm diagnosis (Punglia et al., 2003). The past decade has 
seen the introduction of Colour Doppler (CD) ultrasound, which uses reflected sound 
waves to detect blood flow. Brightly coloured areas can indicate the increased blood 
flow (hyper vascularity) associated with suspected tumours, which then allows for more 
selective biopsies. However, CD ultrasound is thought to have only a minor advantage 
over traditional grey scale imaging. Subsequent tests, used to detect metastasis, include 
an Isotope bone scan, X-ray, MRI, or a CT scan.  
 
Prostate cancer grading and staging are important components of diagnosis due to their 
prognostic value, and are often used to determine a treatment plan (Humphrey, 2004). 
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Gleason grading has long been the most commonly used system and involves the 
histological evaluation of glandular vs. invasive characteristics of tumour cells in 
prostate biopsies (Gleason, 1988). TNM (tumour, lymph node, and metastasis) staging 
determines the extent of the cancer and is also used to assign treatment. This system 
assesses whether the tumour is confined to the prostate, involves the capsule, or extends 
outside the gland as well as if it has spread to the lymph nodes and finally to the bone 
and other areas (Sobin, 2001). 
 
Although existing treatments (such as surgery, radiotherapy, and hormone therapy) have 
radically improved the outcome for prostate cancer patients diagnosed within the early 
stages of the disease, the prognosis of patients diagnosed with advanced or metastatic 
prostate cancer remains poor. 
 
1.1.1 Metastasis 
 
Around 80% of prostate cancer patients with metastatic disease respond to androgen 
ablation and this remains the current first line treatment for advanced/metastatic disease.  
This is usually accomplished medically via treatment with anti-androgens and/or 
Luteinizing-hormone- releasing hormone (LHRH) agonists but surgical castration is 
also still used to remove the major source of circulating androgens in men. Androgen 
ablation results in immediate relief of symptoms in responding patients and varying 
periods of disease remission. Combination treatments, of anti-androgens and medical or 
chemical   castration,   have   also   been   used   together   to   produce   a   ‘complete   androgen  
blockade’  (CAB)  (Suzuki et al., 2008). Although this treatment is commonly used, and 
is an effective strategy to treat advanced stages of the disease, it is not without its 
drawbacks. Androgen ablation therapy has been reported in several studies to cause 
osteoporosis, skeletal fracture, and loss of bone mineral density (Daniell, 1997, 
Diamond et al., 1998),  often  resulting  in  a  dramatic  decrease  in  the  patient’s  quality  of  
life. Whilst treatment with bisphosphonates limits these symptoms, they are mainly 
palliative and do not limit the disease (Diamond et al., 1998, Izumi et al., 2009). 
Bisphosphonates, the most common being Zoledronic acid, can inhibit osteoclast 
activity and therefore reduce the presence of osteolytic bone lesions. Although they 
have been shown to reduce pain and skeletal events in advanced androgen independent 
prostate cancer they can not prevent skeletal metastasis in early stage patients (Saad et 
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al., 2002). The average duration of disease remission with these treatments is ~2 years 
after which patients relapse with progressive disease and have an average survival of 
just 6 months (Whitmore, 1973). 
 
The poor outlook for patients with recurrence of androgen independent prostate cancer 
(AIPC), following androgen ablation therapy, results from the return of the disease that 
is often in a more aggressive, rapidly growing form (Abate-Shen and Shen, 2000). This 
presents a serious clinical problem and has been reviewed by Feldman and Feldman 
(2001), who explored the mechanisms behind androgen-insensitivity in prostate cancer. 
The androgen receptor is phosphorylated and dimerizes in response to DHT, which is 
converted from testosterone, upon cell binding, by   5α-reductase. The phosphorylated 
AR can then acts as a transcription factor that binds to the androgen response element 
(ARE) in the promoter region of target genes. This action mediates the activation of 
downstream genes involved in survival, proliferation and the production of PSA. 
Feldman and Feldman summarized 5 key pathways by which aberrant activation of the 
AR could occur: a) hypersensitivity of the androgen receptor (AR): allowing activation 
by residual low levels of androgen after androgen ablation, b) promiscuity of AR 
activation: by which ARs lose specificity and are activated by alternative ligands c) the 
lurker cell theory, d) AR by-pass, and e) the outlaw pathway - in which AR can be 
activated by the MAPK or AKT pathway via growth factor signalling (Feldman and 
Feldman, 2001). The latter is highlighted in a study by Kumar et al (2010), who studied 
the role of the epidermal growth factor receptor (EGFR) in AIPC. Previous research has 
shown that EGFR gene expression is significantly increased in patients who have 
undergone hormone therapy (Marks et al., 2008). Indeed, using the androgen-
independent cell lines PC-3, DU-145, C4-2B, and the androgen-dependent LNCaP cell 
line, Kumar and colleagues (2010) found that the natural compound Psoralidin not only 
inhibited cell growth by blocking EGFR signalling but also induced apoptosis via the 
activation of the stress mediated protein kinase (SAPK) cascade in AIPC cells. 
Although Kumar et al. (2010) do not acknowledge the idea that EGFR signalling could 
be activating the AR in AIPC, they offer strong in vitro and in vivo evidence that 
Psoralidin could contribute to the treatment of AIPC (Kumar et al., 2010). 
 
The direct phosphorylation of the androgen receptor by Cdc42-associated tyrosine 
kinase Ack1 is also proposed to increase progression in AIPC. Mahajan et al. (2007) 
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indicated a strong correlation between AR phosphorylation and the presence of elevated 
Ack1 in AIPC tumour samples compared to androgen dependent tumours. The authors 
also provided evidence that the constitutive activation of Ack1 promotes androgen-
independent growth of prostate xenograft tumours (Mahajan et al., 2007). Targeting 
tyrosine kinase receptors is an attractive candidate for the treatment of AIPC.  
 
Studies have shown that around 50-75% of prostate cancers carry gene fusions (Tomlins 
et al., 2005) which involves the promoter region of the highly androgen responsive 
transmembrane protease serine 2 (TMPRSS2) and members of the ETS family of 
transcription factors (commonly the ERG gene) (Setlur et al., 2008). In 2008, Setlur et 
al. investigated the relationship between castration-resistant prostate cancer (CRPC) and 
the androgen responsive TMPRSS2-ERG gene fusion. The presence of this fusion event 
is associated with increased mortality in prostate cancer (Demichelis et al., 2007) and, 
although its activity decreases in response to androgen ablation therapy, it has been 
shown to be reactivated after treatment and contributes to tumour progression (Cai et 
al., 2009). Although the prospect of AR reactivation is explored in Cai et al., Setlur and 
colleagues tested the hypothesis that an alternate mechanism is reactivating the 
TMPRSS2-ERG fusion in CRPC. They found that in AR negative NCI-H660 cells, 
positive for the TMPRSS2-ERG gene, treatment with the oestrogen receptor D agonist, 
PPT (propyl pyrazole triol), sustained cell growth and increased TMPRSS2-ERG gene 
expression. Furthermore, treatment with DRN, an oestrogen receptor E agonist, reduced 
cell growth (measured by viability assays) and decreased TMPRSS2-ERG expression. 
Despite the lack of in vivo evidence, these results present a novel mechanism by which 
TMPRSS2-ERG expression is reactivated by the oestrogen receptor D in CRPC. Setlur 
et al. (2008) suggest the potential treatment of TMPRSS2-ERG positive prostate cancer 
patients with Toremifene, an oestrogen receptor D antagonist. However, a phase II 
clinical study conducted in 2001 found no significant reduction in prostate cancer risk 
when patients were treated with Toremifene (Stein et al., 2001). This suggests that the 
extent to which TMPRSS2-ERG expression is regulated by the oestrogen receptor D 
may not be significant enough to be a useful target as a treatment option.  
 
However the results presented in Setlur et al. (2008) do highlight the importance of 
exploring alternate mechanisms by which androgen-responsive elements can be 
activated in CRPC and suggest a potential role for oestrogen signalling. The discovery 
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of the TMPRSS2-ERG fusion, and its association with androgen regulated proliferation 
in prostate cancer, is an important and evolving field. This data highlights that the ETS 
proto-oncogene family plays a role in proliferation/survival in these tumours and loss of 
androgen sensitivity may reflect alternative pathways for ETS/ERG regulation as yet 
unknown.  
 
The negative side effects and the eventual development of androgen insensitivity, both 
indicate that androgen ablation therapy does not represent a long-term effective 
treatment option for advanced prostate cancer. Targeting the earlier stages of metastasis 
and preventing the dissemination of the disease is likely to provide more effective 
treatment whilst limiting sequelae. This is particularly relevant with the current trend in 
clinical practice for earlier diagnosis, when prevention of metastasis is a realistic option.  
 
1.1.2 Current and developing treatments for prostate cancer 
 
Along with osteoclast targeting therapies e.g. Bisphosphonates, radiotherapy remains 
the first line palliative treatment for castration resistant prostate cancer. While 
radiotherapy can offer pain relief and a reduction in tumour burden, it often leads to the 
development of radiation resistant AIPC. A number of new treatments are growing in 
practice, a selection of these are discussed below. 
  
Sipuleucel-T (Provenge®) is an FDA approved therapeutic cancer vaccine that aims to 
boost the patient’s immune response to prostate cancer cells in AIPC. The potency of 
this vaccine has been tested in numerous double-blind randomized phase III clinical 
trials including the IMPACT trial that had a large patient cohort of 512. In the IMPACT 
2010 trial, Sipuleucel-T increased the overall survival of patients by an average of 4.1 
months compared to placebo treated (Kantoff et al., 2010). However, the patients tested 
had metastatic AIPC (mAIPC) that was minimally symptomatic. The effects of 
Sipuleucel-T on advanced mAIPC are currently under evaluation. However a number of 
other immune based treatments are in Phase II clinical trials, including the vaccine 
Ipilimumab. 
 
The ability of the angiogenesis inhibitor Ang-(1-7) was assessed in Krishnan et al. 
(2013). The authors tested the ability of Ang-(1-7) to reduce the incidence of skeletal 
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metastases in SCID mice following the injection of PC-3 cells into the carotid artery. In 
mice pre-treated with Ang-(1-7), the authors found a reduction in the incidence of bone 
tumours when compared to untreated mice (Krishnan et al., 2013). However in the 
VENICE phase 3, double blind randomised trial the use of an angiogenesis inhibitor in 
combination with traditional chemotherapy resulted in no improvement in overall 
survival (OS) in mAIPC patients. The VENICE trial, published in the Lancet Oncology 
in 2013, tested the ability of the angiogenesis inhibitor Aflibercept, which binds the A 
and B isoforms of VEGF and placental growth factor to prevent angiogenesis, to 
increase overall survival in patients with mAIPC. The trial concluded that no 
improvement in OS of patients treated with Aflibercept compared to placebo was noted 
and a number of adverse side effects were associated with the drug (Tannock et al., 
2013).  
 
As mentioned previously, the aberrant activation of the AR in response to low levels of 
androgen, or independently of androgens, caused the recurrence of androgen 
independent prostate cancer (AIPC). The recurrence of AIPC leads to disease 
progression and poor survival in patients. Tyrosine kinase inhibitors are attractive 
candidates for the treatment of AIPC as they can prevent the aberrant phosphorylation 
and activation of the AR following androgen ablation. XL184 (Cabozantinib) is a 
tyrosine kinase inhibitor that blocks MET and VEGF receptor 2 signalling. In a Phase II 
randomized discontinuation trial, XL184 was found to increase progression free 
survival (PFS) after 12 weeks when compared to placebo. In patients with detectable 
skeletal metastasis, as measured by increased radiotracer uptake in bone scans, XL184 
treatment led to an improvement in bone scans compared to placebo. Furthermore, 
patients with a complete or partial resolution of bone scans, as a result of XL184 
treatment, had an increase in PFS after 6 months compared to the placebo (Smith et al., 
2013).   
 
A further importance of the development of tyrosine kinase inhibitors is highlighted in 
Mahajan et al. (2010). The authors provide evidence for the role of Ack1 tyrosine 
kinase in radiotherapy resistant AIPC; radiotherapy resistant castration-resistant prostate 
cancer remains an incurable disease. Mahajan et al. provided evidence of the role of 
Ack1 in the activation of ATM (Ataxia Telangiectasia Mutated) by the binding of 
phosphorylated AR to the gene promoter region. ATM is involved in the repair of 
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double strand DNA breaks (DSB) and cell cycle regulation that can occur after radiation 
treatment. Up-regulation or mutations in this gene are therefore associated with 
radiation insensitivity. The authors used ChIP-on-chip to demonstrate the recruitment of 
phosphorylated AR to the ATM promoter in an Ack1 dependent manner and the 
subsequent increase in ATM mRNA and protein after binding. The authors showed that 
the Ack1 inhibitor AIM-100 suppressed ATM expression and reduced the repair of 
DSB following irradiation. AIM-100 was also shown to decrease the growth of 
irradiated castrate resistant xenograft tumours in mice (Mahajan et al., 2012). 
 
Ski-606 (Bosutinib) is a Src/Abl kinase inhibitor. Rabbani et al. (2010) found that SKI-
606 can decrease Src activation and the proliferation and migration of the invasive 
prostate cancer cell lines PC-3 and DU-145. Interestingly, Rabbani et al. also found that 
SKI-606 can reduce the volume of skeletal tumours (as measured by micro-computed 
tomography) in balb/c mice injected intra-tibia with PC-3 cells. The tumour to bone 
volume ratio was significantly lower in mice treated daily with SKI-606 compared to 
the vehicle alone (Rabbani et al., 2010). Treatment commenced 3 days post inoculation 
with PC-3 cells, so although there is evidence that Ski-606 can reduce bone lesions if 
administered early, the effect on established bone tumours remains to be tested. 
 
In order to target the early stages of metastasis, an understanding of the metastasis 
initiating cell/cells is required. However, identification and potential drug development 
for targets in these cells first requires a so far uncharacterised definition of this sub-
group. 
 
1.2 Tumour/Metastasis initiating cells 
 
1.2.1 Epithelial to Mesenchymal transition and metastasis 
 
Metastases result when cancer cells are shed from the primary tumour and colonize and 
grow in distant organs. Metastatic spread is the results of a complex series of events that 
leads to great attrition between the number of cells that leave the primary tumour and 
the number of cells that eventually form growing lesions in distant sites. This process 
involves cell shedding from the primary tumour, invasion of the basement membrane, 
intravasation into the blood stream and dissemination to distant sites. A small number of 
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cells will then exit the bloodstream (extravasation) and colonize new organs. This is 
often referred to as the metastatic cascade.   
 
EMT is a normal process required for embryonic and developmental progression. In 
cancer it is hypothesised that cancer cells of an epithelial type can hijack this process 
and revert to a more mesenchymal phenotype. This is characterised by a decrease in the 
expression of epithelial markers, including E-cadherin, and an increase in mesenchymal 
cell markers, including vimentin (Tsai and Yang, 2013). This is hypothesised to result 
in the acquisition of a more migratory phenotype and contribute to the development of 
metastases. Evidence suggests that EMT induction is caused by the up-regulation of the 
transcription factors Twist, Snail and Zeb via TGF-β  signalling  (Tsai and Yang, 2013). 
Studies suggest that EMT occurs in the early stages of the metastatic cascade, allowing 
the dissociation of cells from the primary tumour due to loss of cell-cell contact. Cells 
of a mesenchymal phenotype also produce increased levels of MMPs, which contribute 
to increased invasion through the basement membrane. EMT is also thought to occur at 
later stages to allow cell migration into the circulation. Yu et al. (2013), found that 
circulating tumour cells in advanced-stage breast cancer are characterised by a more 
mesenchymal phenotype with increased expression of mesenchymal markers including 
fibronectin by RNA in-situ hybridisation.  
 
In the prostate the androgen receptor, along with TGF- β  signalling,  is  hypothesised  to  
act as an inducer of EMT, as it positively regulates Snail and represses E-cadherin 
(Grant and Kyprianou, 2013). Aberrant activation of EMT in prostate cancer has been 
linked to poor prognosis. Gravdal et al. (2007), found that increased N-cadherin and 
decreased E-cadherin, ‘the  EN-switch’ indicative of EMT, was linked to poor prognosis 
when identified by immunohistochemistry in tissue microarray samples from patients 
with known clinical outcome (Gravdal et al., 2007).  
 
Although there is clear evidence that EMT is important in the metastatic cascade, more 
research is required to understand and exploit this knowledge to aid patient treatment. 
This is particularly significant as there is evidence that cells of a mesenchymal 
phenotype have an increased resistance to chemotherapeutics (Hoshino et al., 2009). 
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1.2.2 Mesenchymal to epithelial transition and metastasis  
 
Mesenchymal to epithelial transition (MET) has recently been implicated as an 
important mechanism in the later stages of metastasis i.e., the epithelial phenotype is 
more associated with secondary site colonization while a mesenchymal phenotype, in 
cancer cells, is linked to increased motility and invasion (Chaffer et al., 2006). Chaffer 
et al. (2006) examined the frequency of metastasis using a mesenchymal-like bladder 
cancer cell line, Tsu-Pr1, and two epithelial-like bladder cancer cell lines, B1 and B2, 
from different sites of inoculation in SCID mice. They found that following orthotopic 
inoculation mesenchymal-like Tsu-Pr1 cells formed more micrometastasis than B1 and 
B2 cells but following intracardiac or intratibial inoculation epithelial-like B1 and B2 
cells formed more metastases (Chaffer et al., 2006). Chaffer and colleagues argued that 
these results show that the epithelial phenotype is more associated with the latter stages 
of the metastatic cascade. Therefore, it is likely that at some point during the metastatic 
cascade, cells that have undergone EMT need to revert back to an epithelial phenotype 
by MET in order to expand in the new metastatic site. Indeed in a study by Tsai et al. 
(2012) using chemically induced squamous cell carcinomas in mice, it was found that 
carcinoma cells that have undergone irreversible TWIST mediated EMT, had an 
increased ability to disseminate to the lung. However, the subsequent reduction in 
proliferation rate of these mesenchymal-like cells resulted in a reduced rate of 
detectable metastases forming. It was found that reversible TWIST induction was 
required to allow proliferation and the development of micrometastatic lesions, 
highlighting the importance of MET in the progression of metastasis (Tsai et al., 2012). 
However, it is currently unclear whether the induction of MET is required for the 
reactivation of cell proliferation or whether proliferation induces MET. The processes 
of EMT and MET and the occurrence of tumour dormancy will be discussed in section 
1.4. 
 
1.2.3 Cell fusion 
 
The potential role of cell fusion in the initiation and progression of cancer remains an 
over-looked and under-researched area. However, studies by Bhatia et al. (2008) 
isolated and characterised low/non-tumourigenic L-cells from PC-3, DU145 and 293T 
cell lines and showed how co-injection with senescent normal human prostate (NHP) 
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epithelial cells increased tumourigenesis in vivo compared to injection of L-cells alone. 
Bhatia and colleagues showed via fluorescent labelling that cell fusion was occurring 
between these cells. As further evidence, stable NHP6/293T-L hybrid cells were 
injected into NOD/SCID mice and showed increase tumourigenicity (6/6) compared to 
the parental cell lines (293T 1/6, NHP6 0/5). However, the role of cell fusion in cancer 
is controversial as it has been found to be both an indicator of good (Larsson et al., 
2007) and poor (Larsen et al., 2009) prognosis in different cancers.  
 
However, evidence that cell fusion contributes to the metastatic phenotype has been 
proposed in Chakraborty et al. (2001). This research builds on the previous observation 
that mouse melanoma cells fused to either mouse macrophages or human monocytes 
had an increased metastatic phenotype, based on increased motility in vitro and 
increased metastatic incidence in vivo (Rachkovsky et al., 1998). Chakraborty and 
colleagues claimed for the first time to show that not only does fusion between human 
cells and mouse cells occur but, via RT-PCR, the human gene SPARC is expressed in 
the resulting, metastatic, hybrid. Although good evidence for cell fusion, SPARC is not 
found to be commonly mutated in human cancer (only one record of a mutation in the 
Catalogue Of Somatic Mutations In Cancer (COSMIC, 2011) in human glioblastoma 
(McLendon et al., 2008)) so any contribution it makes to the cancer phenotype is 
unclear. However, SPARC expression was found to be linked to high-grade tumours in 
prostate cancer patient samples in a gene expression profiling study conducted by 
Lapointe et al. (2003). In which, SPARC expression was found to be associated with 
high grade tumours (classified as a Gleason grade of t4+3) from cDNA microarray 
analysis (Lapointe et al., 2004). However, of the 112 prostate samples taken only 9 were 
from lymph node metastases and none were from bone metastases so the profile of these 
tumours cannot be taken as an indicator of osseous metastases. However, these results 
indicate that SPARC may contribute to tumour progression adding significance to the 
results found in Chakraborty et al. (2001). 
 
The role of cell fusion in tumour progression in breast cancer has been explored in 
Jacobsen et al. (2006). In this study a hybrid cell line, BJ3Z, isolated from a human 
xenograft grown in a nu/nu mouse was shown to be the result of a fusion event as it 
expressed markers of mouse stromal origin but also contained human chromosomes. 
Following in vivo inoculation, the BJZ3 cell line was found to be highly aggressive and 
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metastatic. The authors argue that cell fusion between epithelial tumour cells and the 
host stroma may result in genetic alterations that increase the metastatic potential of the 
tumour (Jacobsen et al., 2006). Cell fusion may therefore present a mechanism that 
contributes to the heterogeneity of tumour cells but until definite studies can clarify the 
frequency of such fusion events it is unclear to what extent fusion can influence cancer 
phenotype. 
 
1.2.4 Cancer stem cell theory 
 
The theory that there may be a specific sub-set of cells that are solely responsible for the 
initiation and maintenance of many cancers is receiving world-wide attention (Visvader 
and Lindeman, 2008). The cancer stem cell (CSC) theory states that cells exhibiting the 
stem cell-like properties of self-renewal and multi-potency are responsible for the 
malignant growth of tumours in the body (Reya et al., 2001). This is an attractive 
concept as it provides for a cellular hierarchy within tumours where CSCs divide 
asymmetrically, generating the phenotypic heterogeneity observed, but are also 
themselves able to act as a reserve population. The latter characteristic implies some 
level of mitotic quiescence or dormancy, which would confer insensitivity to DNA 
damaging drugs and be a driver of chemo-resistance in tumours (Reya et al., 2001). 
Originally the CSC theory was documented in acute myeloid leukaemia in which only a 
single cell population was found to be enriched for clonogenic ability and capable of 
forming tumours in SCID mice (Lapidot et al., 1994). This population was identified by 
the cell-surface phenotype CD33+/CD38-.  
 
The use of putative stem cell markers has since led to the identification of potential 
CSCs in many other cancers including breast (CD44+/CD24-) (Al-Hajj et al., 2003) and 
pancreatic cancer (CD44+/CD24+/ESA+) (Li et al., 2007). Indeed, despite on going 
controversy surrounding CSC theory the identification of novel CSCs in multiple 
cancers is still a lucrative area of research. For example a novel CSC with 
mesenchymal-like, as apposed to radial glial-like, characteristics was recently identified 
in primary glioma samples from 20 patients cells (Brennan and Frame, 2014).  
 
It has been hypothesised that a CSC sub-population exists within prostate cancers. 
Collins et al. (2005) presented evidence for a CD44+/D2E1hi/CD133+ population of 
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cancer stem cells isolated from human prostate tumours. Collins et al. (2005) 
demonstrated the heightened ability of these cells to produce colonies, proliferate and 
survive anchorage independent growth in vitro (Collins et al., 2005). Initially it was 
thought that this sub-population was androgen receptor (AR) negative, however 
Williamson et al. (2012) used a combination of techniques (flow cytometry, quantitative 
Real-time PCR and western blot) to show that isolated D2E1hi/CD133+ did express low 
levels of the AR. It is thought that this may contribute to the development of CRPC 
from the CSC pool (Williamson et al., 2012). However, Collins et al. (2005) did not 
demonstrate the ability of this cell sub-population to produce tumours, or an ability to 
differentiate, in vivo, a hallmark of CSCs. Patrawala et al. (2006) however, showed that 
CD44+ cells isolated from the LAPC-4 prostate cancer xenograft model had an 
increased tumour incidence (67%) when injected into SCID mice compared to CD44- 
cells (6%). Further to this, CD44+ cells isolated from LAPC-9 xenograft models 
(originally extracted from a bony metastasis) showed increased metastasis (33%) in vivo 
following surgical orthotopic implantation (SOI) compared to CD44- cells, also from 
lapc-9, (0%). However, although LAPC9 was bone derived, the metastases were mainly 
confined to lumbar lymph nodes and bladder and not to the bone. (Patrawala et al., 
2006). The theory that tumour cells use the lymph nodes as a starting point to invade 
other   organs   or   whether   they   are   merely   a   ‘dead   end’   in   the process of progression 
(Joyce and Pollard, 2009) remains to be tested in this model. A table summarizing some 
of the key molecules associated with the prostate cancer stem cell phenotype can be 
seen in Table 1.1. 
 
Marker Explanation Evidence 
CD44+ Cell surface 
glycoprotein 
CD44+/D2E1hi/CD133+ prostate cancer cells shown in 
vitro to have an increased ability to produce colonies, 
proliferate and survive anchorage independent growth 
in vitro (Collins et al., 2005). Furthermore CD44+ cells 
had an increased tumourigenic ability in SCID mice 
compared to CD44- cells (Patrawala et al., 2006). 
D2E1high 
(integrin) 
Transmembrane 
protein that mediates 
cellular interactions 
As above (Collins et al., 2005), and has previously 
been characterized as a marker for normal human 
prostate epithelial stem cells (Collins et al., 2001). 
 
CD133+ Cell surface 
glycoprotein 
As well as characterization in vitro in prostate cancer 
(Williamson et al., 2012) (Collins et al., 2005), 
CD133+ cells also show stem cell properties and 
increased tumourigenicity in vivo in small and non-
Chapter 1: Introduction 
30 
 
small cell lung cancer (Eramo et al., 2008). 
CD24- Cell surface 
glycoprotein 
CD44+/CD24- cells display stem cell properties, such 
as anchorage independent growth, and show high 
tumourigenesis in SCID mice (with as low as 100 
cells) a characteristic of CSC. CD44+/CD24- cells also 
show an ability to give rise to other cell types, shown 
by FACS in the tumours removed from SCID mice 
(Hurt et al., 2008). 
 
ALDH+ Aldehyde 
dehydrogenase 
enzyme 
When compared to ALDHlow cells ALDHhigh cells 
produced more colonies and were more motile in vitro 
and produced greater tumour burden and increased 
bone marrow growth in mouse models (van den 
Hoogen et al., 2010). 
hTERT Human Telomerase 
reverse transcription 
enzyme 
The established HPET (human prostate 
epithelial/hTERT) cell line was shown to express 
embryonic/progenitor cell markers, such as SOX2 and 
NANOG. These cells were also shown to re-establish 
the parental tumour in vivo indicating hTERT as a 
possible prostate CSC marker (Gu et al., 2007). 
Table 1.1 A summary of the key markers found to be associated with prostate cancer stem cells.  
 
1.2.4.1 Epithelial to mesenchymal transition as a source of CSCs 
Recently Kong et al. (2010) investigated the link between epithelial to mesenchymal 
transition (EMT) and the CSC phenotype in prostate cancer. Kong et al. (2010) 
identified prostate cancer cells with the EMT phenotype (PC-3 PDGF (platelet derived 
growth factor D over expression) and ARCaPm) that also exhibited stem cell-like 
properties, such as self-renewal and high clonogenic ability. Moreover, PC-3 PDGFD 
cells showed increased gene expression of stem cell markers such as Sox2 and Oct4 
(Kong et al., 2010). 
 
Kong and colleagues did not explicitly suggest that EMT could be a mechanism by 
which CSCs are generated but this theory is explored in Santisteban et al. (2010). 
Following EMT via immune-induction in epithelial breast cancer cells, Santisteban and 
colleagues generated tumour cells with stem cell properties and the breast cancer stem 
cell surface phenotype (CD44+/CD24-) as proposed in Al-Hajj et al. (2003) 
(Santisteban et al., 2009). Indeed, this theory is also supported by Mani and colleagues 
(2008) who, following induced EMT in human mammary epithelial cells (HMLE), 
produced mesenchymal like cells that expressed stem cell markers and formed 
mammospheres in vitro, a characteristic of breast epithelial stem cells. However, 
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HMLER cells (HMLE cells transformed with the oncogene V12H-Ras) failed to form 
tumours in vivo unless subject to continuous EMT-induction via Twist or Snail; EMT- 
inducing transcription factors (Mani et al., 2008).  
 
Without further research it is easy to discount these findings as it is unknown how 
realistic constant EMT-induction could be in a real cancer scenario. EMT does, 
however, present an alternate mechanism that seems to contradict the accepted intrinsic 
theory of CSC origin i.e. from an existing stem or progenitor cell that has undergone 
oncogenesis. However in a recent review by Chaffer and Weinberg (2011) they 
speculate that CSCs may originate from both processes and, by the very nature of this, 
contribute to tumour heterogeneity (Figure 1.1.) (Chaffer and Weinberg, 2011). As 
prostate cancer is characterised by extreme heterogeneity this is an attractive prospect 
but requires further research. 
 
1.2.5 CSC and cell fusion 
 
The hypothesis that cell fusion events between a stem cell and an oncogenic somatic 
cell could represent a source of CSCs (Figure 1.1) was explored in Bjerkvig et al. 
(2005). Indeed, a recent study by Xu et al. (2014) found that the co-culture of RFP 
labelled human MSCs with GFP labelled human lung cancer cell lines generated dual 
labelled heterotypic fused or  ‘hybrid’ cells. They found that these hybrids had several 
characteristics of mesenchymal cells e.g. increased expression of vimentin and 
decreased expression of E-cadherin, as well as increased characteristics of stem cells. 
Hybrids expressed higher levels of stem cell markers by quantitative RT-PCR e.g. 
SOX2 and NANOG and had an increased ability to form spheres in soft agar, a 
characteristic of stem cells. These cells were also more tumourigenic in xenograft 
models than the original parental cell lines (Xu et al., 2014). It is clear that cell fusion 
events can lead to the development of hybrids with increased stem cell like 
characteristics and may represent a source of CSCs. However, as with EMT cell fusion 
may represent only a possible mechanism to generate stem cells and multiple methods 
may be employed in a tumour to contribute to heterogeneity and spread. 
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Figure 1.1 The 
proposed 
mechanisms of 
CSC theory.  
A. An existing 
stem/progenitor 
cell receives an 
oncogenic hit 
(Chaffer and 
Weinberg, 2011). 
B. EMT (epithelial 
to mesenchymal 
transition) causes 
the resulting 
mesenchymal cell 
to exhibit stem-cell 
like properties 
(Mani et al., 2008, 
Santisteban et al., 
2009). C. Heterotypic fusion of a stem cell to a genetically altered tumour cell can result in a 
cancer cell with stem cell properties (Xu et al., 2014). 
 
1.2.6 Plasticity of the CSC phenotype 
 
As well as being heterogenic in origin, there is evidence that the CSC phenotype is 
plastic within cell lines and tumours. The review by Tang (2012) summarises some of 
the key evidence that supports this notion. Tang mentions that although normal stem 
cells do not often exhibit plasticity they do retain the potential and in a less stringently 
organised system, such as a tumour, CSC may be in a fluidic state of differentiation and 
de-differentiation (Tang, 2012). 
 
Wang et al. (2010) provided evidence that CD133+ Glioblastoma cells (the proposed 
CSC sub-population in Glioblastoma) have the ability to differentiate into 
CD133+/CD144+ endothelial cells (Wang et al., 2010). Patrawala et al. (2006) 
demonstrated that this process can work the other way, in that tumour cells can de-
differentiate into CSC. Using the human prostate cancer cell line DU145, the authors 
showed that CD44- DU145 cells could generate cells that are CD44+ (the proposed 
prostate cancer stem cell phenotype) when seeded in clonal assays. Tang (2012) also 
discussed the hypothesis that this de-differentiation of tumour cells into CSC can be 
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increased by environmental stresses like hypoxia or drug treatment. This highlights the 
importance of developing novel therapeutics that not only target the bulk tumour 
population but also de-differentiated CSC.  
 
1.2.7 Alternative interpretations of evidence for cancer stem cells (CSCs) 
 
Despite the growing body of research, CSC theory has come under criticism for, 
amongst other things, the lack of definitive evidence in many studies that the isolated 
CSC has an increased ability, in vivo, to effectively recreate the original tumour 
phenotype (Lathia et al., 2010). Furthermore, the use of other in vitro assays to 
distinguish stem-cell like properties, such as sphere formation, have been criticised that 
the growth conditions used were not analogous to those present in in vivo tissues (Lathia 
et al., 2010). In addition a limitation for one of the key observations in the CSC theory, 
that only a very small population can initiate tumour growth, was highlighted by 
Quintana et al. (2008). By optimising xenotransplantation conditions and performing 
them in increased immuno-deficient mice (NOD/SCID IL2Rγnull), Quintana and 
colleagues showed an increase in the number of tumourigenic melanoma cells and 
furthermore, could identify no marker that could distinguish tumourigenic from non-
tumourigenic cells (Quintana et al., 2008). The lack of clear markers may however be 
due to the method of detection used, as Eaton et al. (2010) investigated the expression 
of markers in the proposed prostate cancer stem cell population and highlighted the 
difficulty of detecting cell surface markers as well as the potential to miss certain 
markers due to small numbers of cells or technical complications (Eaton et al., 2010).  
 
Despite the criticisms, the concept that CSCs are present in tumours may yet prove 
valuable. Treatments targeted at this population could remove the threat of disease 
relapse that could occur with treatments that leave residual CSCs (Reya et al., 2001). 
Further characterisation of CSCs in a range of cancers, including prostate cancer, may 
reveal key traits or mechanisms that can be exploited to eradicate this threat. 
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1.3 The bone metastatic niche 
 
Despite the advances made in the characterisation of the tumour/metastasis initiating 
cell, Paget’s renowned  ‘seed  and  soil’  theory states that this is only a partial explanation 
for the process of malignancy (Ribatti et al., 2006). An understanding of the 
environment  (the  ‘soil’)  to  which  these  cells  home,  is  also  crucial.  In  the  case  of  prostate  
cancer this is the bone microenvironment, a complex site of resorption and remodelling, 
which has been an active area of research for many years. 
 
1.3.1  The  ‘vicious  cycle’ 
 
It is now widely accepted that the frequent metastasis of prostate cancer to bone is due 
to   interactions   between   these   cells   and   a   ‘bone   metastatic   niche’,   which   creates   a  
favourable environment for attachment and growth. Indeed it has been suggested that 
these  interactions  create  a  ‘vicious  cycle’  that  leads  to,  not  only  tumour  growth  in  bone  
but, damage and destruction of bone tissue. The healthy bone environment depends 
upon a balance of bone resorption (mediated by osteoclasts) and bone formation (by 
osteoblasts) (see Figure 1.2). However, during tumour metastasis to bone this normal 
process is disrupted, resulting in the symptoms previously mentioned, such as 
pathological fracture.  Prostate cancer bone metastases are frequently characterised as 
osteoblastic (or osteosclerotic), which results in increased bone formation and the 
development of osteoblastic lesions.  Breast cancer metastases, on the other hand, are 
frequently osteolytic resulting from increased bone resorption.  However, these 
processes are not distinct in the patient and a mixture of bone formation and resorption 
is likely to contribute to metastasis resulting in both osteolytic and osteosclerotic 
features with the phenotype dependent on the balance between resorption and bone 
formation (Mundy, 2002). The precise location and characteristics of the bone 
metastasis niche to which prostate cancer (PCa) cells home is still unknown however, 
several studies have investigated the role of osteoblast and osteoclast bone cells, as well 
as the tumour cells themselves, and their contribution to this environment.   
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Figure 1.2. A simplified diagram of the remodelling process in bone.  
A variety of growth factors stimulate the differentiation of osteoblasts that lay down the new 
bone surface. This process is also stimulated by WNT signalling which, itself, can be inhibited 
by Dickkopf-related protein 1 (DKK1) (Logothetis and Lin, 2005). Osteoblasts in turn stimulate 
osteoclast differentiation and maturation, via receptor activator of nuclear factor kappa-B ligand 
(RANKL) which binds to receptor activator of nuclear factor kappa-B (RANK) on the surface 
of pre-osteoclasts, and osteoclast proliferation, via macrophage colony-stimulating factor (M-
CSF) (Sims and Gooi, 2008). Osteoprotegrin can act as a decoy receptor for RANKL causing 
osteoclastogenesis to be inhibited (Sims and Gooi, 2008).  
 
1.3.2 Characteristics of the niche 
1.3.2.1 Osteoblasts 
During metastasis to bone, prostate cancer cells increase the activity of osteoblasts via 
the secretion of a variety of growth factors. These can act directly, and include 
fibroblast growth factor (FGF), Platelet derived growth factor (PDGF) and bone 
morphogenetic protein (BMP), or indirectly, (PSA and uPa) by modifying the bone 
environment and existing growth factors (Guise et al., 2006, Logothetis and Lin, 2005). 
Further to this endothelin-1 (ET-1) secreted by tumour cells was found to stimulate 
osteoblast activity, via the endothelin-1 A receptor (ETAR), in breast cancer cell lines 
(Yin et al., 2003). Suppression of ET-1 via Atrasentan (an ETAR antagonist) was also 
shown to reduce bone remodelling in prostate cancer, however the results of this clinical 
trial were accumulated from 74 different medical centres introducing a possible 
sampling bias effect (Nelson et al., 2003). Tumour cell Wnt signalling has also been 
shown to stimulate osteoblastic activity in prostate cancer in vitro and in vivo (Hall et 
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al., 2005). In this study Dickkopf-related protein 1 (DKK1), an inhibitor of Wnt 
signalling, was shown to decrease osteoblastic activity which the authors postulate may 
contribute to the osteolytic lesions seen in prostate cancer. 
1.3.2.2 Osteoclasts 
Increased osteoclast activity has also been shown to contribute to bone metastasis in 
prostate cancer, resulting in osteolytic lesions (Mundy, 2002). In a study by Zang et al. 
(2001), the authors demonstrated that PCa cells induce osteoclastogenesis by the 
production of receptor activator of nuclear factor kappa-B ligand (RANKL). This 
induces pre-osteoclast to differentiate into mature osteoclast via interactions with its 
surface receptor, RANK (Zhang et al., 2001). In subsequent research, Roato at al. 
(2008) compared the levels of osteoclastogenesis in blood samples from metastatic, 
non-metastatic prostate cancer patients and healthy controls and found increased 
osteoclast numbers in metastatic patients compared to the other two sample groups. The 
authors also found that RANKL was increased in this group. Despite this interesting 
finding the sample size was small (only 46) and all the patients were in the early stages 
of diagnosis with newly forming bone metastases so any role of osteoclasts in the later 
stages of metastasis was not explored.  
 
The role of RANKL in osteoclastogenesis and prostate cancer bone metastasis can be an 
effective target from treatment. Denosumab is a human monoclonal antibody that binds 
RANKL and reduces osteoclast differentiation, survival and activation. Denosumab has 
been shown to reduce the risk of osteoporotic fractures in men with prostate cancer in a 
phase III randomised control trial (Smith et al., 2009). However, as with 
bisphosphonates, Denosumab is mainly used to limit symptoms and not prevent disease 
progression.  
  
In Lu et al. (2007), monocyte chemotactic protein-1 (MCP-1) from prostate cancer cells 
was shown to mediate bone resorption via osteoclast stimulation. MCP-1 (with IL-8) 
stimulated human bone marrow mononuclear cells (HBMC) to differentiate into 
osteoclast-like cells. However, MCP-1 was not shown to induce bone resorption in the 
absence of IL-8, but when it is neutralised resorption does decrease. This suggests that 
MCP-1 produced by prostate cancer cells works with IL-8 to induce osteoclastogenesis 
and subsequent bone resorption. Although these results are only shown in vitro the 
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potential influence of MCP-1 on osteolysis does offer an explanation for the low level 
of RANKL observed in PCa cells, in this study and previous work (Zhang et al., 2003), 
as the two may work together with IL-8 to induce bone loss via osteoclast stimulation 
(Lu et al., 2007). 
 
It is proposed that the production of osteoblastic and osteolytic lesions in metastasis 
have a positive effect on cancer cells. Growth factors released by the bone matrix and 
mature osteoblasts, such as TGF-E, are thought to increase tumour cell proliferation and 
support growth in bone (Buijs and van der Pluijm, 2009). Recently, osteoprotegrin 
(OPG) has been implicated in the survival of prostate cancer cells at the bone metastatic 
site (Holen et al., 2002). As previously mentioned OPG can influence bone remodelling 
by acting as a decoy receptor for RANKL (a stimulator of osteoclastogenesis) (Sims and 
Gooi, 2008). However Holen et al. (2002) suggest that perhaps more importantly OPG 
may act to suppress tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) 
induced apoptosis and therefore promote tumour cell survival in bone. Holen et al. 
(2002) demonstrated that PC3 cells, which express high levels of endogenous OPG, 
were protected from TRAIL induced apoptosis (measured by DAPI staining) by 
recombinant OPG in vitro. Furthermore, endogenous OPG also successfully inhibited 
apoptosis when challenged with TRAIL in vitro. As higher levels of OPG are associated 
with bony metastases in prostate cancer, compared with primary tumours or non-bone 
metastases (Brown et al., 2001), OPG may present a further factor that promotes the 
growth of prostate cancer cells in the bone by offering protection from apoptosis. 
However, as shown in Holen et al. (2002), sRANKL can inhibit OPG and therefore 
reduce the protection of cancer cells against apoptosis. As prostate cancer cells have 
also been shown to produce high levels of RANKL (Zhang et al., 2001), it raises the 
question of how these factors interact to promote PCa cell survival in the bone 
metastatic niche. Perhaps further investigation is needed to elucidate the mechanism by 
which these factors are regulated. A summary of the processes and the factors involved 
in PCa bone metastasis are shown in Figure 1.3 and Table 1.2.  
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Figure  1.3.  The  ‘vicious  cycle’  of  osteoblastic  and  osteolytic  bone  metastases.     
Prostate cancer cells that arrive in the bone secrete growth factors, such as FGF, as well as other 
factors, such as ET-1, that that can stimulate osteoblast activity (Guise et al., 2006, Logothetis 
and Lin, 2005, Nelson et al., 2003). This induces increased bone formation and the 
accumulation of osteoblastic lesions. This process can stimulate tumour growth by the release of 
growth factors from mature osteoblasts (Buijs and van der Pluijm, 2009). PCa cells can also 
stimulate osteoclast activity via the release of RANKL (Zhang et al., 2003) and MCP-1, which 
has been shown to work with IL-8 to induce osteoclast differentiation (Lu et al., 2007) . This 
results in osteoclast-mediated breakdown of the bone surface causing osteolytic lesions. The 
release of bone derived growth factors from the mineralised bone matrix can then stimulate the 
proliferation and growth of PCa cells (Buijs and van der Pluijm, 2009). OPG released by 
tumour cells may also promote survival by inhibiting TRAIL induced apoptosis of cancer cells 
(Holen et al., 2002). 
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Factor Origin Effect 
Bone Morphogenetic 
Proteins (BMP) 
Prostate 
cancer cells 
Stimulates osteoblast proliferation (Logothetis 
and Lin, 2005). 
Bone derived growth factors 
Mineralized 
bone matrix 
Stimulated tumour proliferation (Buijs and van 
der Pluijm, 2009). 
Endothelin-1 
(ET-1) 
Prostate 
cancer cells 
Binds to ETAR and promotes osteoblast growth 
(Nelson et al., 2003). 
Fibroblast growth factor 
(FGF) 
Prostate 
cancer cells 
Stimulates osteoblast proliferation (Logothetis 
and Lin, 2005). 
Insulin-like growth factor 
(IGF) 
 
Prostate 
cancer cells 
Stimulates osteoblast proliferation (Logothetis 
and Lin, 2005). 
Interleukin-8 
(IL-8) 
Prostate 
cancer cells 
Acts with MCP-1 to promote osteoclastogenesis 
(Lu et al., 2007). 
Monocyte chemoattractant 
protein-1 (MCP-1) 
Prostate 
cancer cells 
Promotes osteoclastogenesis with IL-8 (Lu et 
al., 2007). 
Osteoblast derived growth 
factors 
Mature 
osteoblasts 
Promote tumour cell growth and proliferation 
(Buijs and van der Pluijm, 2009). 
Osteoprotegrin 
(OPG) 
Prostate 
cancer cells 
In vitro evidence shows that recombinant and 
endogenous OPG produced by PC-3 cells can 
protect from TRAIL induced apoptosis (Holen 
et al., 2002). 
Platelet-derived growth 
factor 
(PDGF) 
Prostate 
cancer cells 
Stimulates osteoblast proliferation (Logothetis 
and Lin, 2005). 
Prostate-specific antigen 
(PSA) 
Prostate 
cancer cells 
Acts indirectly to modify the bone environment 
and activate growth factors to stimulate 
osteoblasts (Logothetis and Lin, 2005). 
Parathyroid hormone related 
peptide (PTHrP) 
Prostate 
cancer cells 
Stimulates osteoblast proliferation (Logothetis 
and Lin, 2005). 
Receptor activator of 
nuclear factor-κB ligand 
(RANKL) 
Prostate 
cancer cells 
Binds to RANK on the surface of pre-
osteoclasts to promote differentiation (Zhang et 
al., 2001). 
Transforming growth factor 
(TGF) 
Prostate 
cancer cells 
Stimulates osteoblast proliferation  
(Logothetis and Lin, 2005). 
Urokinase-type plasminogen 
activator 
(uPA) 
Prostate 
cancer cells 
Acts indirectly to modify the bone environment 
and activate growth factors to stimulate 
osteoblasts (Logothetis and Lin, 2005). 
Vascular endothelial growth 
factor 
(VEGF) 
Prostate 
cancer cells 
Can act directly or indirectly to either promote 
osteoblast proliferation or increase bone 
angiogenesis (Logothetis and Lin, 2005). 
Wingless and Int-1 
(Wnt) 
Prostate 
cancer cells 
Wnt signalling activates downstream targets that 
induce osteoblast proliferation  
(Logothetis and Lin, 2005). 
Table 1.2. A summary of key factors involved in the formation of prostate cancer bone 
metastasis.  
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1.3.3 Clinical relevance of the vicious cycle 
 
Research has increased our understanding of the vicious cycle and the discovery of a 
number of agents that target this process, for example Denosumab, has led to the 
considerable pain relief of patients with skeletal metastasis. However, once established 
in the bone skeletal tumours can grow independently of growth signals from the 
environment therefore agents that target the vicious cycle may only be effective on early 
stage metastases.  
 
Nevertheless, the use of Fc-OPG (OPG fused to Fc) has been show to reduce the 
progression of established bone lesions in mouse xenograft models. Armstrong et al. 
(2008) provided evidence that fc-OPG alone can reduce bone resorption and the 
progression of osteolytic lesions when administered up to 20 days after intratibial 
injection of PC-3 cells (Armstrong et al., 2008).  
 
1.3.4 Osteomimicry 
 
A proposed feature of bone metastasis is the process of osteomimicry; by which cancer 
cells   become  more   ‘bone-like’   by   taking   on   the   properties   of   osteoblasts   in   order   to  
thrive in the bone niche (Koeneman et al., 1999). The expression of osteomimetic 
markers such as osteocalcein and osteoprotegrin in prostate cancer cell lines has been 
shown to be linked with increased bone metastatic ability (Dorai et al., 2004). 
Zayzafoon et al. (2004) offer a potential mechanism by which osteomimicry is induced 
in osteoblastic prostate cancer cell lines. The authors investigated the link between 
Notch expression, which is involved in signalling events that determine cell fate, and 
osteomimicry. Using RT-PCR Zayzafoon and colleagues showed that notch1 expression 
is 5x greater in the osteoblastic PCa cell lines C42B and MDA PCa 2b compared to 
nonosteoblastic LNCaP and DU145 lines. It was also shown that C42B cells, that 
express both the Notch 1 receptor and the DII 1 ligand, have increased ability to 
produce calcium deposits following osteogenic induction, a feature of osteoblast-like 
bone formation. These cells also express RUNX2, an important transcription factor for 
osteoblast differentiation, in a Notch and ERK dependent manner (Zayzafoon et al., 
2004). Building on this observation, Yuen et al. (2008) found that RUNX2 was also 
positively regulated by TWIST expression. Following osteogenic induction, expression 
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of the transcription factor TWIST was up-regulated in the 22Rv1 prostate cancer cell 
line. This matched the expression of RUNX2 at the protein and RNA level and when 
TWIST expression was reduced, by short hairpin RNA, RUNX2 expression also 
decreased. These results suggest PCa cells can be induced to become  more  ‘osteoblast-
like’  via  the  expression  of  RUNX2,  induced  by  Notch  and  TWIST  factors.   
 
Although both papers provide evidence for the importance of RUNX2 in osteomimicry, 
and the factors that regulate it, neither paper presents a mechanism by which either 
Notch signalling or TWIST transcription is activated in the bone niche i.e., which 
stromal/bone cells are involved. In order to target osteomimicry as a potential therapy 
for advanced prostate cancer an understanding of this process is key. Moreover, the 
22Rv1 cell line was isolated from an organ-confined prostate cancer so further research 
is needed in metastatic cell lines, such as PC3, to confirm the significance of TWIST 
and osteomimicry in metastasis. 
 
1.3.5 The hematopoietic stem cell (HSC) niche and tumour metastasis 
 
Further research to characterise the metastatic niche has led to the identification of 
several HSC markers that are expressed by metastatic prostate cancer cells. These 
include CXCL12 (Taichman et al., 2002) and, recently, annexin II (ANXA2) (Shiozawa 
et al., 2010). It is hypothesised that these markers allow the cancer cells to home to the 
bone by targeting the HSC niche. However, Shiozawa et al. (2011) claim to be the first 
to show evidence that prostate cancer cells directly target, and even compete with HSC 
for, the endosteal niche. Using HSC engraftment in NOD/SCID mice to test this theory, 
Shiozawa and colleagues demonstrated that engraftment was significantly reduced in 
mice injected with metastatic PC3 and C42B cells compared to non-metastatic 
transformed  prostate epithelial (NMPE) cells or surgical controls. The authors argue 
that this shows direct competition between PCa cells and HSC for the niche and go on 
to further characterise this niche by using multi-photon microscopy to show that HSC 
and PCa cells co-localise (within a 5-cell distance) to the endosteal niche. In addition, 
the mobilization of PCa cells out of the HSC niche and into the circulation was 
demonstrated using the known HSC mobilizes; AMD3100 and G-CSF. Both agents 
target interactions between HSC and their niche, interfering with CXCR4/CXCL12 
signalling in the case of AMD3100 and decreasing levels of CXCL12 in the case of G-
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CSF. This, therefore, not only offers a potential treatment to decrease PCa cells in the 
niche, but provides further evidence to the shared characteristics of HSC and 
metastasising PCa cells (Shiozawa et al., 2011a).  In a following review Shiozawa et al. 
(2011b) discuss the potential to target HSC niche-tumour interactions in cancer therapy 
and the need for further study.  
 
The HSC niche has also been implicated in controlling HSC quiescence, the avoidance 
of apoptosis and the maintenance of HSC numbers via Tie2-Ang-1 signalling (Arai et 
al., 2004). As research has also implicated tumour cell dormancy as a factor in 
chemotherapeutic resistance (Naumov et al., 2003) insights into the effects of the HSC 
niche on cancer cell quiescence may open up therapeutic targets (Shiozawa et al., 
2011b). Future perspectives should look to further characterise the HSC niche and the 
direct components that the tumour cells target in order to exploit this process for 
treatment.  
 
1.4 Dormancy in prostate cancer 
 
Prostate cancer is often characterised as a slowly advancing disease, where often the 
prescribed treatment   is   ‘active  monitoring’   rather   than   a   radical   drug   or   radiotherapy  
regimen. However, even when the disease is diagnosed at an early stage, when confined 
to the prostate, patients that receive radical prostatectomy and deemed to be in 
remission can still relapse with aggressive skeletal tumours. The time taken from radical 
prostatectomy to the development of skeletal metastasis has been reported to take up to 
10 years. Around 30% of patients that are diagnosed with early stage disease (T1-T2), 
in which the cancer appears to be confined to the prostate, develop skeletal metastases 
many years after treatment despite having a clear bone scan at diagnosis. We now think 
that up to 60% of these early stage patients have circulating tumour cells at diagnosis 
(Ruppender et al., 2013). However there is an obvious lack of accord between this 
number of patients and the 30% that go on to develop delayed bone metastases. The 
difference between circulating tumour cells (CTCs) and disseminated tumour cells 
(DTCs) is important here. CTCs are present in the blood but may never find a 
favourable environment to grow. However, DTCs have by definition migrated to an 
environment where they may form metastases. DTCs can be found in the bone marrow 
of prostate cancer patients without evidence of disease after surgery (Morgan et al., 
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2009). Although many will not go on to form metastases, the sub-set of patients in 
which these DTCs are triggered to grow will eventually develop incurable bone 
tumours. This period of dormancy and the possible survival advantage that cellular 
quiescence may provide in the bone marrow has been an on-going area of interest in 
prostate cancer.  
 
Recently several biomarkers have been hypothesised to be linked with dormancy in 
metastatic prostate cancer. Kobayashi et al. (2011) established a link between tumour 
cell senescence and the bone morphogenetic protein, BMP7. Initially conditioned media 
(CM) collected from human bone marrow stromal cells (HS5) was found to have an 
inhibitory effect on the growth of multiple prostate cancer cell lines, including PC-3 and 
DU145. The authors concluded that it was the action of BMP7 in CM that was inducing 
cell senescence in these cells via the activation of P37, P21 and P27 cell cycle proteins. 
They went on to show that in mouse xenograft models in which PC-3 cells were 
injected directly into the tibia, treatment with BMP7 could suppress the development of 
bone tumours. Several other groups have used cell lines and xenograft models to 
investigate metastasis and dormancy in prostate cancer.  
 
1.4.1 Models of metastasis and dormancy 
1.4.1.1 Prostate cancer cell lines 
Unlike many other cancers there is a relative paucity of human prostate cancer cell lines 
available to study prostate cancer. Those that are available can roughly be divided into 
two groups, those that are androgen dependent e.g. LNCaP, VCaP and DuCaP and those 
that are androgen independent e.g. PC-3, DU145 and the LNCaP variants C4. Several in 
vitro assays exist to characterise cells that may have a more metastatic phenotype. For 
example, a migration assay using a Boydon chamber can be used to test the 
migratory/invasive potential of a cell that may correlate to metastasis ability.  
 
Cell lines have also been used to study dormancy. An example of this was shown in Li 
et al. (2014), who authors showed that when DU145 cells were treated with the 
chemotherapeutic Docetaxel, chemo-resistant cells were present after the 4 day 
treatment period and these cells had a dormant phenotype. The chemo-resistant cells 
were found to be less proliferative than the parental cells, as measured by thymidine 
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uptake, and had higher levels of p21 protein, as measured by Western blot. After 
harvesting and re-plating, the dormant chemo-resistant cells were found to resume 
proliferation and formed colonies (Li et al., 2014).   Interestingly,   these   ‘recurrent’  
colonies were even more resistant to Docetaxel than the parental strain, an observation 
which mimics the chemo-resistance of recurrent tumours in patients.  
 
Although there are several obvious advantages to using in vitro models to study 
dormancy,  i.e.  low  cost,  less  time  consuming,  mouse  xenograft  models  remain  the  ‘gold  
standard’  to  more  accurately  recapitulate human disease.  
 
1.4.1.2 Mouse xenograft models 
The androgen independent cell lines PC-3 and DU145 are most commonly used in vivo 
to study metastasis as they are more comparable to the castration resistant disease that 
occurs in patients. Although, there are de novo mouse models of prostate cancer 
metastasis i.e. Mice carrying the TRAMP (Transgenic Adenocarcinoma of Mouse 
Prostate) transgene which develop progressive forms of prostate cancer with distant site 
metastasis, these are often confined to the lymph nodes or lung. Therefore to study 
skeletal metastases, xenografts into immuno-compromised mice must be used. The most 
common strain used in our lab is Balb/s nude, an immune-deficient strain that lacks a 
thymus. Human prostate cancer cells can be inoculated directly into the tibia of these 
mice to study the development of skeletal tumours. However, most frequently cells are 
injected intracardiac into the left ventricle of mice to study the later stages of the 
metastatic cascade (extravasation, homing, survival and growth in distant sites) to 
monitor the development of bone lesions.  
 
Xenograft models of tumour dormancy and recurrence often involve a lengthy 
procedure of primary tumour growth, resection, delay and study of either DTCs or 
subsequent recurrent tumour growth. Marsden et al. (2012) however, used a method to 
isolate dormant DTCs in the bone marrow of xenograft mice in order to test their 
tumourigenic ability in naïve mice. Marsden et al. cultured tumourspheres isolated from 
primary breast cancer patients and injected them into the fat pads of nu/nu mice. They 
found that up to 12 months after injection DTCs were present in the bone marrow of 
animals without skeletal lesions. The presence of these cells was assessed by 
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immunohistochemistry for the human specific HNA (human nuclear antigen). The 
authors found that these dormant DTCs had acquired a more aggressive phenotype as 
when injected into the fat pad of naïve mice, DTCc from whole bone marrow flushes 
formed more tumours than bone marrow flushes from mice without DTCs.  These cells 
also formed more metastases however, the majority where found in the lungs and livers 
of injected mice and not the bone (Marsden et al., 2012).  
 
1.4.1.3 The use of cellular dyes to track dormancy 
Fluorescent cell dyes can be used to track dormant cells in vitro and in vivo due to their 
ability to bind to the cell and be diluted by distribution to daughter cells at each 
division. Cells that retain a high intensity of these dyes over long periods of culture are 
thought to be mitotically dormant or at least very slow cycling. 
 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent cell staining dye that is 
usually purchased as carboxyfluorescein diacetate succinimidyl ester (CFDA-SE). 
CFDA-SE diffuses into the cell where is reacts with intracellular esterases to form the 
fluorescent ester, CFSE, by the removal of acetate groups. CFSE is covalently bound to 
the cell and is divided equally amongst daughter cells upon division. The advantage of 
CFSE is that when analysed by flow cytometry, subsequent generations of cells can be 
visualised by the amount of fluorescence (shown as individual peaks on the histogram) 
that they retain. CFSE was originally used to track the division of lymphocytes . Today 
CFSE is predominantly used in immunology and not to study cancer dormancy. This 
could be due to high toxicity and its use in studying cycling cells is limited as it can 
only trace around 7-8 cell divisions before it is lost. 
 
PKH fluorescent dyes are vital dyes that consist of a fluorophore attached to an aliphatic 
carbon back- bone. These can irreversibly bind to the lipid bilayer on cell membranes 
and so can be equally partitioned among daughter cells upon cell division. Due to low 
toxicity, PKH labelling enables the monitoring of live cells and can be used to isolate 
slow-cycling cells for subsequent analysis. The PKH dye PKH67 was used by Kusumbe 
and Bapat (2009) to identify dormant cells in the ovarian cancer cell line A4. A4 cells 
stained with PKH67 were injected subcutaneous into NOD/SCID mice and, after 
tumour formation, were collected, retrieved by digestion of the tumour and analysed by 
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flow cytometry. These studies found that within a tumour a gradient of PKH67 was 
present with three sub-sets of cells evolving, PKH67High, PKH67Low and PKH67Negative. 
Clonogenic analysis revealed that the PKH67High sub-population were more clonogenic 
than PKH67Low or PKH67Negative cells. It was also found that the PKH67High cells were 
more tumourigenic in vivo when injected into NOD/SCID mice compared to PKH67Low 
or PKH67Negative cells. The authors hypothesised that these slow-cycling PKH67High cells 
represent a CSC sub-population, as they had significantly higher expression of the stem 
cell markers Oct4, Nestin, Nanog, and Bmi compared to PKH67Low or PKH67Negative 
cells (Kusumbe and Bapat, 2009). 
 
CM-DiI and DiD are further class of lipophilic cell dyes. These intercalate with the cell 
plasma membrane by the presence of a thiol-reactive chloromethyl moiety that allows 
the dye to form covalent bonds with cellular thiols. (Andrade et al., 1996).  When 
excited, Cm-DiI and DiD emit a red (emission 565 nm) and far red fluorescence 
(emission 665), respectively. Fluorescence can be monitored by flow cytometry or 
fluorescent microscope. As with other membrane dyes, fluorescence fades during cell 
division as the cell label is diluted at each division by |50% (Haldi et al., 2006). In this 
way the presence of non-dividing, or dormant, cells can be identified by a persistent 
bright red signal in vivo (using multi-photon imaging) and in vitro. 
 
In our laboratory, we have used these dyes to provided evidence that prostate cancer 
human cell lines can persist in a mitotically dormant state in the bone marrow of mouse 
xenograft models. By using the lipophilic cell membrane dyes Cm-DiI and 
Vybrant®DiD (DiD), dye retaining and therefore non-dividing cells can be observed by 
multiphoton imaging in the mouse bone marrow up to 8 weeks after intracardiac 
injection. The frequency of tumour formation in the bones of these animals is >80%, 
with the majority of tumours being detected by bioluminescence imaging (IVIS®, In 
Vivo Imaging systems) at 3 weeks after injection. However, tumours can begin to 
develop up to 12 weeks after injection (unpublished).  
 
These dyes are an attractive candidate to explore dormancy at a cellular level. The use 
of the lipophilic cell membrane dyes Cm-DiI and Vybrant®DiD to characterise 
dormancy in vitro will be explored in the current thesis.  
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1.5 Conclusions 
 
The high prevalence of prostate cancer in the United Kingdom (CancerResearchUK, 
2011) and the poor survival rate of patients with distant metastases (Jemal et al., 2008) 
highlights the need to develop an understanding of the processes involved in the 
development of metastases and progression of the disease. Although androgen ablation 
remains the first line treatment for advanced prostate cancer, the development of 
androgen insensitivity and the return of advancing disease is a serious clinical problem. 
Other existing treatments for advanced prostate cancer, mentioned earlier in this thesis, 
mainly target bone resorption but do not limit the disease. Furthermore, the negative 
side effects associated with androgen ablation, and the dose related complications of 
some bisphosphonates, suggests a need to develop alternative therapies that target the 
early stages of prostate cancer spread. This requires a better understanding of the 
tumour/metastasis initiating cell population.  
 
As discussed, tumour dormancy and recurrence is a common theme in prostate cancer. 
Detection of the presence and defining the importance of dormant tumour cell 
populations has been possible due to the use of mouse xenograft models and by the use 
of cellular dyes. We have identified a dormant cell population in the bone marrow of 
mice xenograft models using the lipophilic dye DiD. Work presented in this thesis will 
use in vitro techniques to investigate and characterise dormancy in human prostate 
cancer cell lines.  
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1.6 Aims, Hypothesis and Objectives 
 
1.6.1 Aims 
 
The body of work present in this thesis aims to use in vitro models to investigate and 
characterise dormancy in human prostate cancer cell lines.  
 
To address these aims the following hypotheses will be tested. 
 
1.6.2 Hypotheses 
 
1. A dormant cell sub-population exists in human prostate cancer cell lines 
2. This sub-population will allow the identification of conditions that regulate 
dormancy 
3. The dormant cell sub-population is phenotypically distinct re: gene and protein 
expression and certain markers define a dormant phenotype 
4. These markers identify dormant cells in patients where their presence is linked 
to poor prognosis.  
 
1.6.3 Objectives 
 
To test the above hypotheses the following objectives will determine whether:  
 
1. Vital lipophilic membrane dyes can be used to identify slow/non-dividing cells. 
2. Dormancy is subject to changes from the environment that can modulate entry 
and exit from this state 
3. RT-qPCR methods can identify gene expression alterations in the dormant cell 
sub-population compared to the bulk population. 
4. Changes at the RNA level are also observed at the protein level. 
5. Immunohistochemistry for these protein markers can be used to identify these 
cells in patient biopsies. 
6. The presence of these cells correlates to the presence of metastases in these 
patients. 
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2.1 Cell culture techniques 
 
2.1.1 General cell culture materials 
 
Table 2.1. The reagents and suppliers used in standard tissue culture techniques 
 
Material Supplier 
Cryovials, 1.5 mL  Nalgene Nunc Ltd. (New York, USA) 
Disposable Pipettes (5, 10 and 25mL)  Corning Costar® (Tewksbury, USA) 
Disposable  Tips  (10,  200  and  1000μL)   Corning Costar® (Tewksbury, USA) 
Eppendorf Tubes (0.5 and 1.5mL)  Starstedt Ltd. (Beaumont Leys, UK) 
Flasks (T25, T75, T175)  Nalgene Nunc Ltd. (New York, USA) 
Multi Well Plates (6, 12, 24, 48, 96 wells)  Nalgene Nunc Ltd. (New York, USA) 
Petri Dishes (60 and 100mm)  Nalgene Nunc Ltd. (New York, USA) 
Tubes and Bijou (5, 15, 25, 50mL)  Starstedt Ltd. (Beaumont Leys, UK) 
Table 2.2 The disposable materials and suppliers used in general tissue culture techniques 
Reagent Supplier 
70% Industrial methylated spirits  Fisher scientific (Loughborough, UK) 
Dulbecco’s  Modified   Eagle  Medium   (DMEM), 
+ GlutaMax 1x, + 4.5g/L Glucose, - Pyruvate 
Gibco® (Paisley, UK) 
DMSO Invitrogen™  (Paisley,  UK) 
Foetal Bovine serum Sigma-Aldrich® (Dorset, UK) 
Haemocytometer Weber Scientific Int. 
(New Jersey, USA) 
Isoton Solution Beckman Coulter Inc. (High Wycombe, 
UK) 
Penicillin-Streptomycin Gibco® (Paisley, UK) 
Phosphate buffered saline (PBS) Gibco® (Paisley, UK) 
Trypsin/ Ethylenediaminetetraacetic acid 
(EDTA) 
Gibco® (Paisley, UK) 
 
Chapter 2: Materials and methods 
51 
 
2.1.2 Cell lines 
Cell line Source Description Reference 
PC-3 American type 
culture collection 
(ATCC) 
Isolated from a bone metastasis from a 
stage IV prostatic adenocarcinoma by 
ME Kaighn. PC-3 cells are androgen 
receptor negative and insensitive to 
androgens. 
(Kaighn ME, 
1979) 
PC-3GFP Dr. Niel Cross, 
Sheffield Hallam 
University (From 
the original 
ATCC PC-3) 
A derivative of the PC-3 line 
transfected with green fluorescent 
protein.  
(Cross, 2008,) 
PC-3RFP From the original 
ATCC PC-3 
strain, transfected 
Dr. Giancarlo 
Pesce  
A derivative of the PC-3 line 
transfected with red fluorescent 
protein. 
n/a 
PC-3NW1 Transfected by 
Dr. Ning Wang 
from the original 
PC-3 line (ATCC) 
The result of a stable transfection of 
the PC-3 cell line with firefly 
luciferase gene. These cells are 
routinely used in vivo as they can be 
easily imaged by IVIS (In Vivo 
Imaging System). 
(Wang et al., 
2014) 
LNCaP American type 
culture collection 
(ATCC) 
The LNCaP cell line was originally 
derived   from   a   patient’s   lymph   node  
metastasis. Unlike the PC-3 cell line, 
LNCaP cells are androgen-sensitive  
(Horoszewicz 
et al., 1980)  
C42B4 Generous gift 
from Professor 
George 
Thalmann, 
University 
Hospital Bern 
The original C4-2 cell line was an 
androgen insensitive sub-strain of 
LNCaP, derived from a tumour grown 
from LNCaP cells in castrated mice. 
The C42B4 cell line was derived from 
an osseous tumour in a castrated 
mouse model following orthotropic 
injection of the C4-2 cells. 
(Thalmann et 
al., 1994) 
Table 2.3. The main cell lines used for in vitro experiments during the project 
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2.1.3 Maintenance of cell cultures 
 
All cells were routinely grown in T75 sterile tissue culture flasks in DMEM plus 10% 
foetal bovine serum (FBS) and 1% (5 ml of a 10,000 units/ml added to 500 ml media) 
Penicillin-Streptomycin (Pen-Strep) with the exception of PC-3RFP/GFP cells which 
were grown in 5% foetal bovine serum. Cells were grown in an incubator at 37 degrees 
Celsius (°C) supplied with 5% CO2 and 95% humidity.  
 
Cells were passaged every 3 days or between 80 and 60% confluence, as assessed by 
Olympus CK2 Inverted microscope at 10x magnification.  
 
2.1.4 Cell harvesting  
 
To harvest cell cultures for either sub-culturing   (‘passaging’)   or   counting   to   set   up  
experiments, the media was eluted from the well or flasks, washed with a specific 
volume of PBS (As defined in Table 2.4) and subject to 0.25% Trypsin/EDTA for 5 
minutes at 37q. Trypsin was then neutralized with an appropriate volume of standard 
media. The resulting cell suspension was either counted or centrifuged at 300 x g for 5 
minutes, at room temperature, and the resulting cell pellet re-suspended in 10 ml of 
media, with either 1 ml (1in10 split) or 2 ml (1in5 split) added to a further 10 ml of 
media in a sterile T75 flask. 
 
Flask type Vol.  PBS wash/ml Vol. trypsin/ml Vol. neutralisation media/ml 
T175 10 5 15 
T75 6 2 8 
T25 4 1.5 3.5 
Table 2.4 The reagent volumes required in standard passage 
 
2.1.5 Cell counting by Haemocytometer 
 
For routine cell counting a Haemocytometer was used. This consists of a thick 
microscope slide with two laser etched counting grids scored in the centre of the slide. 
The indentation either side and between the two counting grid allows a capillary space, 
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of 0.1 mm depth, to be created when a cover slid is applied to the Haemocytometer 
slide.  
 
To  count  cells,  10  μl  aliquots  of  cell  suspensions  were  injected  into  the  capillary  space  
in each counting grid by pipette and counted, using a clicker counter, under a 10x 
optical zoom on the Olympus CK2 Inverted microscope. The number cells in all 8 of 
the 1 mm2 squares (the blue box indicates one 1 mm2 square, Figure 2.1) were counted 
and the resulting tally divided by 8 to get the average cell number per 1 mm2 square. As 
each 1 mm2 square holds 100 nl of liquid the number of cells per ml in the cell average 
was calculated by multiplying by 10,000.  
 
 
 
Figure 2.1 Schematic 
representation of a 
Haemocytometer 
The parts of the Haemocytometer are 
illustrated in the top diagram. The 
grid below represents one of the laser 
etched counting grids. In which, the 
blue outlined square represents a 1 
mm2 area which holds 100 nl. 
 
 
 
 
 
 
2.1.6 Cell counting by Coulter Counter 
 
The Z2 Coulter particle count and size analyser from Beckman Coulter (High 
Wycombe, UK) was developed to measure the number of cells or particles in a 10 ml 
suspension by using a sensitive electrical probe. As the cell suspension passes through 
the probe the electrical conductance is altered which gives a measure of the number of 
cells or particles present.  
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The probe can be set to measure particles of a particular diameter e.g. between 10-25 
μm   for   PC-3 cells and sub-strains. The Coulter counter measures 0.5 ml of the cell 
suspension and therefore, the total in a 10 ml suspension was calculated by multiplying 
by 20. All cultures were collected into a 10 ml volume for controlled counter analysis. 
Two measurements were taken per sample and the average was calculated.  
 
2.1.7 Growth curves in routine serum concentrations 
 
To establish the base line growth of cell lines in standard conditions, growth curves 
were generated over 12 days for all human prostate cancer cell lines used. Cells were 
harvested from 60-80% confluent flasks by trypsinisation and counted using a 
Haemocytometer. Cells were then centrifuged and the resulting cell pellet was made up 
to a 1x106 cell suspension by adding the appropriate volume of standard media and 
counted again to ensure the suspension was accurate. A 1 in 100 dilution was  
performed to acquire 25 ml of a 1x104  cell suspension. 1 ml of solution was added, per 
well, into a 12 well plate to equal 10,000 cells per well.  
 
Cells were counted every other day for 12 days using the Z2 Coulter particle count and 
size analyser from Beckman Coulter (High Wycombe, UK). The plates were subject to 
media change on day 2, day 6 and day 10. On each count day the media was removed 
from each of the 4 replicate wells and added to a 15 ml falcon tube. The wells were  
washed with 1 ml of PBS, which was also added to the tube. 0.5 ml of trypsin/EDTA 
was added and the plate was incubated at 37q for 5 minutes and viewed under a 
microscope to ensure all the cells had detached. 0.5 ml of standard media was added to 
neutralize, and the cell suspension was added to the falcon. The resulting 3 ml cell 
suspension was made up to 10 ml with the addition of 7 ml of Isoton II Diluent 
(purchased from Beckman Coulter). The tube was inverted several times and added to a 
25 ml Accuvette and counted using the Z2 counter. Each growth curve was repeated 
three times. 
 
2.1.8 Determining the exponential growth phase  
 
The exponential growth phase was determined for all cell lines from growth curves 
generated in routine serum. Following guidelines outlines in the ATCC® ANIMAL 
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CELL CULTURE GUIDE tips and techniques for continuous cell lines the lag, 
exponential and stationary growth stage could be identified (Figure 2.2). 
 
The lag phase was characterised as the time taken from initial seeding (day 0) to the 
time that the cells reach linear/exponential growth. The exponential phase was defined 
as the steep increase in cell number after the lag phase until growth begins to plateau as 
cells reach the non-exponential/stationary phase, defined as the time after exponential 
growth when cell division slows down. These stages could be easily defined as long the 
growth  curves  followed  a  sigmoidal  or  ‘S-shaped’  curve  which  allowed  these  stages  to  
be easily discernable.  
 
 
Figure 2.2 Determining 
the stages of growth  
The lag phase is 
characterised as the time 
taken from initial seeding 
to the time that the cells 
reach exponential growth. 
The exponential phase is 
the steep increase in cell 
number after the lag 
phase until growth begins 
to plateau as cells reach 
the non-exponential 
/stationary phase, defined 
at the time after 
exponential growth when 
cell division slows down.  
 
 
 
2.1.9 Determining the effect of serum on exponential cell growth; serum titration 
experiments  
 
An assessment of how serum concentration affects growth in mid-exponential growth 
(as defined by the guidelines above from growth curves in routine serum) was 
performed. FBS was added to standard DMEM + Pen-Strep to make nine different 
concentrations, 0%, 1%, 2%, 4%, 6%, 8%, 10%, 12% and 15%. Cells were seeded into 
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12 well plates at a density of 1x104 cells per well, as described above, in standard 
media. At day 2 the media was removed and the wells were washed once with 1 ml of 
PBS. 1 ml of new media, of each of the designated serum concentrations, was added to 
well plates in replicates of 4. At the point of mid-exponential growth the cell number 
was determined by Coulter counter, in all four replicate wells for each serum 
concentration. 
 
2.1.10 Growth curves in FBS concentrations for ½ maximum proliferation 
 
The ½ maximum growth condition was determined from serum titration experiments 
and a growth curve was performed. The half maximum growth condition was defined as 
the serum concentration that stimulates a 50% reduction in growth (measured by cell 
number) compared to growth in optimum serum concentrations during mid-exponential 
growth. To determine the ½ maximum growth conditions, the cell number at day 6 
(mid-exponential growth) in optimum serum was halved. This number was then referred 
to the serum titration graph and the FBS concentration that best produced this number 
was taken as the ½ maximum. To perform a growth curve in the ½ maximum 
conditions, 1x104 cells were plated per well into 12 well plates in 10% FBS 
DMEM+PenStrep. On day 2 the media was removed, wells were washed with 1ml PBS, 
and 1ml of the ½ maximum serum media was added. The cells were cultured for a 
further 10 days in the new media and counted by Coulter Counter every other day. The 
media was refreshed on day 6 and day 10.  
 
2.1.11 Clonogenic assays in monolayer 
 
To assess the cloning ability of cell lines, cells were seeded at clonal density in 60mm 
petri dishes and cultured for 14 days. Clonal density is defined as the minimal cell 
seeding density that produces colonies that can be detected by the Biocount colony 
counter; for the prostate cancer cell lines this is 1x103 cells/60mm dish. Prostate cancer 
cell lines were harvested from 60-80% confluent flasks and counted by 
Haemocytometer. A 1x103 cells per ml suspension was made by serial dilution. 1 ml of 
this suspension was added to 5 ml of DMEM + PenStrep, with multiple FBS 
concentrations, in a 60mm diameter sterile petri-dish. Dishes were prepared in 
quadruple replicate for each treatment/ cell type to be analysed. After 14 days of 
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incubation the dishes were removed from culture. The media was removed and the 
dishes were washed with 5 ml PBS. Dishes were left to air dry for 5 minutes and cells 
were  ‘fixed’  by  the  addition  of  2  ml  of  100% methanol for 5 minutes. This was removed 
and the dishes were air dried for 5 minutes. 2 ml of Giemsa stain solution (Purchased 
from VWR International Ltd. (Poole, UK)) was added to the dish for 5 minutes then 
removed and washed twice with distilled water and left to air dry overnight. 
 
The number of colonies was determined from images of the dishes taken by the 
Biocount colony counter, which were converted to greyscale images for analysis by 
GeneTool software (Figure 2.3). This software allows a region of interest to be selected 
(red circle) in which individual colonies are highlighted (yellow circles) and counted. 
The generation of false positives is reduced by the exclusion region function, which 
allows the user to highlight areas of shadow or non-specific stain (yellow cross region).  
 
Figure 2.3 Colony number 
analysis by GeneTool 
software 
The area of interest (red circle) 
defines the boundaries of the 
plate. The colonies are 
highlighted (yellow circles) 
which allows any false 
positives to be excluded by the 
user (yellow circle with cross) 
and  number of colonies is 
calculated. 
 
 
2.1.12 Conditioned media 
 
Conditioned media was generated over rapidly growing cell cultures to act as a 
stimulant for dormant cells. To ensure consistency across replicates, 3.5x105 cells were 
seeded into T175 flasks to replicate the seeding density in growth curves. Flasks were 
cultured for 6 days in 10% FBS media, after which the media was removed and the cells 
were washed with PBS. 20 ml of DMEM containing 1% FBS was added to the flask 
and cultured for 24 hours.  
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After 24 hours the conditioned media was removed and centrifuged to remove any 
detached   cells.   The  media  was   also   sterile   filtered   through   a   0.2   μm  mesh   to   further  
ensure the media was free of contaminating cells. This medium was then directly 
applied to experimental plates without freezing.  
 
 
2.2 Lipophilic membrane dyes 
 
CellTracker™  CM-DiI and Vybrant® DiD cell-labelling solutions (detailed in Table 
2.5) were purchased from Life Technologies Ltd. (Paisley, UK).  
 
 Molecular 
formula 
Excitation (nm) Emission (nm) Working 
concentration 
CellTracker™  
CM-DiI 
C68H105Cl2N3O 549 565 10 PM 
Vybrant® 
DiD 
C67H103ClN2O3S 644 665 5 PM 
Table 2.5 The specifications of the lipophilic membrane dyes utilised in experiments 
 
2.2.1  CellTracker™  CM-DiI staining method 
 
Prostate cancer cell lines were harvested from 60-80% confluent flasks and counted by 
Haemocytometer. After centrifugation, cell suspensions of 1x106 cells  per  ml  in  Hank’s  
Balanced Salt Solution (HBSS) from GIBCO (Paisley, UK) were prepare in 25 ml 
tubes. 10 Pl of CM-DiI per 1x106 cells was added and the tube was wrapped in foil and 
placed in a 37°C incubator for 5 minutes. Tubes were then transferred to an ice bucket 
for 15 minutes. Suspensions were centrifuged at 300 x g for 5 minutes and re-suspended 
in 5ml of ice cold PBS. Cells were re-pipetted/ re-suspended 3 times as above to remove 
unbound dye. Before the final wash, the cell suspension was counted using a 
haemocytometer and the final cell pellet re-suspended in standard media to make a 
1x105 cells/ml suspension. 1x105 cells were seeded into 5, T25 flasks in 6ml of 10% 
DMEM plus 1% Pen-Strep. These flasks were cultured for 21 days. The percentage of 
CM-DiI positive cells was assessed by BD FACS calibur (BD Biosciences (San, Jose, 
USA)) flow cytometer analysis and Leica fluorescent microscopy at time points; 0, 3, 7, 
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10, 14 and 21 days.  Cells were allowed to grow and kept at high density following the 
protocol in Table 2.6.  
 
2.2.2 Vybrant® DiD staining method 
 
Cell lines were harvested from flasks of between 60-80% confluence and counted by 
Haemocytometer. Cells were re-suspended in serum-free DMEM to make 1x106 
cells/ml suspensions in 25 ml tubes. The suspension was stained with 5Pl of DiD per 
1x106 cells. The tube was wrapped in foil and placed in a 37°C incubator for 20 
minutes. Suspensions were centrifuged at 300 x g for 5 minutes and washed 3 times as 
in 2.2.1 with 5 ml of serum-free media instead of PBS. Before the final wash, the cell 
suspension was counted using a haemocytometer and the final cell pellet re-suspended 
in standard media to make a 1x105 cells/ml suspension. 1x105 cells were seeded into 5, 
T25 flasks in 6ml of 10% DMEM plus 1% Pen-Strep. These flasks were cultured for 21 
days. The percentage of DiD positive cells were assesses by BD FACS calibur (BD 
Biosciences (San, Jose, USA)) flow cytometer analysis and Leica fluorescent 
microscopy at time points: 0, 3, 7, 10, 14 and 21 days.  Cells were allowed to grow and 
kept at high density following the protocol in Table 2.6.  
 
Day Procedure 
0  Cell stain 5x T25 flasks set-up, FACS Calibur analysis. 
3 FACS Calibur analysis of 1x T25 flask, remaining 4 undisturbed in culture 
7 FACS Calibur analysis 1x T25, transfer of remaining 3 flasks to T75 flasks. 
10 FACS Calibur analysis 1x T75 flask, transfer remaining 2 flasks to T175 flasks. 
14 FACS Calibur 1x T175 flask, split the remaining T175 flask into 3 x T175 flasks 
17 Split one T175 flask 1in4 
21 FACS Calibur 1x T175 (if applicable FACS Aria sort 3x T175 flasks).  
Table 2.6 The protocol followed for all long-term culture and analysis of cells stained with 
lipophilic membrane dyes 
 
2.2.3 Mitomycin C treatment of Vybrant® DiD /CM-DiI cells 
 
Mitomycin C is an anti-neoplastic antibiotic that can be used to generate mitotically 
inactive cells. It acts as an inhibitor of DNA synthesis and nuclear division by 
producing DNA inter-strand cross-links. Mitomycin C was used to arrest the division of 
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stained cells in order to assess dye retention in a known dormant state. Mitomycin C 
was purchased from Sigma-Aldrich (Dorset, UK). PC-3-NW1 cells were stained and 
seeded as in methods 2.2 and allowed to grow for 24 hours. The media was then 
removed and 6 ml of a 5 Pl/ml solution of Mitomycin C (concentration 5mg/ml)  in 
standard media was added. After 3 hours, the media was removed; flasks were washed 
with 6 ml of PBS and replenished with 6 ml of fresh standard media. The percentage of 
CM-DiI or DiD positive cells over 21 days was assessed as above.  
 
2.3 Flow cytometry techniques  
 
2.3.1 Flow cytometry (FACS Calibur) to determine CM-DiI and DiD positive 
percentages 
 
The principles of FACS calibur flow cytometer are shown in Figure 2.4. To determine 
the percentage of CM-DiI or DiD positive cells in culture, one flask at each time point 
was trypsinised and centrifuged at 300x g for 5 minutes at room temperature. A negative 
sample of PC-3-NW1 cells without the dye was also prepared in this way. The resulting 
cell pellet was re-suspended in 0.5 ml of PBS. 2Pl of TO-PRO-3 (for CM-DiI stained 
cells) or Propidium Iodide (PI) (for DiD stained cells) viability dye was added to each 
sample. TO-PRO-3/PI identifies any non-viable cells by entering through the disrupted 
membrane of dead cells. TO-PRO-3 is a long wavelength dye (Max. emission 657 nm) 
and so can be separated from the CM-DiI signal whereas PI emits at 617 nm and so can 
be separated from the DiD signal. 
 
The FACS calibur has two lasers, of wavelength 488 nm and 633 nm. These lasers allow 
excitation of fluorescent proteins. The emission wavelength of fluorescent cell dyes or 
flurophores is detected by the individual channel detectors. This information is analysed 
by an attached computer using the Cell Quest software package.  The percentage of 
viable CM-DiI retaining cells was detected by the FL-2 channel and the percentage of 
viable DiD positive cells was detected by the FL-4 channel.  
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Figure 2.4 The 
principles of FACS 
Calibur.   
The cell sample is 
analysed through the 
flow cell by two 
lasers: 488 nm (blue) 
and 633 nm (red). 488 
nm detects forward 
(FCS) and side scatter 
(SSC) as well as 
channels FL-1, FL-2 
and  FL-3. The 633 
nm laser detects the 
FL-4 channel. The 
laser beam passes 
through a focusing lens (grey oval A), through the flow cell and up through the fluorescent 
collection lens (grey oval B) Cells carrying a fluorescent signal, conjugated to an antibody or as 
a cellular dye, are excited by these lasers and their emission wavelength is reflected by a series 
of mirrors to the channel detectors (coloured cylinders). The detectors feed to a connected 
computer to allow analysis by specialized software.  
 
2.3.2 Fluorescent activated cell sorting (FACS Aria)  
 
In order to perform downstream experiments such as RT-qPCR the DiD stained cells 
were also sorted by BD FACS Aria (BD Biosciences (San, Jose, USA)) on day 14. This 
allowed the isolation of DiD positive cells, which would represent the dormant sub-
population. The principles of FACS Aria are shown in Figure 2.5. 
 
The FACS Aria uses a tri-laser system to detect fluorescence from mixed populations of 
cells. A cell that emits fluorescence upon excitation by these lasers, feeds back to the 
photomultiplier and is given a positive, negative or no charge based on which channel 
the signal is detected in. In this way fluorescent signals in multiple channels can be 
detected and sorted allowing for the separation of multiple cell types (only two 
populations shown for ease in Figure 1.2). The effective sorting of different cell sub-
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populations depends on calibrating the Aria to produce a single droplet from the high 
pressure nozzle, allowing a single cell at a time to be analysed and sorted. After sorting 
the separate collection tubes can be removed and centrifuged to retrieve the cells.  
 
Figure 2.5 The principles of 
FACS Aria.  
The FACS Aria consists of three 
lasers: 405 nm, 488nm and 
633nm. These lasers are focused 
onto a stream of cells released 
from a high-pressure nozzle that 
forms droplets of single cells 
allowing them to be analysed 
individually. Cells carrying a 
fluorescent tag are excited by 
these lasers and emit light, 
which is detected by the 
photomultiplier. This feeds to 
the computer that signals a 
charge to be added to the cell, 
which is then deflected by 
charged electrodes into the 
designated collection tube. 
 
 
2.4 Imaging techniques 
2.4.1 Fluorescent imaging 
 
Fluorescent cell imaging was performed using the Leica AF6000 Automated Inverted 
Microscope. The Leica features a fluorescence axis and enables the excitation of a range 
of flurophores from UV to far red (Table 2.7).  
 
Filter cube Excitation Emission Colour 
A4 BP 360/40 BP 470/40 UV 
L5 BP 480/40 BP 572/30 Blue 
N3 BP 600/40 BP 600/40 Green 
Y5 BP 700/75 BP 700/75 Cy5 Red (Far Red) 
Table 2.7 The filter cubes and excitation/emission ranges featured on the Leica AF600.  
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2.4.2 Colour image analysis 
 
To perform real colour imaging, for use in detecting Beta-galactosidase activity and 
biotinylated antibodies, the Inverted widefield fluorescence microscope Leica 
DMI4000B was used with the assistance of Colin Gray. 
 
2.5 Cell cycle experiments 
 
2.5.1 Ki-67 flow cytometry assay 
 
14 days after DiD staining, PC-3NW1 cells were harvested and counted by 
haemocytometer. 1x106 cells were fixed in formalin for 20 minutes at room temperature. 
The cells were centrifuged for 5 minutes at 300 x g and non-specific binding blocked in 
10% goat serum in 0.5% BSA for 1 hour on ice. The cells were permeabilised by the 
addition of 300 Pl of 1x BD Phosflow™ perm buffer solution (purchased from BD 
Biosciences), made up in distilled water from the 10x stock, per 1x106 cells for 10 
minutes at room temperature. The cells were pelleted (300 x g), re-suspended in perm 
buffer twice and separated into 1x105 cell aliquots for application of the antibody. The 
AlexaFluor® 488 Mouse anti-human Ki-67  was  purchased  from  BD  Pharmingen™.  For  
experiments the aliquots consisted of a no-treatment control, two replicates of a 1:20 
concentration of the antibody and two replicates of a 1:20 concentration of the isotype 
control (Mouse IgG1 k,  purchased  from  BD  Pharmingen™).   
 
The cells were incubated with treatments (isotype, no-treatment or Ki-67 antibody) 
diluted in 10% goat serum PBS  for 30 minutes at 4q C. The cells were then centrifuged 
at 300 x g for 3 minutes and pellets re-suspended/washed 3 times in PBS, centrifuged at 
300 x g between washes. After the final wash the cells were re-suspended  in  300  μl  of  
PBS and analysed by FACS Calibur flow cytometer. A positive and negative control of 
DiD stained and unstained PC-3NW1 cells was used to set the gate to determine DiD 
positive dormant cells. The isotype and no-treatment control were used to set the gate to 
determine KI-67 positive cells. 10,000 events (cells) were analysed per sample. 
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2.5.2 KI-67 immunofluorescence (chamber slide method) 
 
KI-67 status was also qualitatively analysed by immunofluorescence. 1x106 PC-3NW1 
cells were stained with DiD following methods 2.2.2. After serial dilution 300 stained 
cells/well  were  added  to  an  8  well  Permanox®  microscope  chamber  slide  in  300  μl  of  
10% FBS DMEM+Penstrep. Cells were cultured for 14 days, after which the chambers 
were prepared for immunofluorescence. On ice the media was removed from each well 
by pipette and the  wells  were  washed  with  300  μl   ice  cold  PBS  twice.  The  cells  were  
fixed  in  300  formalin  μl/well  for  20  minutes  at  room  temperature Non-specific binding 
was blocked by addition of 300  μl  of  10% goat serum in 0.5% BSA per well for 1 hour 
on ice. The cells were washed in 300 μl PBS twice. The cells were permeabilised with 
300 μl 0.1% triton in PBS for 10 minutes at room temperature and washed twice with 
PBS. 300 μl of a 1:20 dilution of AlexaFluor® 488 Mouse anti-human Ki-67 (purchased 
from   BD   Pharmingen™)   or matched Mouse IgG1 k isotype (purchased from BD 
Pharmingen™)  diluted  in  10%  goat  serum  in  PBS  was  added  to  each  well  in  replicates  
of four. The chambers were incubated overnight at 4°C. After incubation the treatment 
was removed and the chambers were washed  twice  with  300  μl  PBS.  The  chamber  was  
then carefully removed and the slides were mounted in VECTASHIELD Mounting 
Medium with DAPI (purchased from VECTOR laboratories, Peterborough, UK) onto 
coverslips for imaging. 
 
2.5.3 Propidium Iodide (PI) assay 
 
1x106 PC-3NW1 cells 14 days after DiD staining were harvested and centrifuged for 5 
minutes at 300 x g to pellet. The pellet was resuspended and fixed in 1 ml of 70% ice-
cold ethanol, applied drop by drop whilst the cells were gently vortexed. The cells were 
incubated in ethanol for 5 hours at 4qC. The cells were then washed by adding 5 ml PBS 
to the tube and centrifuged for 10 minutes at 300 x g. This wash step was repeated. 300 
μl   (50   μg/ml)   of   PI   and   5   μl   (2   mg/ml)   of   RNAse   were   added   and   the   cells   were  
incubated overnight at 4q. FACS Caibur analysis was the performed to assess the cell 
cycle status of DiD positive cells. A DiD positive and negative control of stained and 
unstained PC-3NW1 cell was used to set the DiD positive gate. A no treatment control 
was used to ensure no cross over from the FL-4 DiD channel and the FL-2 PI channel.  
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2.5.4 Senescence assay 
 
The Senescence Detection kit from Abcam® was used to perform a senescence assay. 
The kit distinguishes cells in a senescent state by the development of a blue stain, which 
is detected upon the hydrolysation of X-gal into galactose and 5-bromo-4-chloro-3-
hydroxyindole when senescent associated beta-galactosidase enzyme is active. It is 
based on the observation that senescent cells have higher endogenous lysosomal beta-
galactosidase which makes the enzyme active in acidic conditions (Lee et al., 2006). 
SA-beta-Gal represents an accumulation of beta-Gal in senescent cells as opposed to a 
unique enzyme. Therefore, when performed at pH 6.0, the kit allows the identification 
of senescent cells by the hydolysis of X-gal under acidic conditions.  
 
The kit components are listed in Table 2.8. PC-3NW1 cells that had been stained with 
DiD and cultured for 14 days were harvested and counted by Haemocytometer. 1x105 
cells were seeded in triplicate into a 6 well plate and left to attach overnight. The media 
in each well was carefully eluted and washed with PBS. 1 ml of the provided Fixative 
solution was added to each well and incubated for 10 minutes at room temperature. The 
fixative was removed and the wells were washed twice with 1 ml of PBS. For each well 
1  ml  of  Staining  Solution  mix  was  prepared   in   an   eppendorf  by  mixing  470  μl  of  1x  
Staining  solution   to  5  μl  of  100x  Staining  Supplement  and  5  μl  of   the  prepared  X-gal 
solution. The plate was covered in foil and incubated overnight at 37qC. The presence 
of blue colour was assessed by Leica DMI4000B colour imaging with fluorescence to 
detect the DiD channel.  
 
Item Preparation 
1x Fixative solution n/a 
X-Gal (150 mg, Lyophilized) 20 mg X-gal dissolved in 1 ml DMSO  
1x Staining solution n/a 
100x Staining Supplement  n/a 
Table 2.8 The items supplied in the Abcam® Senescence detection kit  
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2.6 Molecular biology techniques 
 
2.6.1 RNA extraction 
 
RNA extractions were performed using the ReliaPrep™  RNA  Cell Miniprep System 
from Promega. The components supplied are listed in Tables 2.8 and 2.9. Reagents 
supplied by the user include isopropanol, 95% Ethanol and centrifuge. Following 
preparation the cell pellet was washed once with 5 ml of ice cold PBS and centrifuged 
for 5 minutes at 300 x g. 100-250 µl of BL buffer plus 1-Thioglycerol was added to the 
pellet (100 µl 1 x102 to 5 x105 cell, 250 µl >5 x105 to 2 x106 cells) to effectively lyse 
the cells. The pellet was re-suspended by pipetting 7-10 times to shear genomic DNA 
and transferred to a 1.5 ml sterile eppendorf tube. 35-85 µl of ice cold 100% 
isopropanol was added to the tube and vortexed for 5 seconds (35 µl 1 x102 to 5 x105 
cell, 85 µl >5 x105 to 2 x106 cells). The lysate was transferred to the Minicolumns 
provided which were then placed in Collection tubes and centrifuged for 30 seconds at 
12,000 x g. The Minicolumn is designed to capture nucleic acids due to the presence of 
chaotropic salts in the resin matrix situated at the base of the tube. Centrifugation and 
subsequent wash steps are designed to remove contaminating proteins and DNA whilst 
retaining RNA in the matrix. After centrifugation the elution volume was discarded. 500 
µl of the provided RNA wash solution was added to the Minicolumn which was then 
centrifuged for 30 seconds at 12,000 x g and the elution volume discarded. At this stage 
a DNase treatment was performed by the addition of 24 µl of yellow core buffer, 3 µl of 
MnCl2 and 3 µl of DNase enzyme per sample and left at room temperature for 15 
minutes to remove contaminating genomic DNA.  
 
Columns were washed with 200µl column wash solution and centrifuged for 15 seconds 
at 12,000 x g.  A second RNA wash was performed with a further addition of 500 µl of 
RNA wash solution and centrifuged for 30 seconds at 12,000 x g. The eluted liquid was 
discarded and the Minicolumn transferred to a new Collection tube. A final RNA wash 
step was done, 300 µl of RNA was solution was added and the tubes were spun for 2 
minutes at 12,000 x g. The Minicolumn was transferred to an Elution tube to allow the 
release of the bound RNA from the Minicolum matrix by the addition of Nuclease free 
water. 15 µl of Nuclease free water was added to elute 1 x102 to 5 x105 cell, 30 µl was 
added to elute >5 x105 to 2 x106 cells. After the addition of Nuclease free water the 
tubes were centrifuged for 1 minute at 13,000 x g and the resulting elution liquid 
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containing the released RNA was retained in the Elution tube for analysis by Nanodrop.  
Reagent 
 
Description Preparation prior to use 
DNase I 
 
DNase I is a DNA denaturing enzyme that 
reduces DNA contamination during RNA 
extraction. The potency of this enzyme is 
greatly dependent on the reaction buffer. 
Therefore exact quantities of MnCl2 and 
yellow core buffer are required for its action. 
Add 275µl of Nuclease-Free  
Water (provided) and mix 
gently to dissolve. Store 10-
20 µl aliquots at –20°C. 
DNase is mixed with MnCl 
and yellow core buffer to 
make the complete reaction 
mix.  
 
BL Buffer  
 
The BL buffer is made up of 4M Guanidine 
thiocyanate and 0.01M Tris (pH 7.5). The 
buffer is made up to 2% 1-Thioglycerol, upon 
addition. Guanidine thiocyanate is a strong 
protein denaturant and is used to lyse cells.  
Add 325µl of  
1-Thioglycerol to 32.5ml of  
BL Buffer and store at 4º for 
up to 30 days 
 
MnCl2, 
0.09M 
In the presence of Manganese (Mn) the 
DNase enzyme produces double strand DNA 
‘nicks’   allowing   potent   degradation   of  
contaminating DNA.  
n/a 
Nuclease-
Free Water 
Nuclease-free water is autoclaved and sterile 
filtered water. It is RNase and DNase free. 
n/a 
RNA Wash 
Solution 
 
A mixture of potassium acetate and 
27.1mM Tris-HCl (pH 7.5 at 25°C). (The 
specific action of this buffer is not described. 
However, the known action of potassium 
acetate is to precipitate dodecyl sulfate (DS) 
and DS-bound proteins. It is also used as a 
salt for the ethanol precipitation of DNA. It is 
therefore likely that this buffer acts as a 
purifying wash to remove DNA and proteins 
at each RNA purification step). 
Add 60ml of 95% ethanol  
and swirl to mix prior to first 
use (stable indefinitely at 
room temperature) 
Column 
Wash 
(The components of this buffer are not listed 
on the protocol. However, as the Column 
wash step is performed after the DNase 
treatment and at no other time I would 
assume that this buffer contains a DNase 
inhibitor to effectively stop the reaction. This 
would most likely be a chelating agent such 
as EDTA or SDS due to the presence of 
Manganese).  
Add 7.5mlof 95% ethanol  
and swirl to mix prior to first 
use (stable indefinitely at 
room temperature) 
Yellow Core 
Buffer 
Yellow core buffer is a mixture of 0.0225M 
Tris (pH 7.5), 1.125M NaCl and 0.0025% 
yellow dye (w/v). (Little information is 
available about this buffer but as the activity 
of DNase is greatly altered by the ionic 
strength of the reaction buffer, the presence of 
NaCl may regulate this). The Yellow dye is 
used to ensure complete coverage of the RNA 
capture membrane 
n/a 
1-
Thioglycerol 
Is added to the BL buffer in order to inhibit 
ribonuclease activity and preserve RNA 
integrity upon cell lysis.  
n/a 
Table 2.8 The reagents supplied in the ReliaPrep™  RNA  Cell  Miniprep  System 
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Material Description 
Collection Tubes  The collection tube is a small plastic tube that holds the Minicolumn 
and captures the elution waste after centrifugation, which is then 
disposed.  
Elution Tubes After the final wash step the RNA that is bound to the Minicolumn is 
eluted into the elution tube with nuclease free water. The elution 
tubes can then be stored at -20 to -80°C 
Mini-columns The Minicolumn comprises of a small plastic tube with a tapered end 
holding a membrane designed to capture RNA. The membrane 
comprises of a resin matrix that favours the capture of nucleic acids 
due to the presence of chaotropic salts. These salts disrupt the 
structure of larger molecules such as proteins. The Minicolumn sits 
within the collection tube and allows the elution of proteins and the 
retention of RNA before its final elution with nuclease free water.  
 
Table 2.9 The materials supplied in the ReliaPrep™  RNA  Cell  Miniprep  System 
 
2.6.2 Nanodrop analysis of extracted RNA 
 
The NanoDrop 2000 from Thermo Scientific was used to assess RNA quantity and 
quality after extraction. The Nanodrop is a spectrophotometer device that uses the 
absorbance of ultraviolet light, at a wavelength of 260 nm, to detect RNA/DNA purity. 
0.5-2 ul of sample is pipetted onto the pedestal containing the lower optical surface and 
the arm is lowered to contact the upper and lower optical surfaces to create a sample 
column for analysis. Prior to use and before each sample, the upper and lower optical 
surfaces were wiped with a lint free cloth before the sample was pipetted. 1 ul of 
nuclease   free  water  was   used   to   ‘blank’   the  machine   prior   to   use.  A  measurement   of  
nuclease free water was taken before the samples to ensure that the machinery was 
working properly and to check that there was no RNA/DNA contamination in the 
nuclease free water used for eluting. The RNA was then gently mixed and 1 ul per 
sample was loaded onto the machine. Two readings per sample were recorded and the 
average was taken. A sample with a 260/280 ratio close to or equal to 2.0 and a 260/230 
between 2.0-2.2 was considered high quality RNA suitable for down stream 
experiments.  
 
2.6.3 TapeStation 
 
A further measure of RNA quality was performed using the 2200 TapeStation from 
Aligent technologies. This was particularly useful when optimising the RNA 
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ReliaPrep™  system. The TapeStation gives a measurement of RNA integrity, the RNA 
integrity number equivalent or RINe. The RINe is calculated based on the ratio of 
28s:18s species in the RNA sample as well as the level of degradation in the form of 
small RNA products following gel electrophoresis. Unlike traditional methods this ratio 
is calculated objectively and automatically from a full electropherogram using an 
established algorithm. 
 
 It is important to ensure that the same quantity of RNA is loaded per sample into the 
TapeStation, therefore samples of high concentration must first be diluted with nuclease 
free water. 2 µl of R6K Sample Buffer (purchased from Aligent technologies) was 
added   to   each   sample   in   a   0.2  ml   tube.  The   tubes  were   vortexed   and   ‘pulsed’   on   the  
centrifuge. The tubes were heated to 72°C for 3 minutes using a hot block. They were 
then transferred   to   an   ice   bucket   for   2   minutes.   The   tubes   were   ‘pulsed’   on   the  
centrifuge and loaded into the TapeStation with the R6K screentape. The R6K 
screentape platform (purchased from Aligent technologies) consists of a multi-
channelled well plate into which the RNA samples are automatically loaded. The 
TapeStation automatically analyses the samples and produces the RNA integrity 
number equivalent (RINe). The RINe is used as a measure of the amount of RNA 
degradation  between 1 and 10,  where a RINe value of 10 is completely intact RNA. 
After the sample is run on the screentape system the system produces an image of the 
electrophoresis gel and also an electropherogram, which displays the 18s and 28s peaks 
and  any  ‘ripples’  between  the  peaks  which  would  indicate degraded RNA. The software 
then calculates the RINe  by the rRNA ratio and also the concentration of the RNA.  
 
2.6.4 Reverse transcriptase-quantitative PCR (RT-qPCR): General principles  
 
The polymerase chain reaction (PCR) allows the amplification of a small amount of 
DNA, in the presence of Taq polymerase and DNA oligonucleotides (or DNA primers), 
to produce vast quantities of specific transcripts. Reverse transcriptase PCR generates 
cDNA (complementary DNA) from extracted RNA to allow amplification. qPCR, often 
referred to as Real-time PCR, allows the amplification and simultaneous detection of a 
specific transcript allowing the relative expression level of specific genes to be 
quantified. The TaqMan® assay system, which was used is all experiments, involves 
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the use of sequence-specific DNA probes to detect the level of gene expression based 
on   the   intensity   of   a   fluorescent   signal.  TaqMan®  primers  or   ‘assays’   include  a   gene  
specific  oligonucleotide  sequence  that  has  a  reporter  dye  at   the  5’  end  and a quencher 
attached   to   the   3’   end.   When   the   primer   is   initially   attached   to   the   specific   cDNA  
sequence the quencher prevents the reporter emitting a fluorescent signal. However, 
when the probe is displaced/cleaved during PCR amplification, the reporter is released 
and emits a fluorescent signal. The amount of a specific cDNA transcript is measured 
by Ct (cycle threshold) value, which is the number of PCR cycles required for the 
emitted fluorescent signal to pass a threshold. The TaqMan® probes used in all 
experiments consist of the 6-carboxyfluorescein (FAM) reporter and minor groove 
binder (MGB) non-fluorescent quencher. 
2.6.4.1 Reverse transcription 
The materials and reagents for reverse transcription are listed in Table 2.10. All the 
pipettes, tips and tubes as well as the DEPC water were subject to irradiation by U.V 
light for 20 minutes prior to the start of experiments. As it is important to load the same 
amount of RNA into each reaction, the RNA yield (as indicated by Nanodrop) was used 
to calculate the appropriate volume of RNA to add to DEPC water to equal the same 
amount in ng in a total of 11 µl volume. For each sample a Superscript negative control 
was carried out, therefore each sample was prepared in two replicate tubes. A tube 
containing DEPC water only was also prepared to ensure no contamination in the 
diluent.  
 
Item Supplier 
DEPC-treated Water BIOLINE (London, UK) 
dNTP mix (100mM) BIOLINE (London, UK) 
DTT (0.1M) Invitrogen (Paisley, UK) 
First strand buffer Invitrogen (Paisley, UK) 
Oligo (dt) Primers Promega (Southampton, UK) 
Random Primers Promega (Southampton, UK) 
RNase free 0.5 ml eppendorfs  Alpha Laboratories Ltd (Hampshire, UK) 
RNasIN recombinant RNase Inhibitor Promega (Southampton, UK) 
SuperScript III Invitrogen (Paisley, UK) 
Table 2.10 The materials and reagents for reverse transcription 
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2 µl of Reverse transcription (RT) mix I (prepared as in Table 2.11) was added to each 
sample and the reaction was heated to 65ºC for 5 minutes using a Thermocycler and 
cooled to 4ºC for at least 1 minute. 
 
7 µl of RT mix II Negative (prepared as in Table 2.11) was added to half of the tubes to 
make up a total volume of 20 µl to serve as the RT free control. 7 µl of RT mix II 
Positive (prepared as in Table 2.11) was added to the remaining tubes, including the 
water control, to allow the generation of cDNA from these samples. The reaction was  
heated to 50ºC for 60 minutes, 70ºC for 15 minutes and cooled to 4ºC. The resulting 
cDNA was directly processed in qPCR or stored at -20ºC or -80ºC for long-term 
storage.  
 
RT Mix Components (Volume required per reaction) 
RT Mix I DEPC-treated Water (0.5 µl) 
Oligo (dt) Primers (0.25 µl)                                 
Random Primers (0.25 µl) 
dNTP (1 µl) 
RT Mix II Positive First strand Buffer (4 µl)  
DTT (1 µl) 
RNaseIn (1 µl) 
Superscript III (1 µl) 
RT Mix II Negative First strand Buffer (4 µl)  
DTT (1 µl) 
RNaseIn (1 µl) 
DEPC-treated water (1 µl) 
Table 2.11 The components and volume required for reverse transcription reactions. 
 
2.6.4.2 qPCR using individual TaqMan® assays 
The primers used for individual TaqMan® assay qPCR are listed in Table 2.12. Prior to 
the start of experiments, all the pipettes, tips and tubes as well as the RT-PCR water and 
the 384 well plates were subject to irradiation by U.V light for 20 minutes. 
 
Total volume 2 µl + 
11 µl RNA 
Total volume 7 µl  
Total volume 7 µl  
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3 µl of each 20 µl sample of cDNA, that was generated as described in the previous 
section, was required for a single TaqMan® assay. As multiple assays were investigated 
per sample, a 1in4 dilution with RT-PCR water was made to allow enough volume.  0.5 
µl of TaqMan® assay, 5 µl of TaqMan® Universal PCR Master mix (purchased from 
Applied Biosystems) and 1.5 µl of RT-PCR Grade water (from Ambion®) was added to 
each well of the plate with 3 µl of the diluted cDNA.  
 
The  plate  was  sealed  with  BioRad  Microseal®  ‘B’  seal  and  analysed  using  the  7900HT 
Real-Time PCR system from Applied Biosystems with SDS software Standard Core 
2.4.1 for analysis.  
 
Gene name Product Code 
Beta-Actin (ACTB) Hs1060665_g1 
Gapdh Hs02758991_g1 
HPRT1 Hs02800695_m1 
Angiopoietin 1 (ANGPT1)  Hs00375822_m1 
Chemokine (C-X-C Motif) Ligand 12 
(CXCL12) 
Hs00171022_m1 
Chemokine (C-X-C Motif) Receptor 4 (CXCR4) Hs00976734_m1 
Endothelial Tyrosine Kinase (TEK). Hs00945146_m1 
Jagged 1 (JAG1) Hs01070036_m1 
N-cadherin (CDH2) Hs00983056_m1 
Notch-1 (NOTCH1) Hs01062014_m1 
Table 2.12 The primers used for individual TaqMan® assay qPCR all purchased from life 
technologies™. 
 
2.6.4.3 qPCR using custom designed Low density Array cards 
Two custom designed TaqMan® Array micro Fluidic or Low density Array (LDA) 
cards were designed to cover a broad range of genes of interest. The LDA card consists 
of 12-384 pre-loaded TaqMan® assays which enables the analysis of multiple samples 
(1-8) when loaded through the 8 fill reservoirs.  
 
The TaqMan® low density array cards were stored at 4°C. As the cards must reach 
room temperature before the experiment is started, they were removed from the fridge 
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at least 15 minutes before cDNA is added.  cDNA was prepared from isolated RNA as 
described in section 2.6.4.1.  30-1000 ng of cDNA sample is required per fill reservoir. 
cDNA samples were diluted in nuclease-free  water  to  make  up  a  volume  of  50  μl  of  a  
set concentration to be kept consistent between samples and replicates. This was mixed 
by  pipette  with  50  μl  of  TaqMan®  Universal  Master  Mix  before  adding  to  each  fill  port.   
 
The cards were centrifuged using a Sorvall® Centrifuge complete with Sorvall® 
Custom bucket and card holder for 331 x g for 1 minute, followed by a rest and repeat 
331 x g for 1 minute (Up ramp rate 9, down ramp rate 9). The cards were sealed using 
the TaqMan® Array Micro Fluidic Card Sealer to seal off the main fluid distribution 
channels. The cards were loaded on to the 7900HT Real-Time PCR system from 
Applied Biosystems with SDS software Standard Core 2.4.1 for analysis.  
 
2.7 Immuno-staining techniques 
 
2.7.1 Cytospinning method 
 
To perform Immunofluorescence on cells in culture, detached cell were cytospun onto 
slides. Cytospinning involves the adhesion of cells from suspensions onto a microscope 
slide by centrifugation. Following typsinisation, cell preparations were counted and 
1x106 cells per cell type were fixed in formalin for 10 minutes at room temperature. The 
cells were washed twice in PBS and separated into 1x105 cells/   100   μl   aliquots   per  
treatment (usually consisting of a no-treatment control, isotype control and antibody). 
This was added to a funnel attachment to a superfrost microscope slide (Thermo 
scientific) separated by a blotting paper and centrifuged, using the Shandon CytoSpin 
III  ,  for  5  minutes  at  ‘medium’  speed  with  ‘medium’  acceleration.   
 
The cells form a tight circle after cytospinning and can be encircled using a ImmEdge 
hydrophobic barrier pen (Vector Laboratories) to allowing immunostaining.  
 
2.7.2 Standard Immunofluorescence protocol 
 
After cytospinning the slides were transferred to an immunostaining tray and non-
specific binding of anti-bodies blocked in 10% goat serum in PBS for 1 hour at room 
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temperature. The cells were permeabilised by washing in PBS with 0.1% Tween (PBS-
T) twice for 5 minutes on a shaker. The slides were blotted dry and the appropriate 
volume of primary antibody or matched isotype control was added. The concentrations 
and volumes used for all antibodies utilised is shown in Table 2.12. The slides were 
incubated at 4°C overnight. The slides were washed 3 times in PBS-T. If no secondary 
was required the slides were mounted with VECTASHIELD Mounting Medium with 
DAPI onto coverslips for imaging. If a secondary antibody was required this was added 
to the slide after washing and incubated for 1 hour at room temperature. The slides were 
then washed twice in PBS-T and mounted with VECTASHIELD onto coverslips for 
imaging. 
 
Antibody Conc. Isotype Secondary Conc.  
Monoclonal mouse Anti-
human CXCR-4-
Phycoerythrin (R&D 
Systems®) 
1:50 Mouse IgG2A-
Phycoerythrin 
(R&D 
Systems®) 
n/a n/a 
Monoclonal mouse Anti-
human DKK1 (Abcam®) 
1:200 Mouse IgG2b 
(Abcam®) 
Goat Anti-mouse IgG 
(AlexaFluor® 488) 
H&L (Abcam®) 
1:200 
Monoclonal mouse Anti-
human FST (Abcam®) 
1:100 Mouse IgG2 
(Abcam®) 
Goat Anti-mouse IgG 
(AlexaFluor® 488) 
H&L (Abcam®) 
1:200 
Rabbit monoclonal anti-
Hif1α  (life  technologies™) 
1:200 Rabbit IgG (life 
technologies™) 
Goat Anti-rabbit  IgG 
(AlexaFluor® 488) (life 
technologies™)  
1:200 
Monoclonal mouse Anti-
human MMP3 (Abcam®) 
1:100 Mouse IgG2b 
(Abcam®) 
Goat Anti-mouse IgG 
(AlexaFluor® 488) 
H&L (Abcam®) 
1:200 
Table 2.12 Details of the antibodies and isotypes used for immunofluorescence. 
 
2.7.3 ImageJ analysis 
 
ImageJ software was used to quantitatively assess the intensity of fluorescent staining 
following immunofluorescent studies. ImageJ was used to analyses original TIFF 
images taken from the fluorescent microscope, which were stacked to produce tiles of 
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the individual channels (Phase contrast, DiD, DAPI and AlexaFluor 488 and/or 
Phycoeerythrin), which allowed the intensity of each channel to be assessed per cell. A 
cell was defined by the region of interest tool. All DiD positive cells per frame were 
analysed with an equal number of DiD negative cells analysed. A background reading 
was taken for each channel to be subtracted from the intensity value to ensure each 
image could be compared to the next. 
 
2.7.4 Immunohistochemistry 
 
The reagents and suppliers for immunohistochemistry are listed in Table 2.13. The 
method and Mouse monoclonal anti human CXCR4 antibody concentration were 
optimised by Jenny Down (Eaton et al., 2010). This concentration was also optimised 
by myself using the purchased test arrays. Primary human prostate cancer arrays were 
purchased from Biomax (PR752). Two test plates were also purchased from Biomax to 
test the staining protocol (T195b). 
 
Item Supplier Preparation 
Anti-mouse biotinylated 
IgG  
 
Vector Laboratories 
(Peterborough, UK) 
n/a 
10x Casein solution  
 
Vector Laboratories  n/a 
Elite ABC kit  
 
Vector laboratories  2 drops solution A to 5 ml 
PBS-T, mix and add 2 
drops solution B. Leave to 
stand for 30 mins  
 
Immpress DAB substrate  
 
Vector Laboratories To 1 ml Immpress diluent, 
add 1 drop DAB 
chromagen substrate 
 
3% Hydrogen Peroxide in 
methanol or water 
 
VWR International Ltd.  Add 6 ml of the supplied 
30% Hydrogen Peroxide 
solution to 200 ml 
Methanol  
Mouse monoclonal anti 
human CXCR4 (2µg/µl)  
 
 
R&D Mab 170 n/a 
Mouse IgG2A Isotype 
Control (Clone 20102) 
R&D Mab 003 n/a 
Normal horse serum Vector Laboratories n/a 
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PBS with 0.1% Tween 
 
Oxoid Ltd. (PBS tablets) 
Fisher Scientific (Tween® 
20) 
10X PBS tablets to 1 L 
distilled water with 1 ml 
Tween 
10mM Tri-sodium Citrate 
pH6  
 
Sigma Aldrich 4.41 g of sodium citrate to 
1.5 L distilled water and 
adjust to pH6 
Table 2.13 The reagents and suppliers for immunohistochemistry 
 
 
The sections were dewaxed and hydrated to 70% alcohol. These were then incubated 
with hydrogen peroxide solution for 15 minutes and washed in water followed by 
distilled water. Antigen retrieval was done by Pre-treatment (PT) module heating in 1.5 
L of 10mM Tri-sodium Citrate for 10 minutes at 80°C. The slides were washed for 5 
minutes in PBS-T. The slides were blocked in 10% casein with 2% normal horse serum 
in PBS-T for 20 minutes at room temperature. The slides were then blotted and 
incubated with the primary mouse monoclonal CXCR4 antibody or matched isotype 
(diluted 1:500 in 2% casein with 2% normal horse serum) overnight at 4°C.  
 
After incubation, the slides were washed twice in PBS-T for 10 minutes each wash. 
They were then incubated with Biotinylated anti mouse IgG 30 minutes at room 
temperature and then washed twice with PBS-T for 10 minutes.  The slides were 
incubated with ABC reagent for 30 minutes at room temperature. This was washed off, 
twice in PBS-T for 10 minutes per wash. The slides were incubated in Immpress DAB 
for 5 minutes at room temperature and washed in water for 5 minutes. The slides were 
counterstained with haematoxylin for 10-15 seconds and washed in water, dehydrated 
and mounted.  
 
2.7.5 Pathological analysis 
 
Pathological analysis of the immunohistochemical stain was conducted by Dr. Colby 
Eaton and Professor Simon Cross.  
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2.8 Miscellaneous techniques 
 
2.8.1 Mouse bone marrow flush to capture metastasising human cells after 
intracardiac injection 
 
1x105 DiD labelled PC-3NW1 cells were injected intracardiac into athymic nude mice 
by Dr Ning Wang and Anne Fowles. After 3 days the mice were culled and the hind 
legs of mice were dissected for flushing. Both the femurs and the tibias were cut at both 
ends to expose the bone marrow. A 23 gauge needle and 10 ml syringe were used to 
flush each bone with 10 ml PBS or until the bone marrow was fully clear (indicated by a 
complete loss of pink colour from the bone). This made up Fraction 1. Any bone 
aggregate was disturbed with the needle and the cell flush was centrifuged for 3 minutes 
at  1500  rpm.  The  supernatant  was  discarded  and   the  pellet  was  retained.  500  μl  of  1x  
red blood cell (RBC) lysis buffer (purchased as part of the Whole blood erythrocyte 
lysing kit from R&D) was used to re-suspended the cell pellet. The suspension was 
incubated at room temperature for 15 minutes and vortexed vigorously. The suspension 
was centrifuges for 3 minutes at 1500 rpm. The supernatant was discarded and the pellet 
was retained for re-suspension in 1 ml RBC wash buffer (purchased as part of the 
Whole blood erythrocyte lysing kit from R&D). After re-suspension the cells were 
washed a further two times with 1 ml RBC wash buffer. After the final wash the pellet 
was re-suspended  in  500  μl  of  10%  FBS  in  PBS  and  filtered  through  a  70  μm  pore  cell  
strainer.  
 
Fraction 2 was made from the remaining bone after flushing. The tibias and femurs 
were sliced into small fractions (1-2 mm in length) using a scalpel. The bone chips were 
then incubated in 2 ml Trypsin-EDTA for 10 minutes at 37°C, voretexing periodically. 
The Trypsin-EDTA   solution   was   then   filtered   through   a   70   μm   pore   cell   strainer   to  
remove the bone chips and the resulting cell suspension was centrifuges at 1500 rpm for 
3 minutes. The supernatant was discarded and the resulting cell pellet was re-suspended 
in  500  μl  of  10%  FBS  in  PBS  and  added  to  Fraction  1.  The  cells  were  then  analysed  and    
sorted, based of DiD retention, by FACS Aria.  
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prostate cancer cell lines and defining the 
presence of a dormant sub-population  
 
Chapter 3: Results 
79 
 
3.1 Introduction 
 
In our laboratory, Vybrant® DiD and CM-DiI were originally used as an addition to 
GFP and RFP transfected cells to track cells injected in vivo due to their high 
fluorescent intensity and ease of discriminating from auto fluorescence in tissues. When 
using the PC-3GFP cell line it was observed that over long periods of time, dye 
retaining cells persisted in the bone marrow of mice while other cells expanded and lost 
the CM-DiI fluorescent signal whilst retaining GFP (to make certain of their human 
origin). When using the PC-3NW1 cell line, Vybrant® DiD retaining cells have been 
identified in the bone marrow of mice up to 8 weeks after injection. Both Cm-DiI and 
Vybrant® DiD (referred to as DiD hereafter) are lipophilic cell membrane dyes that are 
split between daughter cells as the cell divides and therefore red/far-red fluorescent 
signal is lost upon multiple divisions. We proposed the hypothesis that dye retaining 
cells  are  mitotically  quiescent  or  ‘dormant’  and  studied  the  retention  of  dye  by  cells   in 
vitro to test the hypothesis that a dormant cell sub-population is present in prostate 
cancer cell lines. This is of particular significance since the clinical features of prostate 
cancer in patients are periods of latency that proceed skeletal metastases, implying 
dormant status where tumour cells are present but remain undetected.  
 
‘Dormancy’   can   be   defined   as   a period of inactivity or latency in growth and 
development. In a cellular sense, we define dormancy as the reversible arrest of the cell 
cycle at any stage through G0-M phase. This is to say that during dormancy the 
potential for activity or activation is not reduced. Therefore, it is important to 
distinguish dormancy from either quiescence (cells in G0) or senescence (irreversible 
cell cycle arrest).  
 
In  order  to  study  ‘dormancy’  in  more  detail  several  human  prostate  cancer  cell  lines  will  
be utilised. The cell line predominately used in these studies will be PC-3NW1, which 
is most commonly used in in vivo experiments in the research group in Sheffield. PC-
3NW1 has been engineered to express luciferase which can be used to detect cells after 
there have been injected into immunocompromised mice. After injection these cells will 
begin to form tumours which, when luciferin is injected intraperitoneal, will produce 
bioluminescence upon metabolization by the presence of high luciferase at the site of 
lesions. The luciferase gene was stably transfected into the PC-3 cell line by 
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electroporation and expressing cells were selected for by Geneticin resistance. This was 
done  ‘in  house’  by  Dr.  Ning  Wang  in  2011  and  named  PC-3NW1.  
 
This chapter tests the hypothesis that there is a dormant cell sub-population in human 
prostate cancer cell lines. Both the lipophilic cell membrane dyes Cm-DiI and 
Vybrant® DiD were used to detect dormant cells in otherwise rapidly dividing cell 
populations by fluorescent microscopy and flow cytometry technology. Due to the low 
cytotoxicity of these dyes we can trace cell dormancy over long periods of time and can 
use dye retention to isolate these cells for further study. These features make these dyes 
attractive candidates to investigate dormancy. 
 
In these experiments cells referred to as DiD negative (DiD-) identifies the bulk 
population of cells that divide normally and lose the dye in culture. We refer to dye 
retaining cells as dormant or Cm-DiI /DiD positive (DiD+) as they retain dye over long 
periods in culture due to a lack of division. These cells are not quiescent in the 
traditional sense and are not senescent. The characteristics we ascribe to dormancy are 
assessed in detail. 
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3.2 Chapter Aims, Hypothesis and Objectives 
 
3.2.1 Aims 
 
The aim of this study is to functionally characterise the growth of several human 
prostate cancer cell (PCa) lines and to explore the use of vital lipophilic membrane dyes 
to determine the presence of a dormant cell sub-population within them.  
 
To address these aims the following hypothesis will be tested. 
 
3.2.2 Hypothesis 
 
Human prostate cancer cell lines contain a dormant cell sub-population of dye retaining 
cells that persist amongst rapidly dividing cells. 
 
3.2.3 Objectives 
 
To test the above hypotheses the following objectives will determine whether:  
 
1. Vital lipophilic membrane dyes can be used to identify slow/non-dividing cells. 
2. Multiple human PCa cell lines contain a small sub-population of slow/non-
dividing cells. 
3. These cells are identified in cell cycle or in G0. 
4. Dye retaining cells exist in a dormant rather than senescent state 
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3.4 Results 
 
3.4.1 Characterisation of the growth of human prostate cancer cell lines in 
monolayer cell cultures 
 
In preliminary studies the basic growth characteristics of the PC-3 cell line and sub-
strains as well as the human PCa cell lines LNCaP and C42B4 were determined by the 
evaluation of growth over 12 days in serum concentrations routinely used in the 
laboratory to grow these cells (PC-3, PC-3RFP, PC-3GFP, 5%, PC-3NW1, LNCaP and 
C42B4, 10%). All growth curves were done as described in Methods 2.1.7. These 
growth curves were used to determine the time of onset and the duration of exponential 
growth for each cell line. This information was used to test the effects of different 
serum concentrations during mid-exponential growth, referred to as a serum titration 
study (Methods section 2.1.9). The half maximally effective serum concentration for the 
PC-3 cell line and sub-strains was calculated as the FBS concentration that stimulated a 
growth rate 50% of that produced by its maximally effective concentration. Growth 
curves were then done in the half maximally effective serum concentration (the half 
maximum) and in 1% serum. These growth curves were done to determine whether 
cells retained the ability to generate curves at these serum concentrations. The results 
were entered into Prism 6 for Mac OS X (GraphPad Software, Inc.). Cell number on the 
Y-axis represents the average number of cells per well vs. day on the X-axis. 
 
The standard (5% FBS) growth curve for the PC-3 cell line exhibited the classic 
sigmoidal growth characterisation, consisting of an early lag phase followed by an 
exponential and a final stationary phase as outlined in the ATCC® ANIMAL CELL 
CULTURE GUIDE tips and techniques for continuous cell lines. These stages were 
defined following these guidelines and outlined in Methods 2.1.8. The exponential 
growth stage for PC-3 cells begun at day 4 and ended at day 8 at all serum 
concentrations (Part A, Figure 3.1). Mid-exponential growth at day 6 was used as the 
appropriate time point to carry out serum titrations (Part B, Figure 3.1). The half 
maximum serum concentration was determined as 2%. The doubling time in 
exponential growth in 5% FBS was 28.55 hours, this increased to 30.79 in the half 
maximum and 31.50 hours in 1% FBS.  
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Figure 3.1 Characterisation of the growth of the PC-3 Parental cell line  
A. Growth curves for the PC-3 parental line in the routinely used 5% FBS in black. The half 
maximum growth curve in 2% FBS in red and a low serum growth curve (1% FBS) in blue. 
Days after seeding is presented on the X-axis and cell number (number of cells per well) on the 
Y-axis. The curve follows the classic sigmoidal growth trend. B. The graph shows the PC-3 
serum titration study showing cell number on the Y axis 6 days after seeding in varying 
percentages of FBS (X axis) in DMEM. For all experiments N = three biological repeats. The 
average cell number of 4 replicate wells is plotted for each repeat at each time point. Error bars 
represent the standard deviation.  
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It was important to determine the growth characterisation of the PC-3NW1 cell strain as 
this is the most commonly used in vivo by the group. This strain was transfected in 
house by Dr. Ning Wang with a luciferase gene to allow imaging by IVIS upon the 
addition of luciferin (see Introduction for more detail). In our experience the PC-3NW1 
line has a high tumourigenic potential in vivo and readily forms skeletal tumours 
(including in the long bones) following intra-cardiac injection into 
immunocompromised mice. Due to this PC-3NW1 will be investigated in the most 
detail in the following results chapters. 
 
 A classic sigmoidal growth curve was observed for the PC-3NW1 cell line. 
Exponential growth begun on day 4 and ended on day 8 at all serum concentrations used 
(Part A, Figure 3.2). The serum titration done on day 6 determined 2% as the half 
maximally effective serum concentration (Part B, Figure 3.2). The doubling time in 
exponential growth of the PC-3NW1 cell line in 10% serum was 27.25 hours, reducing 
to 33.72 hours at the half maximum and 31.08 hours in 1% FBS. 
 
The fluorescently labelled PC-3 sub-strains PC-3RFP and PC-3GFP were also used in 
subsequent experiments, so the growth of these cell strains in standard conditions and in 
response to varying serum concentrations was determined. The RFP variant was 
produced,  ‘in  house’,  by  Giancarlo  Pesce via a stable transfection of the RFP gene into 
the parental PC-3 cell line, originally from the ATCC. The GFP variant was produced 
by Dr. Neil Cross (Sheffield Hallam University).  
 
The doubling time of the PC-3RFP cell line was 31.36 hours in standard (5% FBS) 
media, 28.95 hours in the half maximum (calculated as 2% FBS by the serum titration 
Part B, Figure 3.3) and 31.58 hours in 1% serum (Part A, Figure 3.3). The PC-3GFP 
cell line had the slowest doubling time of the PC-3 sub-strains, 32.30 hours in standard 
5% serum, 31.41 hours at the half maximum (2%) serum concentration and 37.22 hours 
in 1% serum. Although the growth curve in 5% FBS was sigmoidal as expected, due to 
the low growth rate the curve in 2% is only weakly S-shaped and in 1% FBS the curve 
does  not  reach  a  clear  ‘plateau’  (Part A, Figure 3.4). Despite this doubling time in the 
‘exponential’   phase   was   calculated   between   day   4   and   day   8   for   consistency.      The  
serum titration showed that 2% remained the half maximum (Part B, Figure 3.4). 
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Figure 3.2 Characterisation of the growth of the PC-3NW1 cell line  
A. Growth curves for the PC-3NW1 cell line. The standard growth curve in 10% FBS in black. 
The half maximum growth curve in 2% FBS in red and a low serum growth curve (1% FBS) in 
blue. All curves follow the classic sigmoidal growth trend. B. The PC-3NW1 serum titration 
study presents the cell number (the number of cells/well) (Y axis) 6 days after seeding in 
varying percentages of FBS (X axis) in DMEM. For all growth curves and serum titrations N = 
three biological repeats. The average of 4 replicate wells is plotted for each repeat at each time 
point. Error bars represent standard deviation. 
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Figure 3.3 Characterisation of the growth of the PC-3RFP cell line 
 A. The growth curves of the PC-3RFP strain. The standard growth curve in 5% FBS in black, 
the half maximum growth curve in 2% FBS in red and a low serum growth curve (1% FBS) in 
blue. The curve follows the classic sigmoidal growth trend. B. The PC-RFP serum titration 
study presents the cell number (number of cells/well) (Y axis) at day 6 after seeding in varying 
percentages of FBS (X axis) in DMEM.  
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Figure 3.4 Characterisation of the growth of the PC-3GFP cell line 
A. The growth curves of the PC-3GFP strain. The standard growth curve in 5% FBS in black, 
the half maximum growth curve in 2% FBS in red and a low serum growth curve (1% FBS) in 
blue. B. The PC-3RFP serum titration study presents the cell number (number of cells/well) (Y 
axis) at day 6 after seeding in varying percentages of FBS (X axis) in DMEM.  
 
A standard growth curve in 10% FBS for LNCaP (Part A, Figure 3.5) and C42B4 
(Part B, Figure 3.5) as well as response to low serum (1% FBS) was also done. Neither 
the LNCaP or C42B4 cell lines exhibited the sigmoidal shaped growth curve seen in the 
PC-3 sub-strains. In standard media with 10% FBS they exhibited a clear exponential 
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phase starting at day 6 but did not reach a stationary phase within 12 days. Due to this, 
the doubling time in 10% and in 1% FBS was calculated between day 6 and day 12. 
Cell doubling time increased from 43.90 hours for LNCaP in 10% serum to 126.93 
hours in 1% FBS. Cell doubling for C42B4 increased from 54.33 hours in 10% FBS to 
146.18 hours in 1% FBS.  
 
 
Figure 3.5 Characterisation of the growth of the LNCaP and C42B4 cell lines 
 A. LNCaP standard growth curve in 10% FBS in black and in response to low serum (1% FBS) 
in blue. B. The C42B4 standard growth curve in 10% FBS in black and in response to low 
serum  (1%  FBS)  in  blue  Both  cell  lines  do  not  reach  a  stationary  phase  or  ‘plateau’  within  the  
time of the experiment. N = three biological repeats. The average of 4 replicate wells is plotted 
for each repeat at each time point. Error bars represent standard deviation. 
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3.4.2 Identification of dormant cell sub-populations in the PC-3NW1 cell line and 
other sub-strains 
 
Retention of lipophilic dyes DiD and Cm-DiI can be used as a marker of cell division or 
low levels of division in tumour cell populations. As discussed in the Introduction these 
fluorescent dyes become part of the cell membrane and divide amongst daughter cells 
on division so their fluorescent intensity per cell decreases as the cells proliferate. To 
investigate whether a dye retaining and therefore dormant sub-population was present in 
prostate cancer cell lines, 1x106  PC-3NW1 cells were prepared and stained as in 
Methods 2.2.1 and 2.2.2 and cultured for 21 days in standard 10% FBS DMEM + 
PenStrep. Analysis of dye retention by flow cytometry using a FACS Calibur flow 
cytometer took place following the procedure in Methods Table 2.6, at each time point 
(day 0, 3, 7, 10, 14 and 21) a single flask of cells was typsinised, neutralised with media 
and pelleted by centrifuge. The resulting pellet was re-suspended in PBS and 100,000 
events (each event being a single cell) were analysed for dye retention.  
 
The FACS Calibur uses Cell Quest software system which can be used to generate 
FACS data  plots  or  ‘dot  plots’  which  allowed  the  gating  of  the  CM-DiI or DiD positive 
population at each time point based on a negative control of unstained cells and a 
positive control of freshly stained cells on day 0 (DiD used as an example Parts B and 
C, Figure 3.6). At each time point the negative control was analysed prior to the sample 
to ensure the efficiency of the software and machinery this allowed the percentage of 
dye positive dormant cells within the population as a whole to be determined. A 
representative FACS plot at day 14 and the resulting statistics is shown (Part D Figure 
3.6). Three biological repeats were done and the data was entered into GraphPad Prism 
6. 
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Figure 3.6 Identification of a dye retaining population in PC-3NW1 cells by flow 
cytometry A. Illustration to show the principles of dye retention. Cells were stained 
with DiD or Cm-DiI which is incorporated into the cell. As the cell divides the dye is 
lost. A cell representing the non-dividing dormant sub-population is circled. B. 100,000 
unstained PC-3NW1 cells acts as a negative control. C. 100,000 PC-3NW1 stained with 
DiD acts as a positive control that sets the gate for dye retaining cells at later time 
points. D. A representative dot plot at day 14.  
 
At day 0 on average 96.8% and 97.7% of the population were positive for CM-DiI and 
DiD respectively, representing a successful stain (Part A, Figure 3.7). A steep drop 
occurred at day 7, and this decline continued with the dye retaining sub-population 
reducing steeply until at day 21, only 0.04% and 0.37% of the population remained 
CM-DiI and DiD positive, respectively. The X Geometric mean is an indicator of the 
intensity of the stain per cell in the gated positive region (Part B, Figure 3.7). No 
significant reduction in intensity occurred over the 21 day time period in the population 
that retained CM-DiI or DiD. The intensity of the DiD stain was significantly higher 
(Unpaired T-test, P value= <0.0001) than the CM-DiI stain overall. On this basis 
Vybrant® DiD was used to determine dormancy in future experiments. Each 
experiment was repeated three times. 
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Fluorescent images were taken of the DiD stained PC-3NW1 cell line, at each time 
point (days 0, 7 and 14 shown), using the Leica DMI4000 B Automated Inverted 
Microscope (Part C, Figure 3.7). Phase contrast images in grey were layered with a 
fluorescent image taken by the Y5 (far red) filter cube which excited the DiD at 644 nm.  
 
 
 
Figure 3.7 Determination of the dormant cell frequency in the PC-3NW1 cell line 
A. The bar graph shows the mean percentage of DiD positive cells (Y-axis) at each time point 
on the X-axis. The error bars show the standard deviation of the mean of three biological 
repeats. CM-DiI percentages in grey, DiD percentage in black. B. The bar chart shows the 
average dye intensity of a gated DiD positive cell population (Y axis) against time (X-axis). The 
average intensity of the DiD stain is significantly higher than that of CM-DiI (Unpaired T-test, 
PC-3NW1+CmDiI vs. PC-3NW1+DiD P=<0.0001). C. Representative fluorescent images taken 
of cultures of PC-3NW1 cells stained with DiD and maintained in 10% FBS DMEM on day 1 
(24 hours after staining), day 7 and day 14 (white arrows indicate the small percentage of dye 
retaining cells at day 14). 
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The presence/frequency of dormant, DiD positive, sub-populations were also 
determined for the PC-3 parental cell line and the sub-strains PC-3RFP and PC-3GFP. 
These cell lines were stained and cultured in 5% FBS DMEM + PenStrep for 21 days 
and analysed following the same procedure as that used for PC-3NW1. At day 21 the 
DiD positive fraction was identified as 0.07 for PC-3, 0.15 for PC-3RFP and 0.19 for 
PC-3GFP (Figure 3.8).  
 
Figure 3.8 Determination of the dormant 
cell frequency in the PC-3 and PC-
3RFP/GFP cell lines 
 A. The bar graph shows the mean 
percentage of DiD positive cells (Y-axis) at 
each time point on the X-axis in the PC-3 
cell line. The error bars show the standard 
deviation of the mean of three biological 
repeats. B. The bar graph shows the mean 
percentage of DiD positive cells (Y-axis) at 
each time point on the X-axis in the PC-
3RFP cell line. C. The bar graph shows the 
mean percentage of DiD positive cells (Y-
axis) at each time point on the X-axis in the 
PC-3GFP cell line. For all DiD staining 
experiments N = three biological repeats.   
                                                                                                       The error bars represent standard deviation. 
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3.4.3 Identification of dormant cell sub-populations in LNCaP and C42B4 cell lines 
 
The human PCa cell lines LNCaP and C42b4 were also analysed for the presence of a 
dormant sub-population. Cells were stained and cultured as outlined in Methods section 
2.2.2 The dormant cell fraction was evaluated for 21 days by FACS Calibur.  
3.4.3.1 A dormant cell sub-population was identified in the LNCaP cell line 
LNCaP is an androgen sensitive human prostate cancer cell line with weak 
tumourigenicity in vivo. The LNCaP cell line was stained with DiD (as in Methods 
2.2.2) and cultured for 21 days in vitro following the standard protocol to analyse dye 
retention outlined in Table 2.6. Although the growth rate is much lower than that of the 
PC-3 cell lines (the doubling time in 10%= 46.45 hours for LNCaP, 27.25 hours for PC-
3NW1), the same passage times were kept to reduce variables when comparing to the 
PC-3 cell line. 
 
The DiD positive cell fraction was 1.49% on day 14 and 0.06% on day 21 (Part A, 
Figure 3.9), a comparable result to PC-3NW1. Fluorescent images were also taken of 
the DiD stained LNCaP cell line, at each time point (days 0, 7 and 14 shown) using the 
Leica DMI4000 B Automated Inverted Microscope (Part B, Figure 3.9).  
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Figure 3.9 Determination of a dormant cell frequency in the LNCaP cell line  
A. The bar graph shows the mean percentage of DiD positive cells (Y-axis) at each time point 
on the X-axis in the LNCaP cell line. The error bars show the standard deviation of the mean of 
three biological repeats. B. Representative fluorescent images taken of cultures of LNCaP cells 
stained with DiD and maintained in 10% FBS DMEM on day 1 (24 hours after staining), day 7 
and day 14 (white arrows indicate the small percentage of dye retaining cells at day 14). 
 
3.4.3.2 A dormant cell sub-population was identified in the C42B4 cell line 
C42B4 is an androgen insensitive sub-strain of LNCaP that has a higher metastatic  
potential than its parental strain. The C42B4 cell line was stained with DiD (as in 
Methods 2.2.2) and cultured for 21 days in vitro and analysed at routine time points to 
track dye retention. Again despite the reduction in growth rate compared to the PC-3 
strains, (the doubling time in 10%= 49.31 hours for C42B4, 27.25 hours for PC-3NW1), 
the same passage times were kept to reduce variables when comparing to the PC-3 cell 
line. 
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The DiD positive cell fraction was 0.74% on day 14 and 0.02% on day 21. Fluorescent 
images were taken of the DiD stained C42B4 cell line, at each time point (days 0, 7 and 
14 shown) using the Leica DMI4000 B Automated Inverted Microscope (Figure 3.10). 
 
Figure 3.10 Determination of the dormant cell frequency in the C42B4 cell line 
A. The bar graph shows the mean percentage of DiD positive cells (Y-axis) at each time 
point on the X-axis in the C42B4 cell line. The error bars show the standard deviation of 
the mean of three biological repeats. B. Fluorescent images taken of cultures of C42B4 cells 
stained with DiD and maintained in 10% FBS DMEM on day 1 (24 hours after staining), day 7 
and day 14 (white arrows indicate the small percentage of dye retaining cells at day 14). 
 
3.4.4 Lipophilic dyes were retained in a high proportion of cells after growth arrest 
using Mitomycin C 
 
To test that DiD retention was a result of non-division of cells, PC-3NW1 cells were 
stained with DiD and growth arrested by Mitomycin C. FACS Calibur analysis and 
fluorescent microscopy showed that a high number of cells retained DiD as a result of 
mitotic suppression by Mitomycin C (Part A, Figure 3.11). In fact at day 21, 66.89% 
of cells remained DiD positive suggesting that dye retention is a valid marker of non-
dividing cells. The fluorescent image (Part B, Figure 3.11) shows the high proportion 
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of DiD positive cells. The cells are also bigger than usual, an indicator of protein 
accumulation due to growth arrest. The retention of CM-DiI was also assessed 
following Mitomycin C treatment and similar results were found (Part D, Figure 3.11). 
 
 
Figure 3.11 Dye retention following a growth arrest treatment 
A. A bar graph to show DiD retention over 21 days following growth arrest treatment with 
Mitomycin C. A high percentage of cells retain the DiD stain long term after Mitomycin C 
treatment (black bars) compared to untreated control stained cells (grey bars). The graph shows 
the mean percentage of DiD positive cells on the Y-axis at each time point on the X-axis. The 
error bars show the standard deviation of the mean of three biological repeats. B. A fluorescent 
image taken on the Leica DMI4000 B Automated Inverted Microscope at day 21. C. The dot 
plot shows the high number of cells that are DiD positive 21 days after staining with the growth 
arrest. D. CM-DiI is retained at high frequency after a growth arrest, compared to untreated 
CM-DiI stained cells.  
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3.4.5 The addition of DiD has no effect on PC-3NW1 growth rate or colony 
forming ability 
 
To determine if the addition of either CM-DiI or DiD had an effect on PC-3NW1 cell 
growth a growth curve following dye addition was done under standard conditions 
(10% FBS DMEM + PenStrep) (Part A, Figure 3.12). There was no significant change 
in growth with CM-DiI or DiD dye addition (one-way ANOVA P=0223). Any changes 
in the ability to form colonies in monolayer was tested by comparing the cloning 
efficiency of PC-3NW1 cells with and without the addition of DiD following Methods 
section 2.1.10 Briefly 1,000 cells were seeded per 60mm petri dish in quadruplet and 
cultured in 10% FBS DMEM + PenStrep for 14 days in a 37° 5% CO2 incubator. The 
colonies were stained with Giemsa and imaged using the BioCount Colony Counter. 
The number and size of colonies was then measured by the GeneTool software system. 
No significant difference in colony number was seen (Paired T-test P=0.217) (Part B, 
Figure 3.12). A representative comparison is shown in Part C, Figure 3.12. 
  
Chapter 3: Results 
98 
 
 
 
 
Figure 3.12 Dye addition does not affect the growth characteristics of the PC-3NW1 cell 
line 
A. Comparison growth curves of the unstained PC-3NW1 cell line (blue line), CM-DiI stained 
PC-3NW1 cells (red line) and the DiD stained cell line (black) shows no significant difference 
in growth upon either dye addition (one-way ANOVA P=0.223). B. Clonal growth in 
monolayer showed no significant change in cloning ability between control PC-3NW1 cells 
(black bar) and PC-3NW1 cells stained with DiD (grey bar) (Unpaired T-test, P=0.217). C. A 
representative comparison image of the Giemsa stained clone assays. PC-3NW1 on the left 
compared to PC-3NW1 cells with DiD on the right.  
 
3.4.6 Dormant cells were more resistant to the chemotherapeutic drug Doxorubicin 
 
Doxorubicin treatment was used to test whether dormancy could protect cells from a 
chemotherapeutic agent that targets dividing cells. At 14 days post-DiD staining, 
cultures of PC-3NW1 cells were seeded into a 6 well plate at a density of 1x105 /well in 
triplicate. Doxorubicin was administered every 48 hours for 14 days at concentrations 
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1μm,   100nm   and   10nm.  The   percentage   of  DiD   positive   and  DiD   negative   cells  was  
compared to an untreated control after 14 days of treatment. Plates were imaged every 
48  hours  by  fluorescent  microscopy.  1μm  of  Doxorubicin  appeared  to  be  the  optimum 
dose and is given as an example in Part A Figure 3.13.  
 
At the end time point of 14 days the numbers of DiD positive and DiD negative cells 
were counted. To work out the percentage survival of each group the numbers of cells 
in the no treatment control were counted and the percentage of DiD positive cells  
assessed by FACS Calibur. The average of 3 wells in 3 biological repeats was taken. 14 
days after set up there were 1.34 x106 cells per well in the no treatment control with a 
DiD positive fraction of 0.01% (equal to 134 cells/well). After 14 days of treatment 
with 1μm Doxorubicin there were on average 62.55 DiD positive cells per well, which 
shows a 46.47% survival rate. Only 96.33 DiD negative cells/well survived after 14 
days of 1μm Doxorubicin treatment  (0.007% survival rate) which was significantly 
lower than that of the DiD positive cells (Unpaired T-test, P= 0.0002) (Part B Figure 
3.13). This suggests that the DiD retaining dormant sub-population confers a resistance 
to traditional cancer treatments.  
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Figure 3.13 DiD positive dormant cells were more resistant to Doxorubicin treatment  
A. After 14 days of Doxorubicin treatment a higher percentage of DiD positive cells have 
survived (lower panels). The upper panel shows the no treatment control (white arrows indicate 
the presence of dye retaining cells at day 14). B. After counting and comparing to the no 
treatment control, the percentage survival of each cell type after treatment showed that a 
significantly higher percentage of DiD positive cell were resistant to Doxorubicin (Unpaired T-
Test, P= 0.0002) N= 3 biological repeats. 
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3.4.7 Assessment of the cell cycle status of the dormant cell sub-population 
 
The previously reported experiments confirmed that DiD and Cm-DiI could be used to 
identify non-dividing or slowly dividing cells (Mitomycin C experiments, see Figure 
3.11). FACS Calibur analysis showed that there is a dye retaining sub-population 
present in multiple prostate cancer cell lines. To assess the definition of these cells as 
dormant (as stated in the chapter introduction) an investigated their cell cycle status was 
peformed. 
3.4.7.1 Senescence assay 
The Senescence Detection Kit from Abcam® showed that the DiD positive dormant 
cells were not positive for senescence associated (SA) -beta-galactosidase activity and 
were therefore not senescent. SA-beta-galactosidase is active at pH 6.0 and is identified 
as a senescent marker based on the observation that senescent cells have higher 
endogenous levels of this enzyme activity in acidic conditions. Increased SA-beta-gal 
represents an accumulation of beta-galactosidase as opposed to being a unique enzyme 
marker of senescence. The kit was used to histochemically detect senescent cells by a 
positive blue stain for SA-beta-gal activity under pH 6.0. Active SA-beta-galactosidase  
hydrolyses the substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) to 
yield galactose and 5-bromo-4-chloro-3-hydroxyindole (visible as a blue stain). In this 
way cells that are senescent appear as blue stained cells.  
 
On day 14 after DiD staining 1x105 PC-3NW1 cells were seeded in triplicate into a 6 
well  plate.  The  cells  were  fixed  with  the  provided  ‘Fixative  solution’  and  were  stained 
overnight at 37°C with the prepared X-gal solution (Methods 2.5.4). A qualitative 
assessment of blue stain was done by fluorescent microscopy (to detect DiD) and colour 
camera microscopy. This experiment was repeated 3 times and visual assessment 
showed that DiD positive cells were not positive for SA-beta-Gal activity. A 
representative image at 10x magnification is shown in Figure 3.14. 
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Figure 3.14 Dormant cells were not senescent by assay for SA-beta-Gal activity  
A representative image (10x magnification) of the DiD far-red Y5 channel (top-left) and the 
colour camera image (lower-left) with the merged image. The senescence detection kit showed 
that at day 14 after DiD staining, DiD positive dormant cells were not positive for blue stain 
(indicated by arrow 2) although other cells were positive for the blue stain and considered to be 
senescent (arrow 1). 
 
3.4.7.2 KI-67 assay 
Ki-67 protein is present in the nucleus of cells at all active stages of the cell cycle (G1, 
S, G2 and M-phase) but absent from G0. It is therefore identified as a positive marker of 
cell proliferation.  
 
The Ki-67 status of DiD positive cells on day 14 after staining was determined by flow 
cytometry using BD FACS Calibur and  CellQuest™  software.  Cells  were  prepared  as  in  
Methods section 2.5.1 and 10,000 events (cells) were analysed for their Ki-67 status 
using an Anti-Human mouse monoclonal antibody to Ki-67 that is conjugated to 
AlexaFluor 488  (BD  Pharmingen™).  Gating  of the DiD positive population was based 
on a positive control (PC-3NW1 cells stained with DiD and immediately analysed. Part 
A, Figure 3.15). A negative control of untreated PC-3NW1 cells (not shown) and a 
matched isotype control were used to gate the KI-67 negative population (Part B, 
Figure 3.15). The upper left (UL) quadrant shows DiD positive cells which were not 
Ki-67 positive whereas the upper right (UR) shows the shift of DiD positive cells into 
Ki-67 positivity. The lower left (LL) quadrant shows DiD negative, rapidly diving cells 
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which were Ki-67 negative whereas the lower right (LR) quadrant represents cells that 
were DiD negative and KI-67 positive.  
 
10,000 PC-3NW1 cells were analysed 14 days after staining, a representative dot plot 
and the accompanying statistical output are shown in Part A, Figure 3.16. 90.18% of 
the DiD negative, rapidly dividing population were Ki-67 positive. This is significantly 
higher than the percentage of DiD positive cells that were KI-67 positive cells on day 14 
(61.07%) (Unpaired T-test, P=0.015). A significantly higher percentage of DiD+ cells 
were KI-67 negative on day 14 (38.92%) compared to DiD negative cells (9.80%) 
(Unpaired T-test, P=0.015). The bar chart represents the mean value from three 
biological repeats. The error bars represent standard deviation (Part B, Figure 3.16).  
 
 
 
Figure 3.15 Gating of the KI-67 positive population 
 A. A positive control of 10,000 DiD stained PC-3NW1 cells was used to set the DiD positive 
gate to determine the DiD positive fraction on day 14. B. An IgG isotype control was used to set 
the gate to determine cells that were positive for the Ki-67 antibody and therefore in a 
proliferative state.   
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Figure 3.16 The Ki-67 status of the DiD positive PC-3NW1 cells on day 14 
 A. A representative dot plot and the accompanying statistical output of a sample on day 14. B. 
The bar chart shows the Ki-67 status of DiD negative cell in grey and DiD positive cells in 
black. The bar represents the mean value of three biological repeats. The error bars represent 
standard deviation (Unpaired T-test, DiD+ Ki-67+ vs. DiD- Ki-67+ P=0.015) (Unpaired T-test 
DiD+ Ki-67- vs. DiD- Ki-67- P=0.015) 
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3.4.7.3 Qualitative assessment of KI-67 status in the dormant cell sub-population by 
immunofluorescence  
This result was qualitatively evaluated by immunofluorescence. PC-3NW1 cells stained 
with DiD were grown on a Permanox® microscope chamber slide for 14 days. At day 
14 after DiD staining the cells were fixed and stained with a AlexaFluor® 488 Mouse anti-
Human Ki-67 (BD  Pharmingen™) monoclonal antibody overnight at 4°C (Methods 2.5.2). 
A matched isotype and no treatment were also done to control for non-specific binding 
or auto-fluorescence. A representative image at 20 x magnification is shown in Figure 
3.17. The image shows DiD retaining cells were both Ki-67 positive and negative, 
reflecting the quantitative Flow cytometry result 
 
 
Figure 3.17 Immunofluorescence to detect Ki-67 status 
A fluorescent image taken at 40x magnification following immunofluorescent staining with an 
alexa 488 conjugated anti-human mouse monoclonal antibody to Ki-67 (Abcam). Ki-67 is 
present in the nucleus of dividing cells. The nucleus was counterstained with DAPI in blue (top 
left). The far-red Y5 channel detects DiD positive cells in red (top right). The N3 channel was 
used to detect the AlexaFluor 488 conjugated Ki-67 antibody in green (lower left). The merged 
image (lower right) shows an example of two DiD positive cells in the centre that were Ki-67 
negative (arrow 1) and Ki-67 positive (arrow 2).  
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3.4.7.4 P.I assay 
Propidium iodide (P.I) can be used to determine the DNA content of a cell, and so 
determine which stage of the cell cycle it is in, by intercalating with DNA bases and 
emitting a fluorescent signal when exited by a 535 nm laser. To gain more information 
about what stage of the cell cycle the DiD positive cells were in, flow cytometry 
analysis of Propidium iodide staining was used to evaluate cell DNA content in the DiD 
positive fraction at day 14 after staining.  
 
1x106 PC-3NW1 cells on day 14 after DiD staining were prepared and stained for P.I 
following Methods section 2.5.3. A negative control of unstained PC-3NW1 cells 
stained with P.I was used to establish the cell cycle profile (dot plot Part A, Figure 
3.18 and its corresponding cell cycle histogram Part B, Figure 3.18). PC-3NW1 cells 
stained with DiD and immediately processed were used to set the DiD positive gate and 
to ensure that dye addition would not affect the P.I fluorescent signal (Parts C and D, 
Figure 3.18). No change was observed with DiD addition. 
 
Figure 3.18 Setting the P.I gate 
 A. A dot plot of DiD negative PC-3NW1 cells. B. The cell cycle status of these cells 
determined by PI staining of DNA content. C. A dot plot of DiD positive PC-3NW1 cells. D. 
The cell cycle status of these cells show that dye addition has no affect on P.I staining. 
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These controls allowed the DiD positive fraction to be gated and analysed. The dot plot 
shows the expected percentage of DiD positive cells (1.52%) (Part A, Figure 3.19) and 
allowed the cell cycle status of the DiD negative cells to be assessed. 88.03% of the 
DiD negative cells were in G0/G1, 2.90% in S and 8.83% in G2/M (Part B). The DiD 
positive fractions showed that 51.56% of cells were in G0/G1, 10.43% in S and 38.01% 
in G2/M (Part C). There were significant differences between the DiD+/- cells in cell 
cycle distribution (Part B, Figure 3.19). 
 
 
 
Figure 3.19 P.I cell cycle staining of the DiD positive cell population 
 A. A representative dot plot showing the gating of the day 14 population. B. The bar chart 
shows the cell cycle status of the DiD negative (grey) and DiD positive (black) populations. N= 
three biological repeats. C. A representative histogram showing the cell cycle status of the DiD 
negative population on day 14. D. A representative histogram showing the cell cycle status of 
the DiD positive population on day 14. 
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3.5 Discussion 
 
The growth characteristics of the PC-3 cell line and sub-strains were evaluated in 
standard and ½ maximum growth conditions as well as low serum (1%). All the strains 
shared the classic sigmoidal (S-shaped) growth curve: a lag phase, followed by steep 
exponential growth  and,  finally,  a  ‘plateau’  as  growth  rates  decline.  The  differences  in  
doubling time were unlikely to be a result of experimental error as each of the growth 
curves were repeated three times and are more likely to reflect inherent differences in 
the cell strains. It is sometimes expected that cells that have undergone a transfection 
may have a reduced growth rate, due to toxicity of the transfection reagent, compared to 
the parental cell line (in this case PC-3). However, the difference between PC-3 and its 
sub-strains is minimal (PC-3=27.25 hours, PC-3RFP=31.36, PC-3GFP=32.30). The PC-
3NW1 strain was routinely grown in 10% FBS and had the fastest doubling time overall 
(27.25 hours) in this media but this increase could be due to the higher serum 
concentration (10% FBS vs. 5% FBS for PC-3). It is interesting to note that each cell 
line reached its ½ maximum at 2% FBS, despite the difference in the original or 
‘standard’  growth  conditions  (10%  FBS  DMEM  for  PC-3NW1; 5% FBS for PC-3 and 
PC-3RFP/GFP).  
 
All growth curves were performed in quadruplet in a minimum of three biological 
repeats. Each repeat was performed within three passages of each other which explains 
the overall consistent growth rate with only slight variation between repeats. These 
growth curves highlighted differences in the three prostate cancer cell lines that will be 
used in subsequent experimental chapters: PC-3NW1, LNCaP and C42B4. Although 
there is little evidence that doubling time correlates with tumourigenicity (Stiles et al., 
1976), in this case PC-3NW1 with the lowest doubling time is the most tumourigenic in 
the  in vivo models used by the Sheffield group. However, the opposite trend is seen in 
C42B4 and LNCaP as it was expected C42B4 to have a faster doubling time than its 
less metastatic parent strain. Establishing these growth curves early on has led to a 
greater   understanding   of  what   is   ‘normal’   growth   for   each   strain.   This   allows   effects  
such as reducing the serum concentration or lipophilic dye addition to be compared to 
an established baseline.  
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The addition of CM-DiI or DiD had no significant impact on growth compared to the 
unstained PC-3-NW1 cell line (one-way ANOVA P=0.223). No difference in the 
cloning ability of stained and unstained cells was seen, therefore the use of CM-DiI and 
DiD in subsequent experiments could be carried out with an assurance that the basic 
characteristics of the cell line was not affected by dye addition.  
 
3.5.1 Identification of a dormant cell sub-population 
 
The identification of a dormant cell sub-population within the rapidly dividing PC-3 cell 
line and sub-strains is a novel finding but others have recently reported similar results to 
mine in this context (Yumoto et al., 2014). The population doubling time of PC-3-NW1 
cells, even with the addition of CM-DiI or DiD, in culture is <28 hours in 10% FBS 
Part A, Figure 3.13. This is comparatively fast growth for a mammalian cell line and 
suggests that all cells should be rapidly growing. The presence of a low frequency of 
cells that maintain mitotic quiescence in culture, despite signals from cells dividing 
around them, is interesting. These cells represent an attractive candidate for further 
study as a divergent sub-population.  
 
In standard culture conditions (10% FBS DMEM) the frequency of CM-DiI retaining 
dormant cells was 0.04% on day 21. The high X Geometric mean value at day 21 
suggests that these cells are unlikely to have undertaken even a single division as some 
loss in CM-DiI intensity is expected as the cells are cultured over time. Part B, Figure 
3.7 shows that there is a small but not significant difference in the X Geo Mean between 
day 0 and day 21. This could be because CM-DiI is sensitive to bleaching by UV light; 
culturing flasks wrapped in foil would allow a greater degree of control for this variable.  
 
A higher percentage of dormant cells were detected with the use of DiD (day 14 1.61%, 
day 21 0.37%). This is most likely due to the greater intensity of the dye both upon 
staining and over time compare to CM-DiI (Part B, Figure 3.7). This is reflected at the 
level of fluorescent microscopy making DiD a more desirable dye to use in subsequent 
experiments.  
 
It is unclear why a sudden drop in dormant cell frequency and X Geo Mean occurs 
between day 3 and day 7. This could be due, however, to an extended lag phase after 
staining in which the cells are recovering from the process. Growth and divisions then 
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pick up and the dye is rapidly lost as the population expands. Evidence for this was seen 
when the growth curves of PC-3-NW1 with and without the addition of CM-DiI/DiD 
was compared. At first the growth of PC-3-NW1 with dye addition fell behind that of 
cells without the dye. The curve then sharply increased and coincided with that of the 
PC-3-NW1 cells without dye addition. It is also possible that the sensitivity of the 
FACS calibur machine may be insufficient at high levels of DiD loading of cells to 
detect only a small amount of dye reduction as result of cell division immediately after 
DiD  staining  i.e.  the  FACS  detection  is  ‘saturated’  at  high  dye  levels  on  cells  and DiD 
levels need to fall before differences can be identified.  
 
3.5.2 Dormancy in multiple cell lines 
 
My studies showed that the dormant cell sub-population was present in multiple PC-3 
sub-strains including the parental PC-3 cell line itself. This might be expected for 
variants of the same strain with roughly the same growth characteristics. The discovery 
of a dormant sub-population in two separate prostate cancer cell lines (LNCaP and 
C42B4) was an interesting result.  
 
The consistent percentage of the dormant sub-populations present when different cell 
lines are cultured in the same conditions, suggests that dormancy may be a result of 
factors in the culture environment. The effects of the environment on dormancy will be 
explored in subsequent results chapters. It remains possible that this is an intrinsic 
population in prostate cancer, since the low numbers of these cells, fits with the 
paradigm of a cancer stem cell-like sub-population (Collins et al., 2005). The notion 
that cells exist within a tumour that are stem cell like in nature, and solely responsible 
for the initiation and maintenance of the cancer, remains a controversial hypothesis (see 
Introduction). Indeed, recent research has indicated the presence of a cancer stem cell 
(CSC) sub-population in prostate cancer, with a unique expression signature (Collins et 
al., 2005). The presence of this signature in the dormant sub-population will be explored 
in the third results chapter.  
 
3.5.3 Resistance to Doxorubicin 
 
It is perhaps not surprising that the dormant cell sub-population was insensitive to 
Doxorubicin as, like many chemotherapeutics, it targets rapidly dividing cells. This 
effect was illustrated in vivo by Naumov et al., 2003, who showed that Doxorubicin was 
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ineffective in targeting single dormant cells in vivo and could not prevent the 
subsequent ability of these cells to form metastases (Naumov et al., 2003). Whether the 
DiD retaining cells can form colonies after Doxorubicin treatment is an import factor to 
consider and will be tested in the following results chapter.  
 
3.5.4 Cell cycle status 
 
It was important to determine that DiD retaining cells represented a sub-population of 
dormant and not senescent cells which was shown using the Senescent detection kit 
from Abcam. Qualitative image analysis found that DiD positive dormant cells at day 
14 were not senescent as they did not positively stain for SA-beta-galactosidase at pH 
6.0. Although the specificity of SA-beta-galactosidase in senescent cells has been 
debated, it is still the most widely used tool to assess cellular senescence. Lee et al. 
(2006), hypothesise that SA-beta-galactosidase activity at pH 6.0 is due to an increase in 
lysosomal beta-galactosidase. As it has been hypothesised that lysomsomal size and 
content increases in ageing cells, this could account for the increase in activity at sub-
optimal pH (pH 6.0) that is seen in senescent cells. The negative staining result seen 
with the Senescent detection kit supported the hypothesis that the dormant sub-
population was not senescent. It was therefore important to look at the cell cycle profile 
of this sub-population in more detail. 
The results of the Ki-67 status experiments showed that the dye retaining cells did exist 
in a Ki-67 positive state. However the percentages of cells that were Ki-67 negative and 
dye retaining was significantly higher (P=0.015) than cells that have lost the dye after 
14 days in culture. Despite this, over 50% of DiD positive cells were positive for Ki-67 
despite retaining DiD which has been confirmed in previous experiments to be retained 
after growth arrest (Figure 3.3.11) Although this seems counter intuitive it could be that 
these cells are suspended in a prolonged G1 stage in which they will appear Ki-67 
positive but will not progress past this stage for an extended period of time. This is a 
concept  that  was  explored  in  ‘The Ki-67  Protein:  From  the  Known  and  the  Unknown’  
(Scholzen and Gerdes, 2000). This review explores the difficulty of defining the non-
proliferative state and that cells can exist in a range of intermitotic times in which 
quiescent cells can be Ki-67 positive. 
Indeed although Ki-67 is an established marker of proliferating cells van Oijen et al. 
showed that, by using synchronizing inhibitors to arrest cells, osteosarcoma cells were 
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positive for Ki-67 even when arrested in G1/S or G2/M (van Oijen et al., 1998). This 
result seems in agreement to my own and could also explain the variation in cell cycle 
stage when using Propidium iodide.  
Propidium iodide was used to evaluate cell DNA content to gain more information 
about what stage of the cell cycle dye retaining cells are in. This experiment showed 
that dormant dye-retaining cells could exist in all stages of the cell cycle from G0/G1 
through S phase to G2/M. The cell cycle profile of the DiD negative fraction showed a 
high percentage of cells in the G1/G0 compartment which could be due to sub-optimal 
culture conditions at the cells reach maximum confluence at day 14. However, as the 
use of PI cannot differentiate between cells in G0 between cells in G1, based on DNA 
content, it is not possible to distinguish cells in G0 from those on the brink of division. 
An interesting set of experiments could look at whether the variation in DNA content in 
the dormant sub-population is due to variation in ploidy, which may reveal differences 
at the chromosomal level using karyotype analysis. Changes in karyotype number may 
give clues as to the origin of dormant cells. Spontaneous fusion in prostate cancer cell 
lines has been hypothesised to be a source of heterogeneity in tumours (Pesce et al., 
2011). Cell fusion may account for the delay in growth as the cell reorganises after 
fusion however this would need to be shown at the karotype and perhaps microscopy 
level before being considered as a hypothesis. 
  
3.5.5 Conclusion 
 
In conclusion a dormant cell sub-population has been identified in three human prostate 
cancer cell lines. These cells were slow-cycling and dye retaining. They were KI-67 
positive and negative and Propidium iodide staining showed these cells to be in all 
stages of the cell cycle. Cells following a growth arrest with Mitomycin C retained CM-
DiI and DiD at high frequency supporting the use of these dyes as markers of slowly 
dividing cells. The senescence detection kit showed that DiD positive cells at day 14 do 
not  stain  for  β-galactosidase suggesting they may retain the ability to divide and form 
colonies. 
 
An important factor to consider is whether dormancy is reversible and to consider in 
more detail how the culture environment affects dormancy. The following results 
chapter investigates the effects of altering the culture environment on the frequency of 
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the dormant phenotype including how serum and seeding density can change the 
frequency of dye retaining cells. It is important to investigate the mechanisms 
underpinning entry/exit of cells from dormancy. This will be the subject of the next 
chapter. 
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Chapter 4: Investigating dormancy in 
prostate cancer cell lines: exploring 
conditions that affect entry and exit into this 
state in vitro  
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4.1 Introduction 
 
As discussed in the previous results chapter there can be a prolonged period of disease 
‘dormancy’   between   initial   diagnosis,   treatment   and   potential   remission   to   the  
presentation of skeletal metastases. This is extensively reviewed in Ruppender et al. 
2013, which makes the important distinction between micrometastastic, angiogenic and 
conditional dormancy. Micrometastastic dormancy refers to groups of disseminated 
tumour cells that lack the proliferative over apoptotic potential to form a growing lesion 
i.e. the rate of proliferation is equal to the rate of cell death, whereas, angiogenic 
dormancy refers to a group of tumour cells forming a microscopic lesion  (often <1mm 
in size) that cannot proliferate further without a blood supply. These cells are held in a 
dormant state as they lack a supply of oxygen and nutrients that would be provided by 
the angiogenic network. Conditional dormancy, on the other hand, involves single cells 
or very low numbers of cells that are held in a dormant state due to lack of cues from 
the environment to begin cell division (Ruppender et al., 2013). It is also important to 
make the distinction between tumour and metastatic dormancy; this concept is discussed 
in a recent review by Giancotti (2013). Tumour dormancy refers to the initial lag in 
growth of the primary tumour, during tumour initiation where cells sequentially acquire 
additional  mutations to over rule apoptotic signalling and evade host immunity. In 
addition, the level of neoangiogenesis is also important, as the tumour reaches a critical 
mass it remains dormant until spouting a vascular network.  Metastatic dormancy, on 
the other hand, refers to the prolonged phase of cell cycle arrest which can occur as 
disseminated tumour cells adapt to their new environment. In our own studies there is 
evidence that disseminated cells are present as single cells for prolonged periods of time 
in potential metastatic sites (as shown by DiD retention in cells in the bone marrow up 
to 8 weeks after injection) and in other groups (Goodison et al., 2003).  
The previous results chapter identified DiD dye retaining cells in three prostate cancer 
cell lines after long term culture in vitro. The dye retaining cells were by definition non-
dividing or at least dividing very slowly over a prolonged period of time (14-21 days). 
Recent studies in our research group have found that this dormant cell sub-population in 
vitro i.e., PC-3NW1 cells that have retained DiD for 14 days after staining, were more 
metastatic in vivo than PC-3NW1 cells that were DiD negative after 14 days. After 
isolated by FACS Aria, 5x103 DiD positive (dormant) cells were injected intracardiac 
Chapter 4: Results 
116 
 
into athymic mice and the presence of lesions in the bone, as measured by IVIS 
imaging, was compared to 5x103 injected DiD negative (rapidly dividing) cells. We 
found that the DiD positive cells formed more skeletal tumours and specifically more 
long bone tumours than their DiD negative counterparts. This is particularly interesting 
as long bone tumours more accurately epitomize the disease in human patients. This 
result suggests that cellular dormancy confers an as yet unknown colonising or survival 
advantage that results in a greater bone metastatic ability. Dye retention will be used as 
a model to study dormant (or DiD+) cells in order to investigate the factors that 
modulate this state.  
 
Little is know about the mechanisms that hold prostate cancer cells in a dormant state in 
the bone metastatic niche. It has been suggested that prostate cancer cells can express 
markers of haematopoietic stem cells (HSC) in order to hijack the HSC niche and gain 
‘footholds’   in   the   bone   marrow   (Shiozawa et al., 2011b) until receiving, as yet 
unknown, signals to divide. Shiozawa et al. 2011, presented data that suggested prostate 
cancer cells utilise CXCR4 to gain entry into the HSC niche. CXCR4 is a chemokine 
receptor for CXCL12 that is highly expressed in HSCs. This group showed that 
disrupting this interaction by AMD3100 led to a reduction of these cells in the bone 
marrow. Although the HSC niche is hypothesised to be a site of DTCs seeding it is not 
yet know how it may play a role in the mechanisms of dormancy. The expression of 
HSC markers by the dormant cell sub-population, previously identified, will be 
explored in Chapter 5. 
 
There is a clear need to develop methods to study dormancy in vitro but due to the small 
number of dormant cells found in vivo it is difficult to isolate and culture these cells in 
order to investigate their phenotype. Indeed in the book Tumor Dormancy, Quiescence, 
and Senescence, Volume 1: Aging, Cancer, and Non cancer Pathologies, it states that 
due to the importance of dormancy in cancer and the difficulty of obtaining cells from 
in vivo models  “The  development  of  cell  culture  models  of  dormancy  is  therefore  highly  
needed  to  facilitate  the  investigation  of  the  mechanisms  underlying  the  dormant  state”  
(Hayat, 2013).  
 
Our in vivo studies also suggested that early colonising cells in metastatic sites (after 
DiD staining and intracardiac injection) were mitotically dormant as measured by long 
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term DiD retention by multiphoton imaging. This situation is similar to that encountered 
by cells seeded at clonal density where growth is often slow and some cells never form 
colonies. Due to the difficulties of investigating dormancy in vivo, cells held in a 
dormant state by cell culture conditions (dye retention over 14 days and in colony 
assays) was used as a model for dormancy and the factors that control this.  
 
The studies in this chapter will focus on investigating cellular dormancy in vitro using 
the PC-3NW1 cell line, a prostate cancer cell line that was original isolated from the 
bone environment from a skeletal tumour. The conditions that affect clonal growth in 
monolayer and whether dormancy in these conditions is reversible will be assessed. 
Whether the DiD retaining dormant sub-population is regulated by the culture 
environment i.e. is not an intrinsic stem cell like population, and whether dormancy in 
this sub-population can be manipulated will also be assessed. This chapter aims to 
investigate dormancy in a broad sense focussing on dormancy at the cellular level, as 
opposed to tumour or metastatic dormancy. These studies were designed to coincide 
with in vivo experiments in our research group but also aimed to increase understanding 
of how cell lines behave in terms of cell division and the basis of growth arrest.  
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4.2 Chapter Aims, Hypothesis and Objectives 
 
4.2.1 Aims 
The aim of this study is to explore the culture conditions that affect cellular dormancy 
and assess whether dormancy is an intrinsic characteristic or whether this sub-
population emerges under permissive conditions. 
 
To address these aims the following hypothesis will be tested 
 
4.2.2 Hypothesis  
The dormant sub-population is not intrinsic to prostate cancer lines but is induced by 
culture conditions and can re-emerge or disappear under environmental influence.  
 
4.2.3 Objectives 
To test the above hypothesis the following objectives will determine whether:  
 
7. Conditions in culture can affect cellular growth in monolayer clone assays. 
8. Cells held in a dormant state can be stimulated to form colonies. 
9. The dormant phenotype (as defined by DiD dye retention after 14 days in culture) 
can re-emerge in rapidly diving populations. 
10. Culture conditions such as serum concentration and seeding density can affect the 
frequency of the DiD retaining dormant sub-population. 
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4.3 Results 
 
4.3.1 Conditions that affect cellular growth in monolayer clone assays 
 
4.3.1.1 The effects of serum on colony growth 
In these studies cloning ability at low density in monolayer was tested. This tests the 
ability of cells to survive in relative isolation and to form colonies, characteristics 
required by tumour cells that survive in low numbers in metastatic sites. To assess if the 
concentration of FBS could affect clonal growth in standard clone assays in monolayer 
(Methods 2.1.11), PC-3NW1 cells were stained with DiD and seeded at clonal density 
(1x103 cells) into 60mm petri-dishes in quadruplet. Each quadruplet was seeded into 6 
ml of either 10%, 2% or 1% FBS in DMEM+ antibiotics (1% concentration penicillin-
streptomycin: PenStrep). After incubation for 14 days colonies were fixed, stained and 
counted as outlined in Methods 2.1.11. The number of colonies formed in 10% FBS 
was significantly higher than in 2% FBS (Unpaired T-test, P=0.0025). No colony 
formation was found in 1% FBS (Figure 4.1). Each experiment was repeated 3 times. 
 
 
Figure 4.1 The effects of serum on colony growth  
A. The bar graph shows significantly more colonies were formed in 10% FBS media compared 
to 2% FBS media (Unpaired T-test, P=0.0025). No colonies were formed in 1% FBS media. B. 
A representative image of colonies formed in 10% FBS media (top) after fixing and staining 
with Giemsa shows more colonies (seen as purple circles) than in the lower image of colonies in 
2% FBS media. N= 4 petri-dishes/ media type in 3 biological repeats.  
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These cells did not form colonies in 1% FBS but by using DiD dye, the number of 
single cells that had not divided, and therefore retained the dye, could be counted by 
fluorescent microscopy (Figure 4.2). On average 87.77 cells were present after seeding 
in 1% serum at day 14. This suggests that although these cells do not have the potential 
to form colonies at low serum when seeded at clonal density, a fraction can survive and 
be held in a dormant state for up to 14 days. The potential of these cells, held in an 
apparently dormant state, to be stimulated to divide will be presented in results section 
4.3.3.1. 
 
 
Figure 4.2 DiD positive single cells were present in colony assays at low serum 
The bar graph shows that in 10% FBS serum there were no DiD retaining single cells. A small 
number of DiD retaining single cells were counted in 2% FBS media and a high number of 
single cells were found in 1% FBS. N= 4 petri-dishes/ media type in 3 biological repeats. 
 
It was found in the previous results chapter that cell growth can occur at low serum 
conditions when cells are seeded in 10% FBS and transferred to lower serum after 48 
hours (as in the serum titration experiments Figure 3.3), To test whether cells were 
intrinsically unable to grow in 1% serum at clonal density, the above experiments were 
repeated seeding 1,000 PC-3NW1 cells into 6 mL 10% FBS DMEM and, after washing 
with PBS, transferred into 6 mL of either 2% (10-2%) or 1% (10-1%) FBS DMEM after 
48 hours. A significantly higher number of colonies was formed after transfer into 1% 
serum compared to 2% serum (Unpaired T-test, P= 0.0001) (Figure 4.3). 
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Figure 4.3 PC-3NW1 cells can form colonies after transfer from 10% FBS to 1% FBS 
media 
A. The bar graph shows that after initial seeding in 10% FBS cells retain the ability to form 
colonies after transfer into low serum. A significantly higher number of colonies were formed 
after transfer from 10% to 1% serum than after transfer from 10% to 2% FBS in colony assays 
(Unpaired T-test, P= 0.001). B. A representative image after fixing and staining with Giemsa of 
colonies formed after transfer into 2% FBS media (top) shows fewer colonies (seen as purple 
circles) than in the lower image of colonies in 1% FBS media. N= 4 petri-dishes/ media type in 
3 biological repeats.  
4.3.1.2 The effects of seeding density on colony growth 
The previous results chapter also showed that PC-3NW1 cells could grow in growth 
curve experiments when directly seeded into 1% serum when seeded at a density of 
10,000 cells per well in a 12 well plate (approximately 2,631 cell/cm2). Therefore, to 
determine whether PC-3NW1 cells could ever form colonies when seeded directly into 
1% serum the seeding density for colony assays was increased up to about half of this 
value (32x103 cells/60mm petri dish is equal to approximately 1,132 cell/cm2). 1x103, 
2x103, 4x103, 8x103, 16x103 and 32x103 PC-3NW1 cells were seeded per 60mm petri 
dish in 6 mL of 1% FBS media and cultured undisturbed for 14 days. Colony formation 
was then assessed as above. 
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At a seeding density of 32x103 cells/60mm petri dish it was not possible to discern 
colonies by Giemsa staining as the dish had been filled to 100% confluence. Below this 
amount, the number of colonies increased with seeding density increase (as expected). 
Interestingly, increasing the seeding density to only double the number that did not form 
colonies (1,000 to 2,000 cells) allowed colony formation in 1% FBS. As in previous 
experiments, no colonies were detected when cells were seeded at clonal density in 1% 
FBS (Figure 4.4). 
 
 
 
 
Figure 4.4 Increasing the seeding density of colony assays in 1% FBS media allows colony 
formation 
A. 100% confluence was seen when 32x103 were seeded in 1% FBS. As the seeding density 
increased the number of colonies increased (as expected). PC-3NW1 cells could form colonies 
in 1% FBS when clonal density was doubled to 2x103 cells/dish. B. A representative image of 
fixed and stained colonies present when 2x103 were seeded in 1% FBS media showing the small 
number of colonies that were present after 14 days in culture. N= 4 petri-dishes/ seeding density 
in 3 biological repeats.  
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4.3.2 The effects of serum and seeding density on LNCaP and C42B4 colony 
growth 
4.3.2.1 The LNCaP cell line did not readily form colonies in monolayer assays 
The LNCaP cell line formed very few colonies in colony assays in monolayer in either 
10% or 2% FBS, no colonies were formed in 1% FBS media (Part A, Figure 4.5). As 
before, the cells were stained with DiD before seeding so that the number of single cells 
on day 14 could be determined. A much lower number of single cells was present in 1% 
FBS than in the PC-3NW1 cell line but a higher number of single cells were detected in 
2% FBS in the LNCaP compared to the PC-3NW1 cell line. Unlike the results in 10% 
FBS for the PC3-NW1 cell line, there were single cells in 10% FBS in LNCaP (Part B, 
Figure 4.5). These results suggest that LNCaP cells were held in a dormant state in 
colony assays regardless of the serum concentration and they have very limited cloning 
ability and do not survive well in 1% FBS at clonal density.  
 
To test whether LNCaP cells could form colonies in 1% FBS at higher seeding 
densities, the experiments in 4.4.1.2 were repeated with the LNCaP cell line. At higher 
seeding densities in 1% FBS the LNCaP cell line grew as a monolayer, filling the dish 
at increasing confluence as seeding density increased, represented by a percentage 
confluence on the graph in Figure 4.5. Discernible colonies were only detected, and at a 
small number, when 4x103 cells were seeded. No colonies were detected when 2x103 
cells were seeded/ dish (Part C, Figure 4.5). 
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Figure 4.5 The colony forming ability of the LNCaP cell line in monolayer 
A. The LNCaP cell line produced very few colonies in 10% or 2% FBS media when seeded at 
clonal density. No colonies were detected in 1% FBS media. B. A much lower number of DiD 
positive single cell were detected at any serum concentration than in the PC-3NW1 cell line. 
Single cells were present in 10% FBS media. C. In colony assays in 1%, LNCaP cells formed 
monolayer cultures, with varying coverage of the petri dish (represented as a percentage). When 
4x103 cells were seeded a small number (<10) of colonies were detected. N= 4 petri-dishes/ 
media type or seeding density in 3 biological repeats.   
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4.3.2.2 The C42B4 cell line has an increased ability to form colonies in monolayer than 
its parental strain 
The C42B4 cell line also formed very few colonies in either 10% or 2% FBS media. 
C42B4 did produce colonies in 1% FBS media when seeded at clonal density (1x105 
cells/dish). However, this was only a result of two colonies being found in a single dish 
in one repeat. (Part A, Figure 4.6). The numbers of DiD positive single cells were 
counted after 14 days and similar results to the LNCaP cell line were found. Fewer cells 
survived as single cells overall, compared to the PC3-NW1 cell line, and there was a 
higher number in 10% FBS media than in the PC-3NW1 cell line (Part B, Figure 4.6). 
These results suggest that, like the LNCaP cell line, C42B4 cells have limited cloning 
ability and do not survive well in 1% FBS at clonal density.  
 
To test whether seeding density could affect colony formation in 1% in the C42B4 cell 
line the experiments in section 4.4.1.2 were done with the C42B4 cell line. It was 
interesting to find that at higher seeding densities in 1% FBS, the C42B4 cell line 
produced a high number of colonies, when the seeding density exceeded 4x103 
cells/dish, in similar numbers to the PC-3NW1 cell line. However, no colonies were 
formed when 2x103 cells were seeded/ dish (Part C, Figure 4.6). 
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Figure 4.6 The colony forming ability of the C42B4 cell line in monolayer 
A. C42B4 cells produced very few colonies in 10% or 2% FBS media when seeded at clonal 
density. Only 2 colonies were detected in 1% FBS media in a single dish. B. A much lower 
number of DiD positive single cell were detected at any serum concentration than in the PC-
3NW1 cell line. Single cells were present in 10% FBS media. C.  In  1%  FBS C42B4  cells  
readily  formed  colonies to a similar  number  as  those  formed  in  the  PC-3NW1 cell line. N= 
4 petri-dishes/ media type   or seeding density in 3 biological repeats.  
Chapter 4: Results 
127 
 
4.3.3 Cells held in a dormant state can be stimulated to form colonies 
4.3.3.1 Cells seeded at clonal density (1,000 cells/60mm petri-dish) in 1% FBS can be 
stimulated to form colonies 
To assess if cells that have been held in a dormant state in clone assays for 14 days 
when seeded at clonal density in 1% FBS, retain the ability to form colonies, 1,000 PC-
3NW1 cells were cultured in colony assays for 14 days in 1% FBS media then 
transferred into 2% or 10% FBS media or 1% FBS conditioned media (Methods 2.1.12). 
To make conditioned media, 3.5x105  PC-3NW1 cells were seeded into three T175 
tissue culture flasks (approximately equivalent to 2,631 cell/cm2,  the initiating seeding 
density of growth curves) with 20 mL of 10% FBS DMEM+ 1% PenStrep. After 6 days 
in culture, i.e. mid-exponential growth as determined from growth curve experiments in 
Chapter 3, the media was removed and the flasks were washed with PBS. 20 mL of 1% 
FBS DMEM+ 1% PenStrep was then added to the flasks and cultured for 24 hours. 
After 24 hours the media was removed, centrifuged to pellet any contaminating cells or 
debris   and   finally   filtered   through   a   0.2   μm  mesh.   The   resulting   ‘conditioned  media’  
could then be added to petri-dishes of the dormant cells at clonal density. A control set 
was also transferred into fresh 1% FBS media that had also been centrifuged and 
filtered. Each treatment or control was carried out in quadruplet and each experiment 
was repeated 3 times.  
 
After the initial colony assay at 14 days in 1% FBS all surviving cells retained DiD, the 
number of these cells in each well was counted by fluorescent microscopy. This was to 
ensure that no treatment set had significantly more cells that may naturally lead to more 
colonies after treatment. There was no significant difference between the number of 
single cells in any well in all 3 repeats (Part A, Figure 4.7). The media could then be 
changed into either 2% FBS, 10% FBS, 1% conditioned media or 1% FBS control and 
cultured undisturbed for 14 days. Significantly more colonies were formed after transfer 
into 2% FBS than in the control (Unpaired T-Test, P=0.044) and significantly more 
colonies were formed in 10% FBS than in either the 1% control (Unpaired T-test, P= 
<0.0001) or 2% FBS (P= 0.022).  
 
The effects of transfer into conditioned media were more variable, as can be seen from 
the error bars, however the increase in colony formation was significantly increased 
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compared to the 1% control (P= 0.027). No significant difference in colony formation 
was seen between 1% conditioned media and 10% FBS (Part B, Figure 4.7).  
 
 
 
Figure 4.7 Cells that were dormant after seeding at clonal density in 1% FBS retain the 
ability to form colonies 
A. No significant difference in DiD retaining single cell number was seen after the initial 14 
days in 1% FBS media. After this was confirmed the appropriate new media could be added. B. 
After 14 days in culture in the new media type a significant increase in colony number was seen 
after the addition of 2% FBS (Unpaired T-test, P= 0.044), 10% FBS (Unpaired T-test, P= 
<0.0001) and 1% conditioned media (CM) (Unpaired T-test, P= 0.027) compared to the 1% 
control. N= 4 petri-dishes/ media type in 3 biological repeats.  
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4.3.3.2 Cells that are isolated at 14 days after DiD staining in standard culture can 
form colonies when stimulated 
To test if the dormant cell sub-population in the PC-3NW1 cell line, as identified by 
DiD retention after 14 days, could form colonies in monolayer, this sub-population was 
isolated and tested by standard clone assays in varying serum concentrations. After 
following the staining and culture protocol in Methods Table 2.6, three T175 flasks 
were sorted by FACS Aria on day 14 after staining. This allowed the isolations of pure 
populations of either the DiD negative (DiD-) rapidly dividing cells alone or DiD 
positive (DiD+) dormant cells alone.  
 
After FACS sorting 1,000 DiD+ or DiD- cells were seeded into 60mm petri-dishes in 
either 10% FBS, 1% FBS or 10% FBS with transfer into 1% FBS media at 48 hours. 
These dishes were cultured undisturbed for 14 days. Colony formation was tracked by 
fluorescent microscopy every 24 hours to determine when dormant cells began to 
divide. After 14 days colonies were fixed, stained and counted as described previously. 
 
Both DiD+ and DiD- cell types were able to form colonies after isolation. The onset of 
cell division in the DiD positive population was 48 hours (2 days) after seeding (Part B, 
Figure 4.8) whereas the DiD negative cells begun to divide <24 hours after seeding (not 
shown).  
 
The DiD positive cells had an increased ability to form colonies in 10% FBS compared 
to the DiD negative cells (Upaired T-test, P= 0.029). This affect was increased when 
cells were seeded into 10% FBS and transferred into 1% FBS at 48 hours (Unpaired T-
test, P= 0.022). Neither cell type produced colonies when directly seeded into 1% FBS. 
This experiment was done in quadruplet dishes and repeated 3 times. 
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Figure 4.8 DiD positive dormant cells were more clonogenic in monolayer than DiD 
negative cells 
A. When seeded in colony assays the isolated DiD positive cell sub-population, at day 14 after 
staining, formed significantly more colonies in 10% FBS serum (Upaired T-test, P= 0.029) and 
when transferred from 10% to 1% FBS (Unpaired T-test, P= 0.022) than their DiD- 
counterparts. B. Representative fluorescent microscopy images taken every 24 hours for 14 
days. DiD positive cells began to divide 48 hours after seeding and formed discernible colonies 
at day 10. N= 4 petri-dishes/ media type in 3 biological repeats.  
 
4.3.3.3 Cells that survive long term Doxorubicin treatment do not form colonies in 10% 
FBS media 
Following experiments in Chapter 3 (section 3.4.6) the DiD positive and DiD negative 
cells that had survived Doxorubicin treatment for 14 days were washed with PBS and 
fresh 10% FBS media without Doxorubicin was added. These plates were cultured for 
14 days undisturbed and then fixed and stained following the method previously 
described. No colonies were detected in any wells after 14 days (graph not shown). This 
experiment was carried out in triplicate wells and repeated 3 times.  
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4.3.4 The dormant cell sub-population can re-emerge in rapidly dividing cultures 
 
To assess whether all cells within the PC-3NW1 cell line have the ability to enter into a 
dormant state, the DiD retaining dormant sub-population at day 14 was removed by 
FACS Aria. 14 days after DiD staining a single T175 flask was sorted by FACS Aria to 
remove the DiD positive sub-population and retain only those cells that had lost DiD 
due to successive divisions. Due to the high yields of this fraction the resulting DiD 
negative cells could be re-sorted through the FACS Aria to ensure that a pure 
population of DiD negative cells was given (Part A Figure 4.9). This was to ensure that 
if the dormant cell sub-population did re-emerge it was not derived from any 
contaminated DiD positive cells that may act as a source of more dormant cells.  
 
After re-staining with DiD these cells were cultured and assessed by FACS Calibur for 
21 days (as outlined in Methods 2.3.1). It was found that a DiD retaining subpopulation 
did re-merge in re-stained cultures at a frequency of 0.82% at day 14 and 0.03% at day 
21 (Part B, Figure 4.9). There was no significant difference between the percentage of 
the DiD positive population between the original stain, after the initial 14 day culture 
period (graph legend PC-3NW1+DiD), and the re-stained cells (graph legend PC-3NW1 
DiD- Restain) which had been cultured for the initial 14 days sorted as DiD negative, 
re-stained and cultured for a further 14 days (Paired T-test, P=0.095). 
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Figure 4.9 The dormant cell sub-population can re-emerge in DiD negative cultures after 
re-stain 
A. The  dot  plot  confirms  that  a pure  negative  population  is  obtained  after double sorting 
of the DiD negative  cells on day 14.  Shown  below  is the resulting statistical output, 0% of  
the cell were DiD  positive.  B.  The bar chart shows that after re-staining   with  DiD  the 
dormant cell sub-population  can re-emerge  in   the rapidly  dividing  population  and there  is  
no significant difference in the frequency of this population compared to the original stain 
(Paired T-test, P=0.095). N= 3 biological repeats.   
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4.3.5 Conditions in the culture environment can affect the dormant cell sub-
population 
 
4.3.5.1 Serum effects on the dormant cell sub-population 
It was necessary to determine whether the frequency of the DiD retaining dormant cell 
sub-population could be altered by a reduction in FBS concentration. To do this PC-
3NW1 cells were stained with DiD, as previous described, and transferred directly into 
T25 flasks with either 5%, 2% or 1% FBS DMEM+ 1% PenStrep. These cells were 
cultured and the DiD retaining sub-population was assessed following the protocol in 
Methods Table 2.6. 
 
Using a two-way ANOVA to compare the effect of serum on DiD percentage, it was 
found that changes in serum concentration had a significant effect on the dormant cell 
sub-population (P= <0.0001). The DiD retaining sub-population was reduced overall in 
5% FBS but increased in 1% and 2% FBS (Day 7 onwards shown, Figure 4.10).  
 
 
Figure 4.10 The 
effects of serum on 
the percentage of 
the dormant sub-
population 
Overall serum had a 
significant effect on the 
frequency of DiD 
retaining dormant cells 
(P= <0.0001). Culture 
in 5% FBS media 
reduced the frequency 
of the dormant sub-
population, whereas at 
lower serum 
concentrations (1% and 
2% FBS) the sub-
population was 
increased. N= 3 
biological repeats. 
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4.3.5.2 The effects of seeding density on the dormant cell subpopulation 
As with the above colony assays, it was deemed of interest to determine whether the 
frequency of the DiD retaining dormant cell sub-population could be altered by 
changing the initial seeding density of cells after staining. After noticing that the culture 
flasks were close to 100% confluence at the time of passage, the seeding density of the 
flasks was reduced to assess the affects of contact inhibition on the dormant sub-
population. After staining, 25x103, 10x103 and 5x103 cells were seeded into 5x T25 
flasks. These cells were cultured, passaged and analysed as normal (as outlined in 
Methods table 2.6). The frequency of the DiD retaining sub-population at these reduced 
seeding densities was then compared to the control, 1x105 cell seeding density that was 
standard for all previous experiments (Figure 4.11).   
 
Seeding density had a significant effect on the frequency of the DiD retaining sub-
population by two-way ANOVA (P= <0.0001). The DiD retaining sub-population was 
reduced in all three of the lower seeding densities tested.  
 
 
Figure 4.11 The 
effects of seeding 
density on the 
percentage of the 
dormant sub-
population 
Overall seeding 
density had a 
significant effect on 
the frequency of 
DiD retaining 
dormant cells (P= 
<0.0001). 
Decreasing the 
seeding density 
appeared to reduce 
the frequency of the 
dormant cell sub-
population. N= 3 
biological repeats. 
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4.3.6 Hypoxia: A potential mechanism for dormancy in the PC-3NW1 cell line 
 
The above experiments indicated that factors in the culture environment could be 
responsible for inducing the presence of dormant sub-populations. As this sub-
population was reduced when seeding density was decreased, it was hypothesised that 
induction of the dormant state was due to lack of available nutrients or hypoxia 
resulting from overcrowding in the flask. It was decided   to   look   at   Hif1α   (hypoxia-
inducible factor 1α) as an indicator of hypoxia. 
 
Hif1α  is  present  in  the  cytoplasm  of  all  cells  in  normoxia  and  is translocated to the cell 
nucleus under hypoxia, where is acts as a transcription factor to several downstream 
genes to regulate cell response to environmental stress. At 14 days after DiD staining, a 
single T175 flask was prepared and cytospun as in Methods 2.7.1. Immunofluorescence 
was used to  detect  Hif1α  nuclear  translocation  using  a  primary  rabbit  monoclonal  anti-
Hif1α  antibody  with  a  matched  IgG  isotype  control  followed  by  a  Goat  anti-Rabbit IgG 
AlexaFluor® 488 (all life technologies) following the protocol in Methods 2.7.2.  
 
To   test   the   affinity   of   the   purchased   Hif1α   antibody, a positive control of DMOG 
treated PC-3NW1cells (14 days after DiD staining) was done. DMOG is a cell 
permeable prolyl-4-hydroxylase inhibitor, which up-regulates Hif1α   nuclear 
translocation and can be used as a hypoxia mimetic (Chan et al., 2002). 0.1mM DMOG 
was added in the media of these cells for 6 hours before harvesting; 6 hours was 
determined as the optimum incubation time after optimisation tested 4 hours, 6 hours 
and 8 hours. (Figure 4.12).  
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Figure  14.12  DMOG  treatment  as  a  positive  control  to  test  the  Hif1α  antibody 
DiD stained PC-3NW1 cells at day 14 were treated with 0.1mM DMOG for 6 hours before 
harvesting for the immunofluorescence. The L5 channel (green) shows the Alexa488 conjugated 
Hif1α  antibody.  All  cells  were positive for nuclear translocation.  
 
 
 
Using the tile scan system on the Leica microscope, 25 tiled images at 40x 
magnification of the central section of the cytospin were automatically captured. Using 
both the phase contrast, DAPI, DiD and AlexaFluor® 488 channels the DiD status of 
cells   could  be   correlated   to  Hif1α   status.  Representative   images of an isotype control 
and an antibody stained image are shown in Parts A and B of Figure 4.13, 
respectively. The white arrows show the DiD positive cells that were strongly positive 
for   the   presence   of   nuclear  Hif1α.  This   is   shown  by   the   positive   correlation of green 
AlexaFluor®  488  staining  for  Hif1α  and  the  blue  Dapi  stain  for  the  cell  nucleus.Nuclear  
translocation  was  scored  by  eye  for  all  cells  in  each  image  and  the  percentage  of  Hif1α  
nuclear translocation for DiD negative (DiD-) and DiD positive dormant (DiD+) cells 
was  plotted.  A  significantly  higher  percentage  of  DiD  positive  cells  had  Hif1α  nuclear  
translocation than DiD- cells (Unpaired T-test, P=0.026) (Figure 4.14).  
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Figure 4.13 Representative images of the immunofluorescent assay to detect Hif1α  nuclear  
translocation  
A. The isotype control shows the A4 (blue) DAPI channel, the Y5 (far red) DiD channel, the L5 
(green) Alexa 488 channel and the merged image. There is only a very small amount of 
background when using the isotype. B. The antibody image shows the A4 (blue) DAPI channel, 
the Y5 (far red) DiD channel, the L5 (green) channel and the AlexaFluor® 488 merged image. 
The  white  arrows  show  DiD  positive  cells  that  have  clear  Hif1α  nuclear  translocation. 
Chapter 4: Results 
138 
 
 
 
 
 
 
Figure 4.14 The dormant cell sub-population  has  a  higher  percentage  of  cells  with  Hif1α  
nuclear translocation 
The  percentage   of   cells  with  Hif1α  nuclear   translocation  was   significantly   higher   in   the  DiD  
positive (DiD+) cell sub-population compare to the DiD negative (DiD-) cells (Unpaired T-test, 
P=0.026) 
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4.4 Discussion 
 
4.4.1 Analysing cell growth in colony assays 
 
The PC-3NW1 cell line was found to be highly clonogenic in monolayer in both 10% 
and 2% FBS. These cells did not form colonies in 1% FBS but survived in a mitotically 
dormant state for up to 14 days, as measured by the retention of DiD dye by fluorescent 
microscopy. However, PC-3NW1 cells could form colonies in 1% FBS serum at clonal 
density when seeded in 10% FBS for 48 hours and then transferred into 1% FBS. This 
result is interesting and suggests that after the initiation of growth in favourable 
conditions, i.e. 10% FBS, cell growth and colony formation is independent of the 
culture conditions. This may be of particular importance in consideration of tumour 
growth in vivo and suggests that targeting the initiation of growth/loss of dormancy, to 
prevent colony initiation in the early stages of the metastatic cascade, might be more 
effective than preventing autonomous growth once initiated. Another interesting result 
of this experiment was that cells transferred into 1% FBS from 10% FBS at 48 hours, 
formed more colonies than cells transferred into 2% (conditions previously shown to 
support clonal growth). This could be due to the selection of a more aggressive 
phenotype after transfer into 1% FBS which, once established, has an increased 
clonogenic potential. It would be interesting to test the tumourigenic ability of cells 
treated in this way in xenograft models. Alternatively it is likely that FBS contains a 
mix of clone promoting and apoptotic factors and that different concentrations of FBS 
in media allow these competing additives to be more or less effective: at 1% the balance 
favours colony formation, at 2% apoptotic factors may be more effective.  Increasing 
the seeding density in 1% FBS allowed the formation of colonies in the PC-3NW1 cell 
line at densities as low as only double clonal density (2x103 cells/ dish). The LNCaP 
and C42B4 had a much lower cloning ability in monolayer.  
 
It was found that LNCaP cells did not readily form colonies either at high FBS 
concentration (10% FBS media) or when seeded at high density in low FBS media 
(1%). They instead preferred to grow as monolayer cultures at high density and did not 
form discernible colonies that could be counted. This may reflect high motility within 
higher densities, with cells proliferating and spreading rather than forming colonies. 
However, studies published by Havard et al., 2011 found that the clonogenicity of the 
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LNCaP cell line is increased when cultured in RPMI. They found that LNCaP cells 
produced 100-1,000 times more colonies when cultured in RPMI +10% FBS compared 
to DMEM +10% FBS. They hypothesised that this effect was due to the higher osmotic 
pressure of DMEM media making it slightly hyper-tonic (360 Osm/L) compared to 
RPMI (310 Osm/L), as when osmotic pressure is reduced in DMEM the ability of 
LNCaP cells to form colonies increased. Interestingly, Havard et al. also found that the 
LNCaP cells were held in a dormant state in DMEM+ 10% FBS and had a similar cell 
cycle profile as the PC-3NW1 dormant cell sub-population (characterised in Chapter 3) 
by Propidium Iodide staining. They found that LNCaP cells that could not form 
colonies in DMEM, but remained in a dormant state, were found in both G2/M and 
G0/G1 phases as well as at a low frequency in S-phase (Havard et al., 2011). Future 
work could look at the cell cycle profile of the PC-3NW1 cells held in a dormant state 
when seeded at clonal density in 1% FBS but this would be difficult as the number of 
these cells was low. 
 
The C42B4 cell line, although weakly clonogenic at high serum concentration, formed 
colonies when seeded at higher density in 1% FBS media. This suggests that, like the 
PC-3NW1 cells, when cells are kept at low density in an unfavourable environment they 
lack signals to divide. However, when the number of cells is increased there is a trigger, 
possibly an accumulation of growth signals, which allows cells cultured in close 
proximity to divide and form colonies. 
 
To test the ability of the PC-3NW1 cell line to provide clonogenic signals to dormant 
cells, conditioned media from rapidly growing cultures in 1% FBS (to remove any 
serum effects) was added to cells seeded in 1% at clonal density at day 14. Conditioned 
media was very carefully eluted from rapidly growing flasks and centrifuged for 10 
minutes at 300 x g to prevent any cells being transferred to the dish, so we could be sure 
that any colonies were a result of the originally seeded cells.  This caused cells that had 
previously been held in a dormant state, at clonal density in 1% FBS media, to be 
triggered out of dormancy and stimulated to form colonies. It was also found that 
increasing the serum concentration, by the addition of 10% and 2% FBS media at day 
14, could stimulate dormant cell to form colonies. These results suggest that it is 
possible for these cells to exist as solitary dormant cells for long periods of time whilst 
retaining the ability to divide under favourable conditions. This is interesting and in 
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agreement to what is seen in vivo studies. Our group (unpublished) have shown that 
metastases in the bone marrow arise from low numbers of initiating cells, often a single 
clone that has remained dormant for varying periods of time that is then triggered (by 
unknown factors) to form a colony.  
 
The effects of serum increases were less variable than the effect of conditioned media, 
which may be due to the variability of factors released by conditioning cells. Despite the 
fact that 1% FBS media was conditioned over a known number of cells for the same 
period of time it is not possible to re-create the exact environment in every flask so 
some variability between repeats is to be expected. It is not know what the exact 
component present in conditioned media stimulated cell growth in my study. This was 
explored in Havard et al., 2001, who found that LNcaP cells remained mostly dormant 
when seeded at clonal density in 10% FBS DMEM. Havard et al. seeded LNCaP cells at 
clonal density in DMEM+10% FBS that had been conditioned over rapidly diving cells 
and found that colonies were formed. After screening several metabolites, they 
narrowed this effect down to citric acid and showed that an increase in citric acid in un-
conditioned 10% FBS DMEM could promote LNCaP cells to produce colonies (Havard 
et al., 2011). Future work could look at the levels of citric acid in the PC-3NW1 
conditioned media to determine if this had the same effect in this cell line.  
 
The reversal of dormancy at clonal density provided a framework to test whether 
dormancy was reversible in the dormant cell sub-population that was characterised in 
Chapter 3.  
 
4.4.3 Assessing the plasticity of the DiD retaining dormant cell sub-population 
4.4.3.1 Dormancy is reversible 
Following FACS Aria sorting at day 14 after DiD staining, 1x103 DiD positive cells 
were seeded per 60mm petri-dish in 1% and 10% FBS media. Following the results 
obtained with the earlier clone assays, cells were also seeded into 10% FBS media to be 
transfer into 1% FBS media at 48 hours. As a comparison 1x103 DiD negative cells 
were also set up under the above conditions. 
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It was significant to find that not only did the dormant DiD retaining cells produce 
colonies, they  did  so  at  a  higher  rate  than  the  DiD  negative  ‘rapidly  dividing’  cells.  This 
clearly shows that the dormant DiD+ cells retained the ability to form colonies once 
placed in conditions favourable for colony formation. That they did so more effectively 
than the DiD- cells seems counter intuitive, it is possible that the DiD retaining sub-
population is better able to survive when plated at clonal density than the DiD- cells. 
This was not tested here. This also indicates that the dormant state is reversible and is a 
state that prostate cancer cells can move in and out of depending on their environment. 
To explore this further, whether dormancy could be induced in the PC-3NW1 cell line 
as well as reversed was tested.   
 
4.4.3.2 The dormant phenotype can re-emerge 
Evidence that rapidly diving cells i.e. cells that have lost the DiD dye after 14 days in 
culture can enter into the dormant state (shown by DiD dye retention after a further 14 
days) suggests that previously non-dormant cells have the ability to become dormant 
and that dormancy is not an intrinsic characteristic of a defined population. This 
suggests that the dormant sub-population may not be stem cell-like in nature and may 
not be the same as the proposed CSC sub-population in prostate cancer (Collins et al., 
2005). This will be investigated in the following results chapter. 
 
4.4.4 Dormancy is driven by the culture environment 
 
It was also shown that the dormant cell sub-population can be increased or decreased in 
response to factors in the culture environment i.e. serum and seeding density. The 
frequency of the dormant subpopulation, as a proportion of the total, increases at high 
seeding density and at lower serum concentrations. This strongly suggests that 
entry/exit from dormancy is driven by culture conditions: when cells are at high density, 
the competition for factors/nutrients may result in deprivation for some cells which then 
switch from proliferation to dormancy. Conversely, when serum levels are low, the 
factors required to stimulate transition from dormancy to proliferation are in short 
supply. To investigate the mechanism that may be responsible for dormancy, that could 
be increased at high density, hypoxia in the cells was assessed. The experiments in 
section  4.3.6  provided  evidence  that  Hif1α  nuclear  translocation  was  increased  in  DiD  
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retaining cells. It has previously been shown that  Hif1α  specifically,  can  act  as   an  up  
regulator of p21cip1, which provides a break to cell division resulting in cellular 
dormancy (Koshiji et al., 2004). It is tempting to speculate that this could be responsible 
for the DiD retaining phenotype however, more studies at the molecular level are 
required to further evaluate hypoxia as a driver of dormancy. 
 
4.4.5 Conclusion 
 
Clonogenic assays have proved useful to study dormancy in vitro. These indicate that at 
clonal density, cells seeded in low serum concentrationscan be maintained in a dormant 
state but that this state can be reversed by stimulation with FBS or conditioned media. 
Cells characterised as dormant by the retention of DiD at 14 days also have the ability 
to exit from the dormant state when transferred out of their usual culture conditions and 
stimulated with 10% FBS. These experiments provide evidence that cells that were DiD 
retaining at day 14, and were ‘dormant’  as distinct from senescent, since they have the 
ability to re-enter the cell cycle and begin division. Dormancy appears to be regulated 
by the environment and the studies provide evidence that hypoxia, as measured by 
Hif1α  nuclear  translocation,  is part of the mechanism that drives entry into this state.  
 
The molecular mechanisms that induce/suppress dormancy have been extensively 
studied. For example, studies have indicated the importance of uPaR and EGFR 
(epidermal growth factor receptor) as drivers of dormancy (Almog, 2010). Although 
these molecular determinants are important, the following results chapter will use qRT-
PCR in the form of individual TaqMan assays and custom designed low density arrays 
(LDAs) to define the gene expression profile of the dormant cell sub-population in order 
to use these differences as a marker set to identify dormant cells.   
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Chapter 5: Gene expression profiling of the 
dormant cell sub-population: defining a 
gene signature for dormancy
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5.1 Introduction 
 
In an attempt to define the metastasis initiating phenotype, the majority of studies have 
focused on profiling circulating tumour cells (CTCs). This is in part due to the 
availability of these cells from patient blood samples compared to the availability of 
bone marrow aspirates. However, a number of studies have looked at the molecular 
mechanisms of disseminated tumour cells (DTCs) in the bone marrow of prostate 
cancer patients. Weckerman et al., 2009 found that DTCs had significantly more 
chromosomal aberrations than in cells isolated from the primary tumour by comparative 
genomic hybridisation (CGH). This suggests that in order to survive in the bone marrow 
a number of genetic alterations must take place for cells to have the potential to 
metastasize.   
 
A number of groups have also investigated the specific gene alterations that characterise 
tumour dormancy and also the switch from this state to rapid growth. Almog et al., 2013 
found that microRNA 190 can be responsible for the initiation of tumour dormancy in 
glioblastoma and osteosarcoma cell lines. Over expression of MicroRNA 190 was 
found to induce tumour dormancy in an orthotopically injected rapidly growing 
glioblastoma cell line. However, after long periods it was found that this cell line did 
eventually form rapidly growing tumours similar to the parental strain (Almog et al., 
2013). Almog et al., 2009 also published what they consider to be a consensus 
fingerprint of tumour dormancy in vivo. Using genome-wide transcriptional analysis 
they identified genes that were significantly altered in four slow growing cell lines in 
vivo compared to their rapidly growing counterparts. They found that the most 
significant alterations were seen in angiogenesis related genes that seemed to 
characterise  the  ‘switch’  from  tumour  dormancy   to  rapid  growth   (Almog et al., 2009). 
This work, although comprehensive focused on tumour dormancy in vivo and did not 
use any prostate cancer cell lines.  
 
Despite   it’s   clinical   relevance,   metastatic   dormancy   has   not   been   extensively  
researched. However, recently, a number of groups have published experiments that 
have provided evidence for the importance of the bone microenvironment in the 
mechanisms that control metastatic dormancy. Specifically molecular factors, such as 
stress signalling (Aguirre-Ghiso et al., 2001) or osteoblast/tumour cell signalling 
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(Taichman et al., 2013) have been highlighted to regulate how disseminated tumour 
cells survive and grow in the bone marrow. As previously mentioned, results in our 
laboratory suggest that the DiD retaining dormant sub-population are more metastatic in 
vivo as when injected intracardiac DiD positive cells at day 14 formed more skeletal 
tumours than DiD negative cells at day 14. This result was significant and it was 
therefore deemed crucial to assess the molecular characteristics that distinguish this 
dormant phenotype in order to gain information about their behaviour in vivo. 
 
The following studies will look specifically at the molecular profile of the dormant sub-
population in the PC-3NW1 cell line. This is in order to establish a phenotypic 
‘signature’  of   cellular  dormancy.  By  using   individual  TaqMan arrays and two custom 
designed low density array cards, the gene expression profile of the PC-3NW1 dormant 
cell sub-population will be analysed. Although genetic alterations may highlight 
potential mechanisms for dormancy in this sub-population, the primary aim is to 
characterise a marker set that is associated with dormancy. The aim is that this can then 
be used to compare cells under various conditions of dormancy i.e., dormant cells 
grown at clonal density in 1% FBS. It is also aimed that these LDA cards can also be 
used to assess the gene expression profile of early colonising cells in vivo. 
 
It has been hypothesised that the bone metastatic niche is similar to the HSC niche and 
shown   that   prostate   cancer   cells   ‘compete’  with  HSCs   for   access   to   this niche in the 
bone marrow (Shiozawa et al., 2011a). It has also been argued that prostate cancer cells 
may interact with the niche in order to remain dormant until activation (Pedersen et al., 
2012). RT-qPCR, using individual TaqMan assays, will be used to assess gene 
expression differences of HSC niche related factors in the dormant vs. rapidly dividing 
cell lines in the PC-3NW1 cell line. 
 
Building on this, a 96 gene custom Low Density Array (LDA) card from Applied 
Biosystems was designed to cover five areas of interest that may define differences in 
the PC-3NW1 dormant cell sub-population and the rapidly dividing cells. These were 
HSC niche related markers, stem cell markers, osteomimetic markers, markers of 
epithelial to mesenchymal transition (EMT) and endocrine or miscellaneous markers (A 
full list of the genes studied with abbreviations as they appear in the Results is found in 
Appendix 1.1).  
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In the context of previous work relating to metastasis initiating cells discussed in the 
Introduction (1.2.1), several gene assays relating to stem cell function were included on 
the array. Primarily, it was important to assess whether the dormant cell sub-population 
differentially expressed the same gene markers as the proposed prostate cancer stem 
cells,  CD44+/α2β1hi/CD133+  as  discussed  in  previous chapters. However, it was also 
necessary to determine whether the dormant cell sub-population represented a 
primordial or de-differentiated population, therefore classic stem cell markers such as 
OCT4 (LDA card synonym POU5F1), NANOG and SOX2 were included on the card. 
Epithelial to mesenchymal transition (EMT) has been hypothesised to induce a more 
migratory phenotype in tumour cells that may lead to a heightened metastatic ability. 
Specifically the expression of matrix metalloproteinases (MMPs) are considered key 
drivers of this change (Radisky and Radisky, 2010). Another proposed mechanism that 
leads to an increase in, specifically bone, metastases is osteomimicry. This process 
describes the heightened ability of tumour cells to express markers of bone cells, for 
example osteocalcin and osteoprotegerin, in order to survive and grow in the bone 
marrow. Several other miscellaneous markers were included on the card for example 
genes related to hormone response (the estrogen and androgen receptor) and several 
proposed markers of poor prognosis in prostate cancer patients e.g. the TMPRSS-ERG 
fusion. 
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5.2 Chapter Aims, Hypothesis and Objectives 
 
5.2.1 Aims 
The aim of this study was to characterise the gene expression profile of the dormant cell 
sub-population in the PC-3NW1 cell line to establish a molecular signature for 
dormancy.  
 
To address these aims the following hypothesis were tested 
 
5.2.2 Hypothesis  
The dormant sub-population has a unique gene expression profile compared to rapidly 
dividing cells.  
 
5.2.3 Objectives 
To test the above hypotheses the following objectives will determine whether:  
 
1. The DiD retaining dormant cells express different levels of HSC niche related 
genes compared to rapidly dividing cells by TaqMan RT-qPCR. 
2. Dormant cells have a unique gene expression profile by Low-density array (LDA) 
analysis. 
3. LDA card analysis can be used to assess the gene expression profile of DiD labelled 
cells that have been injected intracardiac into mice and homed to the bone at 3 days 
post  injection,  i.e.  early  colonising  or  ‘bone  homing’  cells.   
4. This unique expression profile is the same in cells that have been forced into 
dormancy i.e., cells grown at clonal density in 1% FBS and in rapidly dividing cells 
that have been restained with DiD and retained the dye for long periods i.e., 
restained DiD positive cells.  
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5.3 Results 
 
5.3.1 Optimising the RNA extraction method 
 
To   ensure   that   high   quality   RNA   could   be   obtained   using   the   Reliaprep™   RNA  
extraction kit from Promega, even when using low cell numbers, RNA was extracted 
from populations of reducing size and analysed using the 2200 TapeStation from 
Agilent Technologies. 
 
PC-3NW1 cells from routine growing cultured were trypsinised and 1x105, 1x104, 
3x103 and 1x103 cells were prepared for RNA extraction following Methods 2.6.1. 
Following  extraction  using  the  Reliaprep™  RNA  extraction  kit  from  Promega  the  RNA  
was analysed by NanoDrop (using the NanoDrop 2000 from Thermo Scientific) to 
check for the quantity and purity of RNA extracted. Table 5.1 shows the values of the 
RNA extracted. The 260/280 ratio should be ~2.0 and the 260/230 between 2.0-2.2, but 
above 1.5 is generally acceptable. DEPC (Diethylpyrocarbonate) water was used as a 
normaliser  as  when  using  the  Reliaprep™  system  this  is  the  final  elution  liquid.     
 
Sample/Number of cells Yield  (ηg/μl) 260/280 260/230 
Water 0.6 6.81 8.14 
1x105 271.9 2.14 2.14 
1x104 15.4 1.98 1.71 
3x103 5.5 1.87 1.37 
1x103 2.5 1.97 0.9 
Table 5.1 Nanodrop values of decreasing cell number 
DEPC water was used as a normaliser. A 260/280 ratio ~2.0 indicates pure RNA, a 260/230 
between 2.0-2.2, but above 1.5 is acceptable.  
 
To give a measure of the integrity of the RNA extracted i.e., to ensure that the product 
is good quality and not fragmented, the 2200 TapeStation from Aligent was used 
(Methods 2.6.3). The TapeStation analyses the RNA product by gel electrophoresis 
after it is loaded into the complimentary R6K screentape platform. This allows for fully 
automated electrophoresis and the generation of an objective measure of RNA quality, 
the RNA integrity number equivalent (RINe). The RINe is used as a measure of the 
amount of RNA degradation between 1 and 10, where a RINe value of 10 is completely 
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intact RNA. This value is calculated based on the ribosomal RNA 28:18s ratio 
calculated from the electrophoresis gel and also the corresponding electrophrenogram 
(not shown).  
 
Figure 5.1 shows the gel electrophoresis result. A ladder was loaded into A0 and the 
four samples were compared, from left to right E1=1x103 cells, F1=3x103  cells, 
G1=1x104 cells and H1 =1x105 cells. A first look at the RNA gel showed that most of 
the RNA was good quality as there was a roughly 2:1 ratio of the 28:18s bands and 
there  was  ‘smearing’  between  and  above  the ribosomal RNA but not below. There were 
also no low molecular weight species towards the bottom of the gel. This result showed 
that high quality RNA was extracted from as little as 3,000 cells (RINe=9.7) but below 
this value (1,000 cells) the quality was low despite a good 260/280 ratio by Nanodrop. 
 
 
Figure 5.1 TapeStation gel 
electrophoresis result 
The ladder (A0) shows the 
nucleotide (nt) length of the 
bands. The samples run from 
left to right E1 is 1x103 cell, F1 
3x103, G1 1x104 and H1 1x105. 
A RINe value ~ 10 denotes 
intact RNA. Intact RNA can be 
extracted from as little as 3x103 
cells (RIN= 9.7). 
 
  
Chapter 5: Results 
151 
 
5.3.2 Investigation of HSC niche related gene expression in the PC-3NW1 dormant 
sub-population 
 
To test if dormant cells, i.e., PC-3NW1 cells that have retained DiD after 14 days in 
culture, expressed higher levels of genes related to the HSC niche individual Taqman 
assays were done using primers for Angiopoietin 1 (ANGPT1), N-cadherin (CDH2), 
Chemokine (C-X-C Motif) Ligand 12 (CXCL12), Chemokine (C-X-C Motif) Receptor 
4 (CXCR4), Jagged 1 (JAG1), Notch-1 (NOTCH1) and Endothelial Tyrosine Kinase 
(TEK). On day 14 after DiD staining 3 T175 flasks of PC-3NW1 cells were sorted by 
FACS Aria to separate the DiD positive dormant cell sub-population and the DiD 
negative  rapidly  dividing  cells.  RNA  extraction  was  done  using  the  ReliaPrep™  RNA  
Cell Miniprep System from Promega. cDNA was generated using Superscript® III RT 
enzyme  from  life  technologies™  following  Methods 2.2.4.  
 
RT-qPCR was done using an Applied Biosystems 7900 Real-Time PCR machine. The 
results were entered into Prism to generate bar charts to compare the delta Ct values. 
Each graph represents three biological repeats consisting of two replicate wells for each 
assay. A superscript negative control was run in each plate, for each sample, and was 
negative in all experiments. Three housekeeper genes were used to normalise the data 
and generate delta Ct values (The Ct value of the assay minus the Ct value of the 
housekeeper) to compare expression levels. On all bar charts, the lower the bar the 
higher the gene expression level as a low Ct (cycle threshold) means a more abundant 
gene transcript as fewer cycles are needed to reach the fluorescent threshold.  
 
These assays showed that the expression of CXCR4 was significantly up-regulated in 
the DiD positive dormant cell sub-population (graph legend DiD+) compared to the 
DiD negative rapidly dividing population (graph legend DiD-). This result was 
significant using all three housekeepers as the normalisation method (GAPDH Unpaired 
T-test, P=0.009, HPRT11 P=0.0001, Beta-actin P=0.035) (GAPDH shown Figure 5.2). 
There were no other significant differences between the DiD+ and DiD- populations in 
the expression of putative HSC niche genes although there was a trend towards 
increased expression of Jag 1 in the DiD+ population using these individual RT-qPCR 
assays. 
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Figure 5.2 Investigation of HSC niche related gene expression by individual TaqMan 
assays 
CXCR4 was significantly up-regulated in the dormant cell sub-population by RT-qPCR 
(Unpaired T-test, P=0.009). The mean value of 3 biological repeats with standard deviation is 
plotted. 
 
5.3.3 Low Density Array technology to investigate the PC-3NW1 dormant cell sub-
population 
Three housekeeper genes were assigned to the LDA card GAPDH, HPRT1 and Beta-
actin as well as the standard 18s housekeeper included by Applied Biosystems. 
DataAssist™  software  from  life  technologies  was  used  to  analyse  the  data  and  select  the 
most stable housekeeper to use as an endogenous control. GAPDH was shown to be the 
most stable, having the lowest standard deviation amongst the three repeats 
(negative/positive 1-3) by Pairwise comparisons and was therefore selected as the 
control for all subsequent analyses (GAPDH: 0.47, HPRT1: 0.56, 18s: 0.57, Beta- actin: 
0.74) (Figure 5.3).  
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Figure 5.3 Selection of the most stable housekeeper 
Across the three biological repeats GAPDH had the lowest standard deviation and was selected 
as the housekeeper to use for normalisation. (Standard deviation of GAPDH: 0.47 (green 
line), HPRT1: 0.56 (yellow line), 18s: 0.57 (red line), Beta- actin: 0.74 (blue line)). N=3 
biological repeats. 
 
As detailed above RNA was extracted from isolated PC-3NW1 DiD positive cells and 
DiD negative cells and cDNA was generated to perform RT-qPCR. Each card 
(considered  as  one  biological  repeat)  had  8  ‘fill  ports’  allowing  DiD  positive  and  DiD  
negative samples to be run alongside each other in replicate. Each experiment was 
repeated 3 times. Genes that had a Ct value >35, due to low expression, and were 
therefore undetected at this sensitivity level are not plotted on the graphs (A complete 
table of the genes included in this LDA card (LDA card 1) and their gene expression 
values is found in Appendix 1.1 and 1.2). The following sections will present the 
results obtained in each of the five areas of interest. Heat Maps were generated using 
DataAssist™   software.   In all graphs the mean value of 3 biological repeats with 
standard deviation is plotted. 
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5.3.3.1 Differences in the expression of HSC niche related markers in the dormant cell 
sub-population 
LDA card analysis showed that by Unpaired T-test the expression of CXCR4 was 
significantly up-regulated in the PC-3NW1 dormant cell sub-population (DiD+) 
compared to the rapidly dividing cells (DiD-) (P= 0.038). This result is in agreement 
with the original Taqman assay. A significant up regulation in Jagged 1 (JAG1) 
expression was seen in the dormant cell sub-population (Unpaired T-test, P= 0.001). 
This increase was not significant at the level of individual TaqMan assays however the 
trend is the same.  
 
By Unpaired T-test a significant down regulation in the gene expression of melanoma 
cell adhesion molecule (MCAM) was found in the dormant cell sub-population 
(P=<0.0001) (Part A, Figure 5.4). The Heatmap (Part B, Figure 5.4) shows the gene 
expression levels of the dormant DiD positive cells (positive) and the rapidly dividing 
DiD negative cells (Negative). The scale bar to the right (shown only in this figure) 
represents delta Ct values, which are given a colour based on their value. The lower the 
delta Ct, and therefore the higher expressed the gene, the closer to the red end of the 
scale the gene is. High delta Ct values denote low gene expression and are closer to the 
blue end of the scale. The mid-point (shown by the grey arrow at delta Ct 12) represents 
the median delta Ct value across all three biological repeats for all genes and is used as 
the mid-point for all analyses.  
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Figure 5.4 Investigation of HSC niche related genes by LDA card analysis 
A. The bar chart shows the differences in the delta Ct values of the dormant  (DiD+) cell sub-
population compared to the rapidly dividing (DiD-) cells. CXCR4 (P=0.038) and JAG1 
(P=0.001) were both significantly up-regulated in the DiD + cells. MCAM was significantly 
down regulated in the dormant cells (P=0.0001). B. The heat map shows the gene expression 
difference between the dormant DiD positive (Positive) cell sub-population and the rapidly 
dividing DiD negative cells (Negative). N= 3 biological repeats. 
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5.3.3.2 Differences in the expression of stem cells markers in the dormant cell sub-
population 
The dormant cell sub-population did not differentially express the proposed prostate 
cancer   stem   cell   phenotype,   CD44+/α2β1hi/CD133+. Although   integrin   α2 (ITGA2) 
was significantly up-regulated in the dormant cells, the P value was weak (0.048) and 
these  cells  do  not  express  significantly  higher  levels  of  integrin  β1 (ITGB1) or CD44 or 
CD133 (Figure 5.5).  
 
 
 
Figure 5.5 Investigation of proposed cancer stem cell (CSC) markers by LDA card 
analysis  
A. The   bar   chart   shows   that   only   integrin   α2 (ITGA2) was significantly up-regulated in the 
dormant cells (P=0.048). B. The differences in gene expression by heat map. N= 3 biological 
repeats. 
 
 
However, other proposed stem cell markers were differentially expressed by the 
dormant cells. By Unpaired T-test the expression of Annexin 2 (ANAX2) (P=0.001), 
CD24 (P= 0.006) and Prostate stem cell antigen (PSCA) (0.0004) were significantly up-
regulated in the dormant cell sub-population. A significant down regulation in the 
expression of Lactate Dehydrogenase B (LDHB) and Nestin (NES) was seen in the 
dormant cells (P= 0.014 and 0.013, respectively) (Figure 5.6). 
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  Figure 5.6 Investigation of Stem cell markers by LDA card analysis 
A. The bar chart shows the differences in the delta Ct values of stem cell marker genes in the 
dormant (DiD+) vs. the rapidly dividing cell population (DiD-). ANAX2 (P=0.001), CD24 
(P=0.006) and PSCA (P-0.0004) were all significantly up-regulated in the dormant sub-
population. LDHB and NES were both significantly down regulated in the dormant cells (P= 
0.014 and 0.013, respectively) B. The heat map shows the differences in delta Ct values. N= 3 
biological repeats. 
 
5.3.3.3 Differences in the expression of markers of EMT in the dormant cell sub-
population 
The dormant cell sub-population had increased gene expression levels of several 
proposed drivers of epithelial to mesenchymal transition (EMT). These were CXCL1 
(Kuo et al., 2012), P=0.0002 by Unpaired T-test. MMP2 and MMP3 (Radisky and 
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Radisky, 2010), P= 0.004, <0.0001 respectively. Tenasin C, another proposed driver of 
EMT in tumours (Takahashi et al., 2013) was also significantly up-regulated (P=0.007) 
as well as markers of mesenchymal/fibroblast cells; fibroblast growth factor 2 (FGF2) 
(P=0.037), fibronectin (FN1) (P=0.0004) and vitronectin (VTN) (P=0.043) (Figure 
5.7). 
 
 
Figure 5.7 Investigation of markers of EMT by LDA card analysis  
A. The bar chart shows the differences in the delta Ct values of markers of EMT in the dormant 
(DiD+) vs. the rapidly dividing cell population (DiD-). A number of markers of EMT transition 
were significantly up-regulated in the DiD positive cells by Un-paired T-test: CXCL1 
(P=0.0002), MMP2 (P=0.004), MMP3 (P=<0.0001), TNC (P=0.007), FGF2 (P=0.037), FN1 
(P=0.0004) and VTN (P=0.043). B. The heat map shows the differences in delta Ct value in the 
dormant DiD positive (Positive) vs. DiD negative (Negative) cells. N= 3 biological repeats. 
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5.3.3.4 Differences in the expression of osteomimetic markers in the dormant cell sub-
population 
It has been hypothesised that cancer cells can acquire features of bone cells, in 
particular osteoblasts, that allow them to survive and proliferate in the bone (Rucci and 
Teti, 2010). It was found that only BMP7 was significantly up-regulated in the dormant 
cells (P=0.030) (Figure 5.8).  
 
 
 Figure 5.8 Investigation of osteomimetic markers by LDA card analysis  
A. The bar chart shows that only BMP7 was significantly up-regulated in the dormant cell sub-
population (P=0.030). B. The heat map shows the differences in delta Ct value in the dormant 
DiD positive (Positive) vs. DiD negative (Negative) cells. N= 3 biological repeats. 
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5.3.3.5 Differences in the expression of endocrine and miscellaneous markers in the 
dormant cell sub-population 
The final spaces on the LDA card were used to investigate several markers of interest 
that had either been proposed by members of the lab group or had recently appeared in 
the literature (Figure 5.9).  
 
 
Figure 5.9 Investigation of endocrine / miscellaneous markers by LDA card analysis  
A. The bar chart shows that FST (P=0.001) as well as MATN2 (P=0.0001), ESR1 (P=0.020) 
and TMPRSS2 (P=0.010) were significantly up-regulated in the dormant sub-population B. The 
heat map shows the differences in delta Ct value in the dormant DiD positive (Positive) vs. DiD 
negative (Negative) cells. N= 3 biological repeats. 
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Follistatin (FST) was significantly up-regulated in the dormant sub-population 
(P=0.001). Along with Matrillin 2 (MATN2) (P=0.0001) and the estrogen receptor 1 
(ESR1) (P=0.020). Expression of the androgen regulated gene TMPRSS2 was 
significantly increased in the dormant cell sub-population (P=0.010), however 
expression of the TMPRSS2-ERG fusion was not detected in either sub-population (Ct 
value >35, not shown on the graph). The negative presence of the TMPRSS2-ERG 
fusion was expected for a sub-strain of the PC-3 cell line. 
 
5.3.4 Assessment of the in vivo bone homing DiD positive population  
 
As previously mentioned, recent work in our lab has found that PC-3NW1 cells can 
survive in a dormant state for long periods of time in the bone marrow of mice. These 
cells can remain DiD positive up to 8 weeks after intracardiac injection. It is not yet 
known whether these cells represent the same sub-population as those identified in 
vitro, by DiD retention for 14-21 days.  
 
The first aim of this study was to use LDA card analysis to assess the genetic profile of 
cells that had homed to the bone in xenograft models. 1x105 PC-3NW1 cells were 
stained with DiD and immediately injected into balb/c nude mice via intracardiac. After 
7 days, the mice were culled and their hind limbs were dissected to remove the tibia and 
femur.  These  bones  were  ‘flushed’  following  the  protocol   in  Methods  2.8.1.  The  cells  
were retained for FACS sorting based on DiD retention to isolate the human PC-3NW1 
cells for RNA extraction. These cells would represent the early colonising population. 
The aim of this was to use this profile to compare these cells to those that were dormant 
in vitro and, eventually, cells that were dormant in vivo, i.e. DiD retaining 8 weeks after 
intracardiac injection.  
 
The bones from three mice were prepared for bone marrow flush and the resulting cell 
suspensions were each individually sorted by FACS Aria to retrieve the DiD positive 
cell fraction. However, despite increasing the positive gate to sort cells that had low 
DiD intensity but still remained outside of the negative control gate, very low yields of 
DiD positive cells were obtained (Figure 5.10). It was therefore decided that quality 
RNA could not be isolated from these cells for LDA card analysis.  
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Figure 5.10 FACS analysis 
following the bone marrow flush 
The flow cytometry plot and 
statistical output. The plot shows 
the gated DiD+ population, which is 
drawn just outside of the DiD- gate. 
The upper   square   of   blue   ‘dots’  
represents large events, which could 
be doublets or dead cells and were 
excluded from analysis. 7 days after 
intracardiac injection of DiD 
stained PC-3NW1 cells the hind 
limbs of 3 mice were dissected and 
the   tibia   and   femur   ‘flushed’   to  
remove the marrow. The cells were 
sorted by FACS Aria. Only a very 
small number of DiD positive cells 
were retrieved in this way 52 out of 
1,253,172, which was deemed 
insufficient for LDA card analysis. 
 
 
5.3.4 Using the LDA card information to create a signature for dormancy 
 
The previous results show that there were significant gene expression differences 
between the PC-3NW1 dormant cell sub-population and rapidly dividing cells. The next 
stage was to test whether these differences were also seen in other dormant cells i.e., 
PC-3NW1 cells grown at clonal density in 1% FBS media (referred to as Clonal 
dormancy) and rapidly dividing PC-3NW1 cells that had lost DiD after the initial stain 
but retained it after FACS sorting and re-staining (referred to as Restained dormant 
cells). A second LDA card was designed, containing 22 genes of interest plus the 
endogenous control GAPDH and 18s (Applied Biosystems standard). These included a 
number of genes that were identified in the previous section as significantly different 
but also novel genes added after group discussion (a full gene list of this LDA card 
(LDA card 2) is shown in Appendix 1.3). This smaller card allowed the direct 
comparison of different cell sub-populations as multiple samples could be loaded per 
card.  
5.3.4.1 LDA card 2 analysis of the original PC-3NW1 dormant cell sub-population 
To clarify the markers identified with the first LDA card (LDA card 2), PC-3NW1 cells 
stained with DiD and cultured for 14 days were sorted by FACS Aria to separate the 
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dormant  (DiD+) and rapidly dividing (DiD-) populations. The delta Ct values were 
compared and it wad found that eight genes were significantly up-regulated (none were 
down regulated) in the dormant cell sub-population by Unpaired T-test. These were 
CD34 (P=0.020), CXCL1 (P=0.039), CXCR4 (P=0.024), DKK1 (P=0.0127), MMP3 
(P=0.012), SOSTDC1 (P=0.0112) TNC (P=0.037) and VTN (P=0.043) (Figure 5.10). 
The bars that pass above the perforated UD (undetected) line represent genes that had a 
CT value of above 35 and are therefore undetected (UD) at this level. The results from 
LDA card 2 were consistent with the first LDA card in the overlapping genes analysed.  
 
5.3.4.2 LDA card 2 analysis of dormancy in restained PC-3NW1 cultures 
Following Methods 2.3.2 and 2.6 PC3-NW1 cells that had retained DiD after restaining 
were sorted by FACS Aria to separate the now dormant restained DiD positive cells and 
the rapidly dividing restained DiD negative cells for RNA extraction and LDA card 
analysis i.e. cells that were all initially classed as fast growing by loss of detectable DiD 
after 14 days were stained a second time with DiD which, after a further 14 days in 
culture, allowed the identification of a DiD retaining sub-population of cells within the 
previously rapidly growing population that   had   ‘switched’   to   the   dormant   phenotype.  
The gene expression differences of these cells (‘Restained+’) compared to cells in the 
same cultures that had lost DiD, after the second staining, (‘Restain-’) was then 
compared by LDA card 2 analysis.  
 
By Un-paired T-test seven genes were significantly up-regulated in the restained DiD 
retaining dormant cells (graph legend: ‘Restain+’) compared to restained DiD negative, 
consistently rapidly dividing cells (graph legend: ‘Restain-’). These were DKK1 
(P=0.029), FN1 (0.044), MMP3 (0.003), SOSTDC1 (0.012), TNC (P=0.017), TP63 
(0.014) and VTN (P=0.044) (Figure 5.11). There was a trend towards increased 
CXCR4 expression in the restained DiD+ cells (Restain+) compared to the DiD- cells 
(Restain-) but this failed to reach significance. Although slight differences were seen 
between the PC-3NW1 dormant cells and the restained dormant cells by two-way 
ANOVA overall there was no significant difference between these cell types (P=0.651). 
There is also no significant difference by two-way ANOVA between the PC-3NW1 
DiD negative cells and the DiD negative cells after re-staining (P=0.277) across the 
complete gene set.  
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Figure 5.10 Investigation of a signature for dormancy in the PC-3NW1 cell line                   
CD34 (P=0.020), CXCL1 (P=0.039), CXCR4 (P=0.024), DKK1 (P=0.0127), MMP3 (P=0.012), 
SOSTDC1 (P=0.0112) TNC (P=0.037) and VTN (P=0.043) were  all  significantly  up-
regulated in the dormant cell sub population (DiD+) compared to the rapidly  dividing  cells 
(DiD-). N= 3 biological repeats.   
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Figure 5.11 Investigation of a signature for dormancy in dormant restained cells 
DKK1 (P=0.029), FN1 (0.044), MMP3 (0.003), SOSTDC1 (0.012), TNC (P=0.017), TP63 
(0.014) and VTN (P=0.044) were all significantly up-regulated in the dormant cell sub 
population (DiD+) compared to the rapidly dividing cells (DiD-). N= 3 biological repeats. 
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5.3.4.3 LDA card analysis of clonal dormancy 
To investigate whether dormant single cells grown at clonal density in 1% FBS 
differentially expressed these same markers, cells isolated from these conditions were 
compare by LDA card 2 analysis to a control population. The ‘Control’   population  
consisted of DiD stained PC-3NW1 cells that were seeded at clonal density into 10 x 
T175 flasks in 10% FBS DMEM + 1% PenStrep and harvested after 14 days to be used 
as a comparison. These cells formed growing clones and were used as a reference 
population (graph legend: ‘Control’). In order to gain enough cells for RNA extraction, 
to investigate the dormant single cells at clonal density (graph legend: ‘Clonal’), the 
experiments performed in Chapter 4.3.1 had to be scaled up. 6x103 DiD stained PC-
3NW1 cells were seeded into 10 x T175 flasks with 37 mL of 1% FBS DMEM + 
PenStrep (equivalent to the conditions used in the colony assays, 35.3 cells /cm2 and 
0.21 mL of media/cm2 ). These flasks were cultured for 14 days, after which RNA was 
extracted and cDNA was generated for RT-qPCR.  
 
By Unpaired T-test, seven genes were significantly up-regulated in the Clonal 
dormancy cell sub-population compared to the Control. These were CXCL1 (P=0.011), 
CXCR4 (P=0.034), MMP3 (0.002), PSCA (0.006), SHH (0.011), TNC (0.042) and 
VTN (0.008) (Figure 5.12). Although there were a number of differences between cells 
that were dormant at clonal density and cells that have retained DiD due to dormancy 
after 14 days by two way ANOVA there was no significant difference between the two 
cell types (P=0.723) across the complete gene set. 
 
 
 
 
 
Chapter 5: Results 
167 
 
 
 
Figure 5.12 Investigation of a signature for dormancy in dormant cells cultured at clonal 
density in 1% FBS media compared to cells growing in colonoies (Control) 
CXCL1 (P=0.011), CXCR4 (P=0.034), MMP3 (0.002), PSCA (0.006), SHH (0.011), TNC 
(0.042) and VTN (0.008) were all significantly up-regulated in the dormant cell sub population 
(DiD+) compared to the rapidly dividing cells (DiD-). N= 3 biological repeats. 
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5.3.5 Comparisons of gene expression under different conditions of dormancy 
 
LDA card 2 analysis was useful to investigate the gene expression differences between 
dormant cell sub-populations and their rapidly dividing counterparts. To compare the 
gene expression signature of the three different dormant sub-populations, i.e. between 
sub-populations that were initially dormant (PC3NW1 DiD+) to cells that had re-
emerged as dormant (Restain+) and cells that survived as single dormant cells under 
clonal conditions (Clonal), the Ct value information was pooled in order to construct a 
heat map. This was also useful to compare the three different sub-populations of DiD-/ 
rapidly dividing cells. As reported, two way ANOVAs had shown that there was no 
significant difference between dormant cells identified under any of the three conditions 
mentioned above. This suggests that dormancy, as a phenotype, is characterised by 
common gene expression alterations of the assays included on LDA card 2.  
 
A full heat map to show the comparisons between all cell types is shown in Figure 
5.13. The scale bar to the right shows the mid-point (the grey arrow), which is placed at 
12, the median delta Ct value of all samples for all repeats. The DiD positive dormant 
cells in the PC-3NW1 cell line (PC-3NW1+) were compared to their rapidly dividing 
counterpart (PC-3NW1-) as well as with single cells maintained as dormant grown in 
1% FBS media (Clonal) and their proliferating counterpart growing as clone colonies 
(Control) and also PC-3NW1 cells that have re-emerged as dormant after re-staining 
(Restain+) and their rapidly dividing counterpart (Restain-). The perforate black line 
indicates   the   divide   between   the   ‘dormant’   sub-population   and   the   ‘non-dormant’   /  
rapidly dividing populations. This highlights the key patterns of gene expression that 
were different between the two groups. For example, the heat map demonstrates lower 
gene expression (indicated by colours of paler red or towards the blue end of the 
spectrum)   to   the   left   of   the   perforated   line   in   the   ‘non-dormant’   populations   for   key  
genes such as CXCR4, MMP3 and SOSTDC1 compared to higher gene expression in 
the  ‘dormant’  cell  sub-populations to the right of the perforated line.  
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Figure 5.13 A full heat map to show investigation of a dormant cell signature 
The heat map shows the differences in delta Ct values of the dormant cell sub-populations in the 
PC-3NW1 cell line (PC3NW1+ = sorted DiD positive cells after 14 days ), restained dormant 
cells (Restain+ = sorted DiD positive cells, that were initially DiD negative but were restained 
with DiD and emerged as DiD retaining and therefore dormant ) and clonal dormant cells 
(Clonal = single cells held in a dormant state when seeded at clonal density in 1% FBS media ) 
compared to rapidly dividing cells (PC3NW1-= sorted DiD negative cells after 14 days), 
Restain- (sorted DiD- cells, that rapidly lost DiD a second time after restaining) and Control 
(cells growing in colonies when seeded at clonal density in 10% FBS media). 
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5.4 Discussion  
 
The aim of this study was to characterise a molecular signature for dormancy. Using 
TaqMan assays and two LDA cards the gene expression profile of the dormant cell sub-
population in comparison to rapidly dividing cells was assessed. Initially individual 
TaqMan assays revealed a significant up regulation of CXCR4 expression in the 
dormant sub-population. This result was replicated using the first LDA card and LDA 
card 2.  
 
The initial LDA card highlighted a number of other interesting markers that were up-
regulated in the dormant cell population. In particular, PC-3NW1 dormant cells have an 
increase in gene expression of several stem cell markers including prostate stem cell 
antigen (PSCA). High PSCA expression, although not unique to cancer cells, has been 
linked to higher Gleason grade tumours and bone metastases (Gu et al., 2000). It has 
been suggested that PSCA could be used as a potential prognostic indicator of more 
aggressive tumours but its link to dormancy is as yet unclear. It is interesting to note 
that the isolated PC-3NW1 dormant cells do not differentially express markers of the 
proposed prostate CSC sub-population, apart from ITGA2. However, CD24, a proposed 
marker of a CSC sub-population in Nasopharyngeal Carcinoma (Yang et al., 2014a), 
was significantly up-regulated in the dormant cells of the PC-3NW1 cell line. 
Therefore, although dormant cells have many characteristics of stem cells at the gene 
expression level as well as other CSC like features such as high cloning ability and 
increased chemotherapeutic resistance, they were distinct from the previously identified 
prostate CSCs although they may be a sub-set of these cells.  
 
A clear up-regulation in markers of EMT was seen in the dormant cell sub-population in 
the initial LDA card analysis. This was verified in LDA card 2. MMP3, a proposed 
driver of EMT (Radisky and Radisky, 2010), was significantly up-regulated in all three 
dormant cell sub-populations by LDA card 2 analysis. It has been proposed that EMT 
can act as a driver of a more migratory phenotype in cancer cells but in order for this 
de-differentiated phenotype to initiate metastasis, MET (mesenchymal to epithelial 
transition) must take place (see Introduction for a more detail discussion of this). In a 
review by Thiery (2009), it is hypothesised that EMT is needed to act as a suppressor of 
proliferation in order to promote a more invasive phenotype that has an increased 
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resistance to cell death and drug treatment but once in the bone marrow this is reversed 
to allow proliferation and metastatic growth (Thiery et al., 2009). The role of EMT as a 
driver of cellular dormancy still remains unclear and in order to build on the work 
presented here, knockdown studies of EMT drivers would be needed to see if the 
dormant phenotype was affected. 
 
The only osteomimetic marker that was significantly up-regulated in the dormant cell 
sub-population, by LDA card 1 analysis, was BMP7. The link between BMP7 as a 
driver of dormancy has already been published by Kobayashi et al., 2011 who found 
that BMP7 secreted from bone stromal cells induces ‘reversible senescence’ in prostate 
cancer cells by the activation of P38, P21 and NDRG1 (Kobayashi et al., 2011). As this 
was the only marker of its kind to be significantly altered in my studies, and it had 
previously been linked to dormancy, it was not including on LDA card 2. Interestingly 
however, studies by Buijs et al., 2007 indicated that increased BMP7 correlated to 
increased E-cadherin and reduced vimentin in prostate cancer cells, which, the authors 
suggest, indicates a role for BMP7 in inducing an epithelial rather than mesenchymal 
phenotype (Buijs et al., 2007). These results appear to be in disagreement to my own, 
that suggested that in the dormant cells increased BMP7 correlates to a more 
mesenchymal phenotype. The reason for this could be however, that Buijs et al. looked 
at the E-cadherin : vimentin ratio as an indicator of an epithelial or mesenchymal 
phenotype while these experiemnts looked at a broader range of markers of EMT and 
while there was no significant differences in the gene expression of E-cadherin (LDA 
card synonym CDH1) or vimentin between the DiD+ and DiD- sub-populations, there 
was increased levels of other markers of mesenchymal cells such as FGF2 and MMP2 
and 3. This suggests that while BMP7 could have an effect on the levels of E-cadherin 
and vimentin, increased BMP7 in my studies appeared to correlate to increased 
expression of other mesenchymal markers. Furthermore, the results reported in Buijs et 
al. stated that the PC-3 cell line did not show detectable BMP7 mRNA expression while 
my studies reported detectable levels, although low, of BMP7 in both the DiD+ and 
DiD- sub-populations in the PC-3NW1 cell line. This could suggest differences in the 
specificity of the assays used or could reflect inherent differences in the PC-3 parental 
cell line and the transfected PC-3NW1 derivative.  
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It was interesting to find that although PC-3 cell are widely considered to be androgen 
receptor (AR) negative, the presence of AR RNA was detected in both the dormant and 
rapidly dividing PC-3NW1 cell populations. It has previously been shown that AR 
mRNA is present in the PC-3 cell line by RT-PCR at high cycle number (30 cycles) and 
present as AR protein at a low level by western blot (Alimirah et al., 2006). However, 
as this was not differentially expressed by the dormant cells so it was not included on 
the second LDA card. Furthermore, western blot analysis would be needed to determine 
whether AR RNA in this cell line was translated to protein. 
 
5.4.1 A signature for dormancy  
 
Three markers were significantly up-regulated in all three dormant cell sub-populations 
by LDA card 2 analysis. These were MMP3, TNC and VTN. As mentioned above 
MMP3 and TNC are both proposed drivers of EMT, while VTN is a known marker of 
fibroblast cells. It is tempting to speculate that cellular dormancy in the PC-3NW1 cell 
line is a result of EMT induction in a subset of cells that have become more 
mesenchymal as a result.  However, as mentioned previously, further research is needed 
to investigate the role of EMT and dormancy in these conditions. It is significant to 
note, however, that by LDA card analysis there were commonly up-regulated genes in 
cells with a dormant phenotype in different culture conditions.  
 
CXCR4 expression was consistently up-regulated to significance in the PC-3NW1 
dormant cell sub-population by individual TaqMan assays and LDA card 1 and 2. 
CXCR4 was also significantly up-regulated in the dormant cell population grown at 
clonal density in 1% FBS media. CXCR4 expression was also higher in the restained 
dormant population but failed to reach significance. CXCR4 and its potential as a 
marker of dormancy will be investigated in the following results chapter. Although 
PSCA was significantly up-regulated in the PC-3NW1 dormant sub-population by LDA 
card 1 analysis, this failed to reach significance using LDA card 2 but the trend was the 
same. It was interesting to note that in the dormant cells population grown at clonal 
density, PSCA and SHH were significantly up-regulated. 
 
Although  Hif1α  expression  was  not  significantly  up-regulated in any of the dormant cell 
sub-populations,  as  Hif1α  acts  at  the  protein  level  as  a  transcription  factor  it  would  be  
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more  useful  to  look  at  genes  that  are  targets  of  Hif1α  such  as  glut1  (Chen et al., 2001) to 
determine whether hypoxia could still be a potential driver of dormancy.  
 
Overall LDA card 2 analyses showed that the gene expression signature of all three 
dormant cell sub-populations was not significantly different by two-way ANOVA. This 
suggests that as well as the three genes that were significantly up-regulated in all three 
cell types (MMP3, TNC and VTN) there is an overall consensus gene expression 
signature of dormancy. By two-way ANOVA the gene expression signature of the PC-
3NW1 dormant sub-population was significantly different (P=0.0001) from the PC-
3NW1 rapidly dividing cells using LDA card 2 analysis. The restained DiD positive 
dormant cells were also significantly different (P=0.0001) from the restained DiD 
negative rapidly dividing cells by two-way ANOVA. However, no significant 
difference was seen between clonal dormant cells and the control by two-way ANOVA 
(P=0.116) but a significant difference was seen between clonal cells and PC-3NW1 
rapidly dividing (P=<0.0001). This suggests that the gene expression profile of 
dormancy is distinct from rapidly dividing cells.  
 
5.4.2 Conclusion 
 
Initial LDA card analysis revealed several differences in the gene expression levels of 
dormant vs. rapidly dividing cells. In particular, markers of stem cells (but not the 
proposed prostate CSC) as well as markers of EMT were significantly up-regulated in 
the PC-3NW1 dormant cell sub-population. The utilisation of a second smaller LDA 
card (LDA card 2) showed that under different conditions (re-stain and clonal density in 
1% FBS) the gene expression profile of dormant cells is not significantly different. 
Indeed three key genes were highlighted (MMP3, TNC and VTN) as markers that may 
define the dormant phenotype. However, their functional role in dormancy is yet to be 
defined.  
 
The following results chapter will utilise LDA card 2 to investigate markers of 
dormancy in the human prostate cancer cell lines LNCaP and C42B4.  The aim of these 
studies is to assess whether the dormant cell sub-populations identified in these two cell 
lines in Chapter 3, have the same gene expression signature of the PC3-NW1 dormant 
phenotypes. This chapter will also investigate markers of dormancy, in particular 
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CXCR4, in more detail and how they could be used to identify dormant cells in patient 
samples that may predict poor prognosis.  
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Chapter 6: Defining markers of the dormant 
cell phenotype  
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6.1 Introduction 
 
Results presented in the previous chapter indicate that cells with a dormant phenotype 
share gene expression modifications, as measured by LDA card 2 analysis, in sub-
populations of the PC-3NW1 cell line. The studies in this chapter aim to test whether 
this expression profile is present in the dormant cell sub-population identified in the 
LNCaP and C42B4 cells lines in Chapter 3. This chapter also aims to define a marker 
set that will identify cells of the dormant phenotype by immunostaining techniques. 
This will be used to assess the frequency of dormant cells in patient samples. As 
discussed, results in our own lab have indicated that the dormant PC-3NW1 cell line, 
i.e. DiD retaining cells 14 days after staining, have a higher bone metastatic ability in 
xenograft models. This suggests that cells of a dormant phenotype may represent a 
novel metastasis initiating cell type. It was therefore consider to be of interest to identify 
markers of these cells that could be used as prognostic indicators of metastatic 
progression in patients. 
 
Successful treatment of prostate cancer patients with radical prostatectomy is limited to 
those with organ confirmed disease and while prognostic tests can highlight patients 
who require more intensive treatment, metastatic prostate cancer is still an incurable 
disease. There are already several clinical tests that are used to evaluate prognosis in 
prostate cancer patients. Patient age, Gleason grade and TNM (Tumour, Node, 
Metastasis) staging are all used as clinical indicators of prognosis; as well as several 
biological tests that include PSA level, P53 status and Ki-67 status of tumour biopsies 
(Buhmeida et al., 2006).The limited routine availability of tissue samples from prostate 
cancer patients has hampered the development and use of prognostic markers. 
Realistically, the only prostate cancer samples routinely available are fixed, parrafin 
wax embedded, diagnostic biopsies and a small number of similarly processed radical 
specimens. This means that tests need to be applicable to these materials to be useful.  
For this reason immunohistochemistry has been widely used to assess potential 
prognostic markers in these sample sets. Indeed E-cadherin status in prostate cancer 
specimens has been shown to correlate to survival in patients. Umbas et al. (1994) used 
89 snap frozen cancer specimens and stained for E-cadherin presence using an anti-E-
cadherin monoclonal antibody. The authors found that the 3-year survival of patients 
with  ‘normal’  E-cadherin staining (uniform staining confined to the cell membrane) had 
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a   significantly   higher   survival   rate   than   patients   with   ‘aberrant’   E-cadherin staining 
(defined as heterogeneous, cytoplasmic or negative staining). Indeed, a decrease in E-
cadherin staining correlated to the presence of metastases in patients, with 76% of 
patients  with  distant  metastases  having  ‘low’  E-cadherin staining compared to 33% of 
patients with organ confined disease at the time of biopsy (Umbas et al., 1994). More 
recently, Nakagawa et al. (2011) found that there was a correlation between low 
positive staining for E-cadherin and high Gleason grade (Nakagawa et al., 2011). These 
results suggest that a loss of E-cadherin staining, a characteristic of EMT, is an 
important prognostic indicator and further highlights the important role of phenotypic 
changes in cell type in the metastatic cascade.  
 
Recently, Fisher et al. (2013) published data using samples from a large patient cohort 
(293 men) to support the value of Ki-67 as a prognostic indicator in prostate cancer 
using long term survival as the end-point. While Ki-67 status is considered the most 
promising biomarker for immunohistochemical analysis of prognosis in prostate cancer, 
many of the published studies are confusing with varying cut-off points used to define 
levels of staining (Fisher et al., 2013). This same research group also published 
promising results to support the use of loss of PTEN as an immunohistochemical 
marker of poor prognosis in prostate cancer. Again a large cohort of men were sampled 
(675 patients) with prostate cancer death used as the end-point of long-term follow-up. 
They found that loss of PTEN staining in prostate cancer cores was a significant 
predicator of prostate cancer death and that this corresponded to Ki-67 staining. 
However, although PTEN was shown to be a useful prognostic indicator in univariate 
analysis it was not additionally informative when other markers e.g. Gleason score and 
PSA predicted poor prognosis (Cuzick et al., 2013). 
 
An important step of the studies presented in this chapter was to make the progression 
from measuring gene expression changes to protein expression changes using 
immunofluorescence/immunohistochemistry. It is understood that various modifications 
in the production processes of proteins in cells can mean that mRNA levels do not 
always correlate to protein levels. This can occur at the stage of translation or during 
post-translational modification, in which processes such as the addition of functional 
groups or the trafficking of proteins to their active cellular  domains can be distorted.  
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The studies presented in this chapter will test the identified gene expression profile for 
dormancy in PC3-NW1 populations against those expressed in dormant populations 
from other prostate cancer cell lines to define a consensus set of dormancy markers. The 
studies will also evaluate the presence of proteins encoded by dormancy specific up-
regulated genes in prostate cancer cell populations. Finally, the most consistent marker 
of dormancy will be assessed in prostate cancer specimens from patients and the 
frequency/intensity of cellular staining related to pathology and disease status at the 
time of biopsy.    
Chapter 6: Results 
179 
 
6.2 Chapter Aims, Hypothesis and Objectives 
 
6.2.1 Aims 
 
The aim of this study was to identify common markers of dormancy that are 
differentially expressed at the gene level and present at the protein level in the dormant 
sub-population of all three prostate cancer cell lines previously utilised; PC-3NW1, 
LNCaP and C42B4.   
 
A further aim is to determine if a marker can be utilised to identify dormant cells in 
primary prostate cancer patient samples and whether their presence is linked to the 
occurrence of metastases.  To address these aims the following hypotheses will be 
tested. 
 
6.2.2 Hypothesis 
 
1. Gene expression markers of dormancy in the PC-3NW1 cell line are expressed 
in the dormant sub-population in LNCaP and C42B4 cell lines.  
2. The differential production of these markers is present at the protein level.  
3. High positive staining for a marker correlates with other prognostic indicators 
e.g. Gleason grade 
4.  High positive staining for a marker predicts the occurrence of metastases in 
patient samples. 
 
6.2.3 Objectives 
 
To test the above hypotheses the following objectives will determine whether:  
1. The dormant cell sub-population in the LNCaP and C42B4 cell lines 
differentially express the same dormancy markers as the PC-3NW1 cell line 
using a low density array (LDA) card quantitative RT-PCR approach. 
2. Key markers of dormancy at the RNA level are differentially present in the 
dormant sub-population of these cell lines at protein level using 
immunofluorescence.   
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3. The presence of a marker of dormancy correlates with Gleason grade, Gleason 
score and patient age. 
4. Whether high positive staining for a marker is associated with progression when 
present in patient samples. 
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6.3 Results 
 
6.3.1 LDA card 2 analysis of the dormant cell sub-population in the LNCaP cell 
line 
 
To determine whether the dormant cell sub-population identified in the LNCaP cell line 
in Chapter 3 differentially expressed the same markers of dormancy as the PC-3NW1 
cell line, LDA card 2 was repeated with RNA from LNCaP. As described in Chapter 5 
for the PC-3NW1 cell line, LNCaP cells were stained with DiD and cultured for 14 
days. These cells were then sorted by FACs Aria to isolate the DiD retaining cell sub-
population and the DiD negative, rapidly dividing cells. RNA was separately extracted 
and after reverse transcription, cDNA was loaded into the LDA card 2 to compare gene 
expression differences in the DiD positive dormant (denoted as LNCaP+ on the graph) 
vs. rapidly diving populations (LNCap-). Each assay was run in replicate and 3 
biological repeats (3 separate LDA cards) were performed. The graph shows delta Ct 
values of each assay (gene), which is the average Ct value of all repeats minus the Ct 
value  of  the  housekeeper  GAPDH.  Bars  above  the  perforated  ‘UD’  line  were  undetected  
at this sensitivity level. 
 
There was a significant up-regulation in the gene expression of CXCR4 in the dormant 
cell sub-population in LNCaP cell line  (Unpaired T-test, P= 0.007) similar to the 
increase in expression seen in the PC-3NW1 dormant cells. Follistatin (FST) was also 
significantly up regulated in the LNCaP dormant cells (P=0.002) and although the trend 
was the same in PC-3NW1 the up regulation in these dormant cells was not significant 
(P=0.069) by LDA card 2 analysis. However, vitronectin (VTN) was significantly up 
regulated in the LNCaP dormant cells (P=0.006) and in the PC-3NW1 dormant cells 
(P=0.043). Unlike in the PC-3NW1 line MMP3, CD34, CXCL1, DKK1 SOSTDC1 and 
TNC were not significantly altered in the LNCaP dormant sub-population (Figure 6.1).  
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Figure 6.1 CXCR4, Follistatin and Vitronectin were significantly up regulated in the 
LNCaP dormant cell sub-population 
Gene expression analysis of dormant, DiD retaining LNCaP (LNCaP+) cells compared to non-
dormant, DiD negative (LNCaP-) cells assessed by low density array (LDA2) showed that 
CXCR4 and Follistatin (FST) were significantly up regulated in the LNCaP dormant cells 
(LNCaP+) by Unpaired T-test (P= 0.007 and P=0.002 respectively) compared to rapidly 
dividing cells (LNCaP-). Vitronectin (VTN) was also significantly up regulated in the LNCaP 
dormant cells (P=0.006). The graph represents three biological repeats; error bars represent 
standard deviation. Delta CT values relative to GAPDH are presented so that lower values 
indicate higher levels of gene expression. Top panel shows alphabetical list of genes A-ML and 
lower, genes MM-Z. 
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6.3.2 LDA card 2 analysis of the dormant cell sub-population in the C42B4 cell line 
 
cDNA prepared from the dormant and rapidly dividing populations in the C42B4 cell 
line was also compared by LDA card 2 analysis. There was a significant up-regulation 
in the gene expression level of CXCR4 in the dormant cell sub-population in the C42B4 
cell line (C42B4+) compared to the DiD negative rapidly dividing cells (C42B4-) 
(Unpaired T-test, P=<0.001). Unlike the LNCaP or PC-3NW1 cell lines no other 
significant up or down regulations in gene expression was detected in the dormant cell 
sub-population in C42B4. Although not significant, increases in the expression of 
DKK1 (P=0.0064), Follistatin (FST) (P=0.057), Tenascin (TNC) (P=0.079) and 
Vitronectin (VTN) (P=0.068) were detected in the C42B4 dormant sub-population. This 
follows the same trend as that seen in the PC-3NW1 cell line (Figure 6.2). The graph 
shows delta Ct values of each assay, which was normalised, to the housekeeper 
GAPDH. 
 
Statistical analysis to compare the gene expression levels of the LNCaP dormant cell 
sub-population to the PC-3NW1 dormant cell sub-population, found that by LDA card 2 
analysis these cell types were significantly different by two-way ANOVA (P=0.0069). 
This suggests that although these sub-populations share phenotypic dormancy the gene 
expression levels between them are not alike. However, the dormant cell sub-population 
in the C42B4 was not significantly different from the PC-3NW1 dormant cell sub-
population by two-way ANOVA (P=0.446) and, interestingly, the C42B4 and LNCaP 
dormant cell sub-populations were not significantly different from each other by two-
way ANOVA (P=0.135).  
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Figure 6.2 CXCR4 was significantly up-regulated in the C42B4 dormant cell sub-
population 
Gene expression analysis of dormant, DiD retaining C42B4 (C42B4+) cells compared to non-
dormant, DiD negative (C42B4-) cells assessed by low density array (LDA2) showed that 
CXCR4 was significantly up regulated in the C42B4 dormant cells by Unpaired T-test 
(P=<0.001) compared to rapidly dividing cells. The graph represents three biological 
repeats; error bars represent standard deviation. Delta CT values relative to GAPDH are 
presented so that lower values indicate higher levels of gene expression. Top panel 
shows alphabetical list of genes A-ML and lower, genes MM-Z. 
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As a result of these experiments, CXCR4, DKK1, FST and MMP3 were selected to 
investigate at the protein level by immunofluorescence as possible markers of 
dormancy. CXCR4 was the most attractive candidate as it was significantly up regulated 
at the gene level in the dormant cell sub-population of all three cell lines. DKK1, was 
significantly up regulated in the PC-3NW1 cell line and was increased in the C42B4 
cell line, although this did not reach significance. The gene expression level of FST was 
significantly increased in the dormant cell sub-population of the LNCaP cell line and 
significantly up regulated in the dormant cells in the PC-3NW1 cell line by LDA card 1 
but not LDA card 2 analysis. MMP3 was significantly up-regulated only in the PC-
3NW1 cell line but the fold change (2ΔΔCt) increase was the highest of all assays, 45.29 
fold higher than in the rapidly dividing cells, which made it an attractive candidate for 
study.  As CXCR4 was significantly up regulated in all three cell lines, dual staining 
using the CXCR4 antibody and either the DKK1, FST or MMP3 antibody was 
performed in each experiment.  
 
6.3.3 Antibody optimisation for immunofluorescence  
 
Monoclonal Anti-Human CXCR4-Phycoerythrin conjugated antibody was purchased 
from R&D systems. Phycoerythrin (PE) is a red fluorescent protein that is excited at 
480/565 nm and emits at 578 nm. This allows the excitation of the PE conjugated 
CXCR4 protein to be visualised with minimal cross over into the DiD channel 
(excitation 644 nm, emission 665 nm) allowing each to be visualised separately and also 
merged. Mouse monoclonal antibodies against Human DKK1, MMP3 and Follistatin 
were purchased from Abcam. As no directly conjugated anti-human products were 
available each primary was matched with the AlexaFluor® 488 Goat Anti-Mouse IgG 
secondary antibody from Abcam. AlexaFluor® 488 (excitation 499, emission 519nm) is 
distinct from both the DiD and PE channels allowing all three fluorescent tags to be 
detected in a single image. Fluorescence SpectraViewer from life technologies was used 
to select fluorophores with the desired wavelength. An image is shown in Figure 6.3. 
An IgG isotype control was done for each antibody and the optimum concentration was 
determined using a positive control.  
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Figure 6.3 Excitation/emission profiles and of different fluorescently tagged antibodies 
The two antibodies AlexaFluor 488 and PE are distinct in their excitation (perforated peak) and 
emission peaks to allow visualisation by fluorescent microscope together and alongside DiD. 
 
6.3.3.1 CXCR4 optimisation 
The use of the Anti-Human CXCR4-Phycoerythrin antibody (purchased from R&D 
systems) has previously been published to show a high level of protein presence in the 
LNCaP cell line. Growing stocks of LNCaP were used to determine the appropriate 
antibody concentration to use in subsequent experiments. 1x105 LNCaP cells (without 
DiD staining) were prepared and cytospun onto slides as described in Methods 2.7.1. 
Cytospinning allows the fixation of a high density of cells to be adhered to a 
microscope slide after being directly removed from culture. The cytospin generates a 
cell  “spot”  that  can  be  treated  much  in  the  same  way  as  a  tissue  core  section  without  the  
need for de-waxing and antigen retrieval. A 1:100, 1: 50 and 1:20 dilution of both the 
antibody and matched isotype control (also conjugated to Phycoerythrin) were tested 
following Methods 2.7.2. A 1: 50 dilution was determined as the optimum, which gave 
a bright uniform stain with minimal signal using the isotype  (Figure 6.4).  
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Figure 6.4 Immunofluorescent staining with CXCR4 antibody (showing the optimum 
antibody dilution, using the positive control: LNCaP)   
A. 1x105 LNCaP cells were treated with a 1:50 dilution of a PE conjugated isotype control. B. 
1x105 LNCaP cells were treated with a 1:50 dilution of a PE conjugated Anti-CXCR4 antibody 
(yellow). 
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6.3.3.2 DKK1 optimisation 
The MCF-7 human breast cancer cell line was used as a positive control to determine 
the optimum concentration of the mouse monoclonal Anti-DKK1 antibody. MCF-7 
cells show a high degree of DKK1 staining when using this antibody as demonstrated 
on the Abcam data sheet online. Following the protocol outlined in Methods 2.7.1 and 
2.7.2, 1x105 MCF-7 cells were cytospun onto superfrost slides and two different 
concentrations of primary antibody were tested (1:200, 1:100) in combination with two 
different concentrations of the matched secondary Goat Anti-Mouse IgG H&L (Alexa 
Fluor® 488) antibody (1:200, 1:100). 
 
The optimum combination was determined as a 1:200 dilution of the primary Anti-
DKK1 antibody with a 1:200 dilution of the secondary. This allowed for a bright 
uniform stain with minimal isotype staining (Figure 6.5).  
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Figure 6.5 Immunofluorescent staining with DKK1 antibody (showing the optimum 
antibody dilutions, using the positive control: MCF-7)  
A. 1x105 MCF-7 cells were treated with a 1:200 dilution of isotype control with a 1:200 dilution 
of Alexa Fluor® 488 conjugated secondary. B. 1x105 MCF-7 cells were treated with a 1:200 
dilution of Anti-DKK1 antibody with a 1:200 dilution of Alexa Fluor® 488 conjugated 
secondary (green).  
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6.3.3.3 MMP3 optimisation 
Mouse monoclonal Anti-MMP3 antibody was purchased from Abcam and optimised 
using HeLa cells as a positive control, as recommended by Abcam. Following the 
protocol in Methods 2.7.2, a 1:200 and 1:100 dilution of the Anti-MMP3 primary was 
tested in combination with a 1:200 and 1:100 dilution of the Goat Anti-Mouse IgG 
H&L (Alexa Fluor® 488) antibody. 
 
The optimum combination was determined as a 1:100 concentration of the primary 
Anti-MMP3 antibody with a 1:200 dilution of the secondary. This showed a bright 
uniform stain with minimal isotype signal (Figure 6.6). 
 
 6.3.3.4 Follistatin optimisation 
A mouse monoclonal Anti-FST antibody was purchased from Abcam and optimised 
using HeLa cells as a positive control, as recommended by Abcam. A 1:200 and 1:100 
dilution of the Anti-FST primary was tested in combination with a 1:200 and 1:100 
dilution of the Goat Anti-Mouse IgG H&L (Alexa Fluor® 488) antibody following the 
protocol in Methods 2.7.1. 
 
The optimum combination was determined as a 1:100 concentration of the primary 
Anti-FST antibody with a 1:200 dilution of the secondary. This showed a bright 
uniform stain with minimal isotype background signal (Figure 6.7). 
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Figure 6.6 Immunofluorescent staining with MMP3 antibody (showing the optimum 
antibody dilutions, using the positive control: HeLa cells)  
A. 1x105 HeLa cells were treated with a 1:100 dilution of isotype control with a 1:200 dilution 
of Alexa Fluor® 488 conjugated secondary. B. 1x105 HeLa cells were treated with a 1:100 
dilution of Anti-MMP3 antibody with a 1:200 dilution of Alexa Fluor® 488 conjugated 
secondary (green).  
Chapter 6: Results 
192 
 
 
 
Figure 6.7 Immunofluorescent staining with FST antibody (showing the optimum 
antibody dilutions, using the positive control: HeLa cells)  
A. 1x105 HeLa cells were treated with a 1:100 dilution of isotype control with a 1:200 dilution 
of Alexa Fluor® 488 conjugated secondary. B. 1x105 HeLa cells were treated with a  
1:100 dilution of Anti-FST antibody with a 1:200 dilution of Alexa Fluor® 488 conjugated 
secondary (green).  
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6.3.4 CXCR4 protein levels were significantly up regulated in the dormant cell 
sub-population in all three cell lines 
 
The level of CXCR4 protein presence was significantly up regulated in the dormant cell 
sub-population (DiD+) in all three cell lines. After DiD staining PC-3NW1 cells, 
LNCaP and C42B4 cells were cultured for 14 days. 1x106 cells were harvested at this 
time point and prepared for cytospinning (full protocol Methods 2.7.1 and 2.7.2). After 
fixing in formalin and washing in PBS 1x105 cells were cytospun onto superfrost slides. 
The slides were then permeabilised and dual stained for either CXCR4 and DKK1, 
CXCR4 and MMP3 or CXCR4 and FST. This was to test the hypothesis that multiple 
markers of dormancy (as shown by LDA card) could identify dormant cells by 
immunofluorescence. Three slides per cell line were prepared in this way so that a no 
treatment control slide, an isotype antibody treated control slide and a specific antibody, 
antibody treated slide could be generated for each biological repeat.  
 
25 images were taken using the Leica AF6000 time lapse microscope per slide and the 
antibody staining intensity was evaluated by imageJ. As the Leica AF600 allows 
imaging using multiple channels the far red (DID) channel could be imaged in 
combination with both the red (Phycoerythrin conjugated CXCR4) channel and the 
green (Alexa Fluor® 488 secondary antibody to DKK1, MMP3 and FST) channel. 
Using the tile scan function on the Leica, 25 images could be captured from a defined 
region  in  the  central  quadrant  of  the  cell  “spot”  using  a  fully  automated  system  which 
reduced observer bias during image capture. These images were than analysed in 
ImageJ which gave a score of the antibody intensity per cell which was then correlated 
to the presence or absence of DiD staining. In this way the average antibody intensity of 
these proteins could be compared between the DiD+ dormant cells and the DiD- rapidly 
dividing cells.   
 
When considered on its own, the level of CXCR4 (as measured by Mean antibody 
intensity per cell, Y-axis) was significantly higher in the dormant (DID+) sub-
population compared to rapidly dividing (DID-) cells for all three cell lines tested. This 
is shown in Part A, Figure 6.8. The graph represents three biological repeats (error bars 
show standard deviation), each repeat took the average of three biological replicates 
which consisted of the CXCR4 with DKK1, CXCR4 with MMP3 and CXCR4 with 
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FST. CXCR4 presence when considered on its own is shown on the graph. The mean 
intensity of CXCR4 antibody staining was significantly higher by Paired T-test in the 
DiD+ dormant cells in the PC-3NW1 cell line compared to the DiD- rapidly dividing 
cells (P=0.011). CXCR4 staining intensity was also significantly higher in the dormant 
sub-population (DiD+) in both the LNCaP and C42B4 cell lines (P=0.017, P=0.006 
respectively). This result was in agreement with the significant up regulation in CXCR4 
expression in the dormant cell sub-population of all three cell lines by LDA 2 card 
analysis. A representative image of CXCR4 (yellow) presence in combination with the 
DiD stain (red) in the PC-3NW1 cell line is in shown in Part B, Figure 6.8. 
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Figure 6.8 CXCR4 protein was significantly up regulated in the dormant compared to 
non-dormant cells  
A. The presence of CXCR4 as measured by antibody staining intensity per cell (Y-axis, Mean 
intensity) was significantly higher in the dormant (DiD+) sub-population of all three cell lines 
compared to rapidly dividing cells (DiD-) by Paired T-test (PC-3NW1 P=0.011, LNCaP 
P=0.017, C42B4 P=0.006). N=3 repeats. B. A representative image of the PC-3NW1 cell line 
shows DiD positive cells at day 14 (white arrows) have a higher intensity of CXCR4 staining 
(yellow) than the DiD negative cells that surround them. 
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6.3.5 There were no significant differences in the level of DKK1 protein in the 
dormant vs non-dormant cell sub-populations isolated from each cell line.  
 
When scored in combination with CXCR4 intensity there was no significant up-
regulation in DKK1 present in the dormant (DiD+) cell sub-populations in the LNCaP 
or C42B4 cell lines Part A, Figure 6.9. This could be expected as no significant up 
regulation in DKK1 gene expression was detected by LDA card 2 analysis in these cell 
lines.  
 
However, DKK1 was significantly up regulated in dormant cells at the gene expression 
level by LDA card 2 analysis in the PC-3NW1 cell line but no significant difference 
was detected at the protein level by immunofluorescence. A representative image of 
DKK1 staining (green) in the PC-3NW1 cell line shown in combination with CXCR4 
(yellow) and DiD staining (red) is shown in Part B, Figure 6.9. The graph represents 
the mean antibody staining (Mean intensity, Y-axis) of the DKK1 antibody in three 
biological repeats; error bars show standard deviation. 
 
6.3.6 There were no significant differences in the level of MMP3 protein in the 
dormant vs non-dormant cell sub-populations isolated from each cell line  
 
In all three cell lines tested there was no significant up regulation in MMP3 using the 
anti-MMP antibody in the dormant cell sub-population (DiD+) compared to rapidly 
dividing cells (DiD-) Part A, Figure 6.10. The graph represents three biological 
repeats; error bars show standard deviation. This is despite the observation that MMP3 
was significantly up regulated in the dormant cell sub-population of the PC-3NW1 cell 
line by LDA card 2 analysis and has a very high fold change when compared to rapidly 
dividing cells (>40 times). A representative image of MMP3 staining (green) in the 
C42B4 cell line shown in combination with CXCR4 (yellow) and DiD staining (red) is 
shown in Part B, Figure 6.10. 
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Figure 6.9 There was no significant difference in DKK1 protein in the dormant compared 
to non-dormant cells  
A. The presence of DKK1 as measured by antibody staining intensity per cell (Y-axis, Mean 
intensity) was not significantly higher in the dormant (DiD+) sub-population of any cell line 
compared to rapidly dividing cells (DiD-). N=3 repeats. B. A representative image of the PC-
3NW1 cell line shows a DiD positive cells at day 14 (white arrow) has a high intensity of 
CXCR4 staining (yellow) but not a higher intensity of DKK1 stain (green) compared to the DiD 
negative cells that surround it. 
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Figure 6.10 There was no significant difference in MMP3 protein in the dormant 
compared to non-dormant cells  
A. The presence of MMP3 as measured by antibody staining intensity per cell (Y-axis, Mean 
intensity) was not significantly higher in the dormant (DiD+) sub-population of any cell line 
compared to rapidly dividing cells (DiD-). N= 3 repeats B. A representative image of the 
C42B4 cell line shows a DiD positive cells at day 14 (white arrow) which has a higher level of 
CXCR4 staining (yellow) than many DiD- cells, but a low level of MMP3 staining (green) 
which is comparable to the DiD negative cells that surround it . 
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6.3.7 There was a significant increase in FST protein in the dormant cells in the 
LNCaP cell line compared to non-dormant cells but not in dormant cells in the 
PC3NW1 or C42B4 cell lines compared to their respective non-dormant 
populations  
 
By immunofluorescence, Follistatin (FST) was detected at a significantly higher level in 
the DiD positive dormant sub-population in the LNCaP cell line, by Paired T-test 
(P=0.018), but not in the PC-3NW1 or C42B4 cell lines. This is in agreement with the 
LDA card 2 results; FST was significantly up regulated at the gene expression level in 
the dormant compared to the non-dormant LNCaP sub-population but not the dormant 
PC-3NW1 or C42B4 cell lines compared to their respective non-dormant population.  
The graph represents the mean staining intensity (Mean intensity, Y-axis) of the FST 
antibody in three biological repeats; error bars show standard deviation (Part A, Figure 
6.11). A representative image of FST staining (green) in the LNCaP cell line shown in 
combination with CXCR4 (yellow) and DiD staining (red) is shown in Part B, Figure 
6.11. This result suggests that FST and CXCR4 together can be used to identify 
dormant cells but this is only applicable to the LNCaP cell line.  
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Figure 6.11 There was a significant increase in the level of Follistatin protein in the 
LNCaP dormant compared to the non-dormant cell sub-population  
A. The presence of FST as measured by antibody staining intensity per cell (Y-axis, Mean 
intensity) was not significantly higher in the dormant (DiD+) sub-population of the PC-3NW1 
or C42B4 cell lines compared to rapidly dividing cells (DiD-). However, FST was significantly 
increased in the dormant cell sub-population in the LNCaP cell line (Paired T-test, P=0.018) N= 
3 repeats B. A representative image of the LNCaP cell line shows a DiD positive cell at day 14 
(white arrow) has a high intensity of CXCR4 staining (yellow) and a high intensity of FST stain 
(green). 
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6.3.8 An assessment of CXCR4 presence in primary prostate cancer samples 
 
CXCR4 was the only marker that was significantly higher in the dormant cell sub-
population of all three cell lines. It was therefore decided that increases in CXCR4 
protein were the most likely to be useful in identifying this sub-population in patient 
samples and potentially in predicting disease progression. 
 
A primary prostate tissue microarray was purchased from US Biomax, Inc. The PR752 
array consisted of 75 cores representing 75 patients with Prostate carcinoma and 
hyperplasia (64 cases of adenocarcinoma, 11 hyperplasia (BPH)), single core per case. 
The provided specification sheet included information about the Gleason grade, Gleason 
score and TNM stage of each core. It was therefore known which primary prostate 
samples were taken from patients with metastases. No follow up clinical information 
was available, therefore the information only showed which patients had developed 
metastases at the time of biopsy. It was therefore not possible to assess the use CXCR4 
to predict the development of node or distant metastases but only to correlate the 
amount of CXCR4 staining to the presence of existing metastases. These experimenst 
were also designed to test the hypothesis that an increase in CXCR4 protein in a 
primary patient sample, as assessed by immunohistochemistry, predicted the presence 
of metastases in these patients and to evaluate whether this parameter was 
dependent/independent of Gleason scores.  
 
The array slide was dewaxed, hydrated and stained following the protocol in Methods 
2.7.4. For antibody optimization, a number of the recommended test slides from US 
Biomax, Inc (product code: T125b) were purchased and it was found that the optimum 
antibody concentration was 1:500 with a 1:200 dilution of the biotinylated secondary. 
This protocol had also previously been optimized by Jenny Down (now at the Garvan 
institute, Sydney, Australia) and published in Eaton et al. 2011. A Mouse monoclonal 
anti human CXCR4 (purchased from R&D) and matched Mouse IgG2A Isotype Control 
were used in each experiment. The isotype showed minimal to zero background 
staining. 
 
After staining the array was scored by Dr. Colby Eaton and an independent and 
experienced pathologists (Professor Simon Cross) who were each blinded to the clinical 
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information provided with the array. Each core was given a percentage of CXCR4 
staining; <10% was considered weak, 10-50% moderate, 50-90% strong and 100% very 
strong. A representative image of the scoring system is shown in Figure 6.14. Only two 
cores were excluded from the analysis as the histology could not be scored due to high 
background.  
 
 
Figure 6.14 Immunohistochemistry for CXCR4 in human primary prostate cancer 
specimens: examples of scoring system 
A. Weak <10%. B. Moderate 10-50%. C. Strong 50-90%. D. Very strong 100%. 
 
The array showed that CXCR4 staining was significantly stronger in the 62 prostate 
cancer samples (adenocarcinomas) compared to the 11 BPH samples by Mann-Whitney 
non-parametric test (P=0.0003) (Part A, Figure 6.15). CXCR4 staining was also 
significantly stronger in higher Gleason grade tumours (Grades 3 and 4) compared to 
low Gleason grade tumours (Grade 2) (Mann-Whitney test P= 0.043 Grade 2 vs. Grade 
3, P= 0.016 Grade 2 vs. Grade 4). Although Grade 5 tumours showed the same trend, 
the variation was much greater and this result was not significant (P=0.37) (Part B, 
Figure 6.14). CXCR4 staining also corresponded to Gleason score (the sum of the two 
most common cell grades in the sample). Only 24.0% of low Gleason score tumours (a 
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combined  score  of  ≤  6)  had  strong-very strong CXCR4 staining compared to 55.5% and 
47.4% strong-very strong staining in intermediate (Gleason score 7) and high (8-10) 
Gleason score tumours, respectively. A lower age at diagnosis is often associated with 
poor prognosis and is often an indicator that patients should receive radical surgery. 
66.6% of patients under the age of 50 had strong-very strong staining for CXCR4. This 
result was the same in the 50-60 age group, 66.6% strong-very strong staining and very 
slightly higher in the 61-70 age group, 69.23%. However, this reduced slightly to 50% 
strong-very  strong  staining  in  the  ≥71  age  group.   
 
 
Figure 6.15 Positive CXCR4 staining was significantly stronger in higher grade tumours 
A. Positive CXCR4 staining was significantly higher in prostate cancer samples 
(adenocarcinoma) than in Benign Prostatic hyperplasia (BPH) samples (Mann-Whitney test, P= 
0.0003). B. Positive CXCR4 staining was significantly higher in Gleason grade 3 and 4 samples 
than in low grade (2) tumour samples (Mann-Whitney, P= 0.043 and P= 0.016 and 
respectively). 
 
  
CXCR4 staining did not correspond to the presence of metastases at the time of biopsy.  
57.69% of patients with metastases had strong-very strong CXCR4 staining compared 
to 63.0% strong-very strong staining in patients without metastases. However, strong-
very strong CXCR4 staining was higher in patients with distant metastases (37.5%) 
compared to patients with node but no distant metastases (only 25% of these samples 
had strong-very strong staining). Overall, a strong positive CXCR4 staining did not 
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predict the presence of metastases better than Gleason score, as 47.5% of patients with a 
high Gleason score had metastases compared with only 38.4% of high CXCR4 patients 
with metastases. A representative image of these results is shown in Figure 6.16 with 
the provided clinical information and the percentage of CXCR4 staining shown in 
Table 6.1. 
 
 
Figure 6.15 Immunohistochemistry for CXCR4 in human primary prostate cancer 
specimens: Example of Gleason grade vs CXCR4 staining  
A. A low grade 2 Gleason grade tumour sample with weak CXCR4 staining indicated by the 
low amount of brown DAB stain. B. A high grade 4/5 Gleason grade tumour with strong 
CXCR4 staining indicated by the high amount of strong brown DAB stain. 
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Number Gleason grade Gleason Score Total score TNM CXCR4 staining 
1 2 2+4 6 T3aN0M0 weak 
2 2 2+4 6 T4N1M1c weak 
3 2 2+2 4 T2N0M0 weak 
4 2 3+4 7 T2N0M0 weak 
5 3 3+4 7 T2aN0M0 weak 
6 2 2+4 6 T3N1M1 weak 
7 2 2+4 6 T2N0M0 moderate 
8 2 2+4 6 T2N1M1b weak 
9 2 2+4 6 T2N0M0 weak 
10 2 2+4 6 T2aN0M0 weak 
11 Excluded - - - - 
12 2 2+4 6 T4N1M1 strong 
13 3 3+3 6 T2N0M0 weak 
14 2 2+4 6 T2N0M0 strong 
15 3 3+4 7 T2N0M0 very strong 
16 2 2+4 6 T4N1M1c moderate 
17 3 2+5 7 T2N1M1c           strong 
18 3 3+4 7 T3N1M1b moderate 
19 3 3+4 7 T2aN0M0  strong 
20 2 2+4 6 T2N0M0 strong 
21 3 2+5 7 T3N2M1 weak 
22 2 2+4 6 T3N1M0 strong 
23 3 2+5 7 T2N0M0 strong 
24 3 2+5 7 T3N0M1 very strong 
25 5 4+5 9 T3N1M0  strong 
26 2 2+4 6 T2N0M0 strong 
27 3 2+5 7 T3N2M1 weak 
28 3 2+5 7 T3N2M1 very strong 
29 2 2+4 6 T3N0M1b weak 
30 2 2+4 6 T2N0M0 weak 
31 3 2+5 7 T3N0M1 weak 
32 2 2+4 6 T2N0M0 strong 
33 3 2+5 7 T3N0M0 very strong 
34 3 2+5 7 T2N0M0 very strong 
35 3 2+5 7 T2N0M0 very strong 
36 2 2+4 6 T3N0M0 moderate 
37 2 2+4 6 T3N0M0 very strong 
38 2 2+4 6 T3N1M1b strong 
39 2 2+4 6 T3bN0M0 strong 
40 2 2+4 6 T3N1M0 moderate 
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41 2 2+4 6 T2N0M0 strong 
42 3 2+5 7 T3aN0M0 moderate 
43 Excluded - - - - 
44 5 5+5 10 T4N1M1 weak 
45 5 5+5 10 T4N1M1c weak 
46 5 5+5 10 T2N0M0 strong 
47 5 5+5 10 T4N1M1c  strong 
48 5 5+5 10 T3N0M0 weak 
49 5 5+5 10 T2N0M0 very strong 
50 5 5+5 10 T2N0M0 strong 
51 4 4+5 9 T2aN0M0 very strong 
52 4 4+5 9 T2N0M0  strong 
53 5 5+5 10 T2N0M0  strong 
54 5 5+5 10 T2N0M0 moderate 
55 2 2+4 6 T2N0M0 weak 
56 5 4+5 9 T2N1M1 weak 
57 3 2+5 7 T2N1M1c very strong 
58 4 4+4 8 T2N1M1b strong 
59 3 2+5 7 T4N0M1 moderate 
60 2 2+4 6 T3N1M1b strong 
61 5 5+5 10 T3N1M0 weak 
62 5 5+5 10 T3aN0M0 weak 
63 5 5+5 10 T2N0M0 moderate 
64 5 5+5 10 T2N0M1 strong 
65 BPH –  – weak 
66 BPH –  – weak 
67 BPH –  – weak 
68 BPH –  – weak 
69 BPH –  – weak 
70 BPH –  – weak 
71 BPH –  – weak 
72 BPH –  – weak 
73 BPH –  – weak 
74 BPH –  – weak 
75 BPH –  – weak 
Table 6.1 The summary clinical information and level of CXCR positive stain for each 
patient sample on the PR752 array.  
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6.4 Discussion 
 
6.4.1 Markers of dormancy in multiple prostate cancer cell lines 
 
Low density array (LDA) card 2 analysis revealed that the expression of CXCR4 was 
significantly increased in the dormant cell sub-population (DiD retaining cells at day 
14) in both the LNCaP and C42B4 cell lines. This was in agreement to the increase seen 
in the PC-3NW1 cell line. CXCR4 is an alpha-chemokine receptor, which binds to the 
ligand stromal-derived-factor-1 (SDF-1 also called CXCL12). In addition to the 
increased expression of this receptor in dormant cells, CXCR4 was the only protein to 
have a significant increase in staining in the DiD+ sub-population in all three cell lines. 
It is widely accepted that an increase in CXCR4 increases the migratory potential of a 
cell towards its chemoattractant ligand CXCL12 (SDF-1) (Teicher and Fricker, 2010). 
CXCL12 is abundantly present in multiple locations in the body, including the lung, 
liver and bone marrow. Indeed, the presence of CXCR4 on HSC allows the trafficking 
of these cells to the HSC niche in the bone marrow. CXCR4-CXCL12 signalling via 
PIK3 and MAPK is hypothesised to increases cell migration as well as survival and 
proliferation (Teicher and Fricker, 2010). The presence of CXCR4 in prostate cancer, as 
well as its role in the disease particularly its link to metastasis, has been explored in 
many published in vitro and in vivo studies and there is multiple evidence that 
CXCR4/CXL12 signalling promotes metastasis in experimental models. Xing et al. 
(2008) demonstrated that prostate cancer cells had increased invasion through matrigel 
in response to the CXCL12 ligand, and that invasion was decreased following a down 
regulation of CXCR4 by siRNA (Xing et al., 2008). Sun et al (2005) provided evidence 
that the neutralisation of CXCR4 by targeted antibodies, reduced the size of skeletal 
tumours when PC-3 cells were injected directly into the tibia of NOD/SCID mice (Sun 
et al., 2005). Schiozawa et al. (2011) demonstrated that prostate cancer cells utilise 
CXCR4  in  order  to  home  to  and  establish  ‘footholds’  in  the  bone  marrow  of  xenograft  
mouse models. Although these studies have indicated that CXCR4 is present in prostate 
cancer cell lines and that its presence may confer a heightened metastatic ability, the 
results presented in this chapter present a novel hypothesis in which CXCR4 
expression/presence is not uniform across the cell line and that a specific sub-
population, characterised by dormancy, has a significant higher level of this protein. It 
is tempting to speculate that these cells, with elevated CXCR4, will have a greater 
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ability to home to the bone marrow and therefore have an increased ability to form 
skeletal tumours. Although experiments in our group have shown the increased 
metastatic ability of the dormant cell sub-population, further in vivo imaging studies 
would be required to assess whether DiD+ cells have a greater ability to arrive in the 
bone or whether their high tumourigenic ability is determined at another stage of the 
metastatic cascade.  
 
Many molecules have been implicated in the molecular basis for cancer dormancy in the 
bone marrow, including growth-arrest specific 6 (GAS-6) (Shiozawa et al., 2010b). 
Although CXCR4 presents an attractive candidate as a driver of dormancy, the primary 
aim was to assess the value of this marker as a prognostic indicator. It was important to 
determine whether CXCR4 staining correlated to other prognostic indicators such as 
Gleason grade and Gleason score. A further aimwas to determine if an increase in 
CXCR4 staining in primary prostate cancer samples was an indicator of the presence of 
metastases by correlating the level of CXCR4 staining to the known TNM stage of the 
patients screened.  
 
LDA card 2 analysis also showed that Follistatin (FST) and Vitronectin were both 
significantly increased in the LNCaP dormant cell sub-population compared to their 
rapidly dividing (DiD negative at day 14) counterparts. VTN is a marker of EMT as it is 
associated with mesenchymal/fibroblast-like cells. This increase was significant in the 
PC-3NW1 sub-population but not in the C42B4, however the trend was the same but 
the increase failed to reach significance (P= 0.093). FST is a glycosylated protein that 
binds to and neutralises members of the TGF-ß family including Activin. FST-Activin 
signalling is hypothesised to be involved in the normal development and homeostasis of 
the prostate gland. Therefore, aberrant expression of FST is linked to prostate cancer 
progression and poor prognosis (Sepporta et al., 2013).  Indeed an increase in FST 
expression in the androgen responsive LNCaP cell line is linked to progression towards 
a more malignant androgen-insensitive phenotype. Vaarala et al. (2000) compared the 
gene expression differences by microarray of LNCaP cells to an engineered androgen 
insensitive variant (LNCaP-). The authors found that FST was significantly increased in 
the LNCaP- variant (Vaarala et al., 2000). It would therefore be of interest to assess the 
androgen receptor status of the DiD+ LNCaP cells to see if an increase in FST in my 
studies correlates to a switch to androgen insensitivity. 
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FST was also increased in the dormant cell sub-population, by LDA card 2 analysis, in 
both the C42B4 and PC-3NW1 cell lines however this did not reach significance 
(P=0.0578 and 0.0698 respectively). Interestingly, FST expression was on average 
higher in the androgen insensitive PC-3 and C42B4 cell lines than in the LNCaP cell 
line which may again suggest androgenic involvement in its expression.   
 
Interestingly, an increase in FST was also detected at the protein level by 
immunofluorescence in the LNCaP DiD retaining cells alone. This suggests that in the 
androgen sensitive LNCaP cell line an increase in FST is associated with a more 
dormant, and perhaps more malignant, cell phenotype. Whether the dormant phenotype 
is androgen sensitive re: proliferation has yet to be tested. 
 
No significant increase was detected in the presence of DKK1 protein in the dormant 
cell sub-population of any of the cell lines tested. Although, a difference in the LNCaP 
or C42B4 cell lines was not expected, it was predicted that DKK1 levels would be 
increased in the DiD+ cells in the PC-3NW1 cell line. DKK1 staining was detected at a 
very high intensity in this cell line so that subtle differences between the dormant and 
rapidly growing populations may not have been measurable.  
 
Similarly, there was no significant difference in the presence of MMP3 in the dormant 
cell sub-population of any of the cell lines tested. Again, it was predicted that an 
increase in staining would only be observed in the PC-3NW1 DiD+ population. A non-
significant increase in staining in the DiD+ vs. DiD- PC-3NW1 cells was observed and 
it may be that increasing the number of repeats would allow differences to reach 
significance.  
 
In cases where increased expression of genes were identified using the LDA analyses 
but where protein levels were not altered in dormant vs. non-dormant comparisons, 
there could be several reasons for lack of correlation between RNA and protein 
production. Firstly, and as mentioned previously, the role of transcription and post-
translational modifications are not to be underestimated which may account for the high 
variability. In a review by Vogel and Marcotte (2012), it is suggested that only around 
40% of the variation in protein concentration can be explained by knowing mRNA 
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levels. This can also be attributed to the variation in protein half-life that can mean the 
degradation time of different proteins can vary between minutes and days (RNA has a 
more uniform rate of degradation between 2 and 7 hours) meaning that within an 
experiment the detectable protein levels may change (Vogel and Marcotte, 2012). 
Furthermore, the turnover rate of these proteins may be high and differences may not 
have been captured in the time frame of this experiment. Furthermore, the level of 
protein detection is reliant on the efficiency of the fluorescent microscope used to detect 
antibody fluorescence and also by the experimenter to set the exposure times and light 
intensity based on the controls. Perhaps a less subjective measure of protein levels 
would have been achieved by western blot but the low number of cells retained after 
FACs would be insufficient for protein extraction for this method. Another major issue 
of antibody based techniques is whether the proteins are cell surface or secreted, if the 
protein is cell surface i.e. retained by the cell correlations would be more likely. This is  
the case for the membrane bound CXCR4 protein. If the protein is secreted i.e. lost from 
the cell as is the case with MMP3, FST and DKK1,  then correlation with gene 
expression could be lost since the protein is no longer there to be seen by IHC. This 
means that secreted markers are often less useful to apply to tissue sections as 
prognostic markers.  
 
6.4.2 CXCR4 as a prognostic indicator in primary patient samples 
 
The value of CXCR4 as a prognostic indicator in prostate cancer has previously been 
investigated by a number of groups. However, the published data to date has not 
assigned a definitive role for CXCR4 in predicting patient outcomes and there are many 
conflicting results. The first study to consider this interaction was published in 2004 by 
Mockizuki and colleagues which provide evidence that a higher rate of CXCR4 staining 
(following immunohistochemistry on 25 prostate cancer samples and 9 non-malignant 
prostate samples) was detected in patients with bony metastases compared to patients 
without bone metastases (Mochizuki et al., 2004). The authors concluded that high 
positive staining for CXCR4 was a better predictor of metastases than Gleason score. In 
a similar study, Jung et al. (2011), assessed CXCR4 in 57 prostate cancer patients and 
correlated staining to age, PSA (pre-treatment), Gleason score, Tumour stage, 
biochemical recurrence, local recurrence and distant metastases. They also found 
evidence that a high level of CXCR4 staining was associated with the presence of 
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distant metastases as well with local recurrence but none of the other parameters 
measured (Jung et al., 2011). In contrast to this result, Lu et al. (2013) published data to 
suggest that CXCR4 staining correlated only to tumour residue at the primary site and 
was not associated with metastases. This work was however, carried out on the smallest 
sample set (36 patients consisting of 8 normal, 28 prostate cancer samples) (Lu et al., 
2013). Akashi et al. (2008) used 52 patient samples that all had evidence of bone 
metastases to measure the correlation between high CXCR4 staining and other clinical 
parameters. All 52 patients had metastatic prostate cancer and were receiving hormone 
therapy. The level of CXCR4 staining was assessed by immunohistochemstry on 
primary prostate biopsies taken prior to treatment; the level of staining was evaluated by 
two independent pathologists. Strong positive CXCR4 staining was not associated with 
pathological grade, extent of bony metastasis, or clinical response to hormonal therapy. 
However, high CXCR4 staining did correlate to poor cancer-specific survival (Akashi et 
al., 2008). 
 
The patient array utilised in my studies comprised of the larger patient sample set than 
the previous published work (75 cores: 64 cases of prostate cancer, 11 hyperplasia). The 
array showed that a significantly stronger amount of positive CXCR4 staining was 
detected in prostate adenocarcinoma samples compared to samples of hyperplasia 
(Mann-Whitney, P= 0.0003). Lu et al. (2013) also showed that positive CXCR4 staining 
was  higher  in  prostate  cancer  samples  compared  to  ‘normal’  prostate  tissue.  However,  
the latter was sampled from the peritumoural normal prostate, not from independent 
BPH specimens, as was the case in my array studies. The collection of tumour 
associated normal tissue would require a high degree of accuracy and may not always 
exclude tumour tissue which may confound the results.  
 
Unlike any of the previously mentioned studies, my study showed that strong positive 
CXCR4 staining was associated with a higher Gleason score and a higher Gleason grade 
compared to lower grade tumours. However, this was not significant at the highest 
grade (Grade 5), nevertheless this could be attributed to the increase in variation seen in 
very poorly differentiated cancers. This result was in conflict to the results published in 
Jung et al. (2011), who found that CXCR4 did not correlate to any of the other 
prognostic parameters investigated. The results published in Jung et al. are also the only 
other study that looked at the correlation between patient age and CXCR4 staining and 
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again they found conflicting results to my own. The source of this variation could be in 
the antibody used. These experiments utilised a mouse monoclonal CXCR4 antibody 
from R&D, which ensured love background. The antibody used by Jung et al. was a 
polyclonal Goat antibody that could have produced increased background due to its 
polyclonal nature. Furthermore, the blocking solution used in Jung et al. and in what 
concentration was not specified. The importance of the right blocking solution when 
detecting CXCR4 is highlighted in Eaton et al. (2010) who provided evidence that the 
wrong blocking serum may produce false positives.  
 
My array suggested that a lower age at the time of biopsy correlated to higher CXCR4 
staining. This result was only marginal and the value of age as a prognostic indicator in 
prostate cancer has come under scrutiny. Therefore, the fact that younger patients have 
higher CXCR4 may not be an indicator of poor prognosis. However, perhaps when used 
in combination with age, CXCR4 staining may be useful in assigning prognosis but this 
would require a larger series than that presented here.  
 
Strong positive CXCR4 staining in this study could not be used as an alternative to 
Gleason grading to predict TNM status as while 38.4% of high CXCR4 samples had 
metastases compared to 47.36% of high Gleason grade tumours with metastases. This 
suggests that CXCR4 is not additionally informative when poor prognosis is already 
predicted by other factors but may contribute to prognosis in multivariate analysis.  
 
A limitation of this study was that no follow up clinical information was available for 
the patients sampled on the array. The presence of metastases at the time of biopsy was 
the only information provided, therefore it was impossible to know whether patients 
with high CXCR4 staining would go on to develop metastases in later years. Therefore, 
although the level of positive CXCR4 staining did not correlate to the TNM stage of 
patients in this sample set, this does not exclude a use for CXCR4 as a marker to predict 
later occurring metastases in patients with apparently better prognosis based on 
stage/grade at the time of diagnosis. Given the association of CXCR4 with dormancy in 
my experimental studies, it is perhaps in the context of identifying patients with very 
early disease, apparently confined to the prostate but who present at a later date with 
metastases that CXCR4 staining as a predictor of later metastasis would be most useful.  
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This requires further investigation with different panels of patient samples with good 
follow up over 5-10 years.  
 
It was also interesting that CXCR4 was higher in patients with distant metastases than 
in patients with node metastases without distant metastases suggesting that high 
CXCR4 is associated with a more migratory phenotype once it has invaded the lymph 
nodes. The suggestion that CXCR4 does not correlate to metastases in this study is in 
agreement with the work published by Lu et al. (2013) and counters the claims made in 
Mochizuki et al. (2004) and Jung et al. (2011). However, as mentioned without follow 
up clinical information it was impossible to tell whether strong CXCR4 staining would 
predict the onset of later metastases.  
 
Other limitations include those that are typical of most immunohistochemical stains. It 
is expected that a certain amount of variability exists between experimenters performing 
the   assay   and   even   between   experimental   ‘runs’.   There   is   also   the   caveat   of   inter-
observer variation when is came to scoring CXCR4 staining. However, as two 
experienced scientists scored the samples independently this bias is reduced. There is 
also the limitation that only one core per patient was provided on the array and as 
prostate cancer is known to be a very heterogeneous disease it is not expected that this 
single core will represent the disease. Although Biomax provides information on their 
website that argues that as the 1.5 mm diameter cores used are 6.3 x bigger than 0.6 mm 
standard size cores and therefore represent a better representation of the disease it does 
not account for variation within different regions of the tumour. This would require 
sampling from multiple sites of the prostate to allow a better representation. There were 
however, several advantages to using the commercially available arrays from Biomax 
which reduced other common limitations such as variable processing time and time in 
formalin as Biomax ensures that all of their samples are processed within 15-30 minutes 
of surgical resection and are fixed in formalin for 24 hours. This suggests that the 
results obtained in my experiments should be highly reproducible when using Biomax 
arrays as they are all prepared in a controlled, uniform way.  
 
 
6.4.3 Conclusion 
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CXCR4 has been shown to be a common marker of the dormant phenotype in three 
human prostate cancer cell lines. DiD retaining dormant cells in the PC-3NW1, LNCaP 
and C42B4 cell lines had a significantly higher level of CXCR4 at the gene (as 
measured by RT-qPCR) and protein level (as measured by immunofluorescence). 
Although CXCR4 did not correlate to the TNM status of patients in the tissue 
microarray examined, as measured by immunostaining, high CXCR4 did correlate to 
higher Gleason grade and Gleason score. A positive link between CXCR4 staining and 
Gleason grade and score has previously been contested, however the array used in this 
study had the largest patient sample examined and this may account for these 
differences. It remains a possibility that CXCR4 could have a role as a prognostic 
marker in some important settings but this will require further studies with better patient 
sample sets with more complete clinical histories.  
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7.1 Discussion 
 
7.1.1 Identifying the presence of a dormant cell sub-population in multiple prostate 
cancer cell lines 
 
Staining with the lipophilic membrane dyes CM-DiI and Vybrant® DiD revealed the 
presence of a low frequency dye retaining sub-population in the PC-3NW1 cell line. 
Vybrant® DiD (DiD) was selected to be used in subsequent experiments due to its 
higher fluorescent intensity as measured by flow cytometry (X geometric mean) and 
fluorescent microscopy. Mitomycin C treatment of PC-3NW1 cells to induce mitotic 
arrest, showed that DiD was retained at high frequency following a growth suppression 
treatment. This indicated that dye retention was an accurate measure of cell dormancy.  
 
Dormancy, in this project, was defined as cells that have retained lipophilic dyes past 14 
days in in vitro culture. Dye retaining cells at day 14 in the PC-3NW1 cell line were 
subject to cell cycle analysis by KI-67 and P.I staining. From these experiments it was 
decided   that  DiD  positive  cells  would  be  classified  as   ‘dormant’  and  not  quiescent  as  
they existed in all stages of the cell cycle from S phase to G2/M and not exclusively 
G0/G1: a characteristic of cells in quiescence, and were both KI-67 positive and 
negative suggesting growth arrest had occurred outside G0. This definition is in 
agreement to that published in Fehm et al. (2008), which stated that dormant cells are 
characterised by cell cycle arrest (not specifically in G0) and that dormant cells do not 
undergo apoptosis or proliferation until changes in the microenvironment, or at the gene 
expression level, prompt them to do so (Fehm et al., 2008). In other studies however, 
GO/G1  cell  status  is  used  as  a  marker  of  ‘dormant’  circulating  tumour  cells  (CTCs)  or  
disseminated tumour cells (DTCs) in patients, as discussed in a review by Aguirre-
Ghiso (2007) . In these studies G0/G1 status is often used to identify cells in a quiescent 
state   that   are   then   labelled   as   ‘dormant’   that   are   present   in   patients   and   not   as   a  
definition of cells that have a dormant phenotype. My studies aimed to observe the 
dormant phenotype (defined as long term DiD retention) and then look at the cell cycle 
profile. This is different from traditional methods that have used cell cycle status: 
GO/G1 as a marker of dormancy, which is then used to identify these cells in 
experimental models  in  order  to  study  ‘dormancy’. 
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There   is   also   debate   as   to   whether   ‘dormant   cells’   detected   in   patients   represent  
quiescent (retaining the ability to proliferate) or senescent cells (Aguirre-Ghiso, 2007). 
The results presented in my own studies suggest that dormant cells in this context are 
not   senescent.  A   senescence   detection   kit  was   used   to   assess  whether   ‘dormant’   cells  
were senescent and it was shown that DiD positive cells at day 14 after staining did not 
stain positively for blue Senescent Associated-beta-galactosidase activity which is 
thought to be a marker of senescent cells. Further evidence that the DiD retaining cells 
represented a dormant and not senescent sub-population was provided by experiments 
in Chapter 4 which showed that DiD retaining dormant cells isolated at day 14 after 
staining were capable of forming colonies in monolayer clone assays. This was an 
important distinction as in the development of cancer the avoidance of senescence after 
the accumulation of mutations in the cell is seen as an important step in tumourogenesis 
and that senescence, as opposed to dormancy, does not result in disease relapse 
(Aguirre-Ghiso, 2007). This does not rule out the possibility that dormancy is a result of 
a perturbed senescent pathway but this requires further study.  
 
It was significant to find that the presence of a DiD retaining population was not limited 
to the PC-3 cell line or the tested PC-3 variants (PC-3NW1, PC-3RFP and PC-3GFP) 
but was present in both the LNCaP and C42B4 cell lines. Whether the presence of this 
sub-population is exclusive to cancer cell lines remains to be tested. Future experiments 
would be required to assess DiD dye retention in normal human primary prostate 
epithelial cells or   in   immortalised   ‘normal’  prostatic  epithelium such as PNT2 or in a 
BPH (benign prostatic hyperplasia) cell line such as BPH-1 (Hayward et al., 1995) to 
test this. However, the identification of a dormant population in prostate cancer cell 
lines may reflect the observed clinical manifestations of the disease in patients where 
many have prolonged periods where they appear to be disease free after diagnosis and 
removal of the primary cancer until they present with incurable bone metastases. This 
implies the presence of relatively indolent cells taking up residency in the skeleton at an 
early   stage   in   the   disease   and   remaining   ‘dormant’   for  many   years   until   triggered   to  
proliferate. The use of lipophilic dyes presents a novel protocol to investigate 
dormancy, which may enable us to gather more information relevant to the dormant 
phenotype, its drivers and mechanisms for activation.  
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The use of DiD to identify dormant cells in vivo and in vitro has been published by 
Yumoto et al. (2014) since the start of this thesis. The authors provide further support 
that DiD can be used to identify cells with limited proliferation, as measured by EdU 
incorporation during DNA synthesis. However the authors have not looked at the use of 
this dye to investigate the mechanisms that regulate dormancy or the characteristics of 
the DiD retaining population. The use of this type of technology has however been 
demonstrated in other cancers. For example, and as discussed in Introduction 1.4.13, 
retention of the lipohilic cell membrane dye PKH67 was used by Kusumbe and Bapat 
(2009) to identify dormant cells in the A4 ovarian cancer cell line. The authors stained 
A4 cells with PKH67 and injected cells sub-cutaneous into NOD/SCID mice. They 
found that a PKH67High population was present after long-term incubation. In agreement 
to my studies this dye retaining sub-population had, upon isolation, a higher clonogenic 
ability in monolayer and also an increased ability to form tumours when re-injected into 
immunocompromised mice.  My studies provide support to the hypothesis presented in 
Kusumbe and Bapat that dye retaining cells were not characterised by G0/G1 cycle 
status as in experiments similar to my own, the authors found that a percentage, albeit a 
small one, of dye retaining cells were KI-67 positive by flow cytometry and that 
PKHHigh cells when stained with Propidium Iodide also have a variable cell cycle profile 
that includes S-phase and G2/M as well as G0/G1.  
 
7.1.2 Mechanisms that regulate dormancy 
 
The experiments presented in Chapter 4 aimed to use DiD to investigate dormancy and 
assess the factors that may regulate entry and exit into this state. Clone assays in 
monolayer showed that altering the serum concentration of the culture media affected 
the cloning ability of the PC-3NW1 cell line and the C42B4 cell lines (LNCaP cells did 
not readily form colonies in monolayer).  Low serum (2% FBS) decreased the ability of 
these cell lines to form colonies compared to routine serum (10% FBS) and, 1% FBS 
prevented colony formation entirely at clonal density in all cell types. DiD staining 
before plating indicated that these cells, seeded in 1% FBS at clonal density, were 
maintained in a dormant state after 14 days in culture. This suggested that cells could be 
‘forced’  into  dormancy  and  prompted  the  further  characterization of these cells in more 
detail in Chapter 5. These results perhaps go against the previously accepted paradigm 
of hierarchical tumour cell organisation. In which, a small sub-population of stem cell-
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like cells give rise to uni-directional tumour heterogeneity. However, more research into 
cancer cell plasticity and the role of the microenvironment on cell phenotype has led to 
a greater appreciation of the fluidity of cancer cell properties regardless of hierarchical 
organisation (Meacham and Morrison, 2013). Further experiments in Chapter 4 showed 
that the re-staining of cells that had lost DiD at day 14 after initial DiD staining, and 
were therefore considered to be rapidly dividing, could give rise to slow cycling cells 
that were DiD retaining. This suggests that in the PC-3NW1 cell line, cells can transit 
between   rapid   growth   and   dormancy   so   that   phenotypes   are   ‘plastic’   rather   than  
intrinsic. This result is in agreement to research published by Roesch et al. in 2013. The 
authors identified a slow-cycling sub-population in Melanoma cell lines that was 
characterised by the retention of the PKH26 cell dye. This sub-population was 
characterised by high expression of the H3K4 histone demethylase JARID1B. 
Interestingly the authors found that the expression of JARID1B was dynamically 
regulated and that cells that were JARID1Blow could give rise to cells of a JARID1Bhigh  
phenotype and vice-versa. Furthermore, the authors found that JARID1B expression and 
the subsequent accusation of the slow-cycling phenotype was temporally regulated by 
the environment (Roesch et al., 2010). This again has parallels to my own work which 
indicated that the acquisition of the dormant phenotype was regulated by the 
environment, as changes in the FBS concentration and initial seeding density of the 
culture environment were found to have altered the frequency of the dormant cell sub-
population. The decrease in the frequency of the dormant sub-population in less 
crowded cultures may suggest that dormancy results from environmental stress and 
suggested the hypothesis that hypoxia was a driving force for dormancy. This 
hypothesis was also considered by Roesch et al. (2013) who found that JARID1B 
expression was enhanced at low oxygen (3 days, 1% pO2) but reverted to normal under 
atmospheric oxygen. Although, immunofluorescence studies in Chapter 4 provided 
evidence   that   Hif1α   nuclear   translocation was increased in the DiD retaining sub-
population in my experiments, which serves as a marker for hypoxic conditions, more 
evidence would be required to add support to this hypothesis. Hypoxia as a driving 
force for cancer cell quiescence was considered mathematically in a theoretical paper 
published by Alarcon et al. (2004). The authors postulate that through increased p27 
expression, cancer cells can enter quiescence in response to increasing levels of hypoxia 
which would be lethal to a normal cell (Alarcon et al., 2004). The effect of hypoxia on 
cancer cell proliferation was demonstrated experimentally by Heddleson et al. (2009). 
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The   authors   found   that   hypoxia   induced   a   more   ‘stem   cell-like’   phenotype   in  
Glioblastoma cells that was characterised by reduced proliferation in the short-term, 
followed by increase proliferation after long-term culture. The authors did not consider 
the effect of cell cycle proteins but did find that cancer cells exposed to hypoxia had 
increased expression of traditional stem cell markers including Nanog and Oct4 
(Heddleston et al., 2009). Although this appears in disagreement to my own studies, that 
found no significant difference in the expression of these markers in the dormant cell 
sub-population, other stem cell markers such as PSCA were increased in the dormant 
cell subpopulation and furthermore the DiD retaining cells were not directly exposed to 
extreme hypoxia, hypoxia was only considered as a result of overcrowded culture 
conditions. Therefore an interesting set of experiments could investigate the effect of 
hypoxia exposure on stem cell marker gene expression and how it differs between DiD 
retaining and rapidly dividing cells.  
 
Further investigations into cell growth were done in Chapter 4 to measure serum factors 
and cloning ability. To assess whether cells were intrinsically unable to form colonies in 
1%, PC-3NW1 cell were seeded at clonal density in 10% FBS then transferred to 2% 
FBS and 1% FBS. It was found that more colonies were detected as a result of transfer 
into very low serum (1%) than transfer into 2% FBS. This could be due to a reliance on 
one set of factors in serum for the initiating stages of colony formation after which, 
transfer into low serum provides conditions that favour the expansion of cells that have 
already begun to grow. Serum contains both growth inhibitory/differentiating and 
mitogenic factors and cell fates are driven by this combination of influences which will 
vary with serum concentration. Furthermore, transfer into 1% FBS may select for a 
more resilient, autonomously growing cell type, than cells that survived transfer into 
2%, which once established have a higher clonogenic ability.  
 
Interestingly, increasing the seeding density in 1% FBS allowed increased colony 
formation in both the PC-3NW1 and C42B4 cell lines and the LNCaP cells to rapidly 
form monolayer cultures at varying confluence. This suggested that factors generated by 
the cells themselves, that are released into the culture media at sufficient concentrations 
when cells where at high density, could stimulate colony formation. To test this, and 
also to determine whether dormancy when induced at clonal density in 1% FBS was 
reversible, dormant cells at clonal density were treated with different media types at day 
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14 after seeding in 1% FBS. It was found that 10%, 2% FBS and conditioned media 
containing 1% FBS (media conditioned over rapidly growing cells at high density) 
could stimulate colony formation in previously dormant cultures. This suggested that 
dormancy is reversible and cells retain the ability to divide despite long term inactivity 
and that cells themselves were able to generate signals that initiated colony formation if 
present in high enough numbers. What these signals are remains to be determined, 
however, this was explored in Havard et al. (2011). The authors found that citric acid 
when added to unconditioned media was able to reproduce the stimulating growth effect 
observed when conditioned media was added to growth arrested LNCaP cells in 
monolayer clone assays. Furthermore, experiments published in 1983 by Hamburger et 
al. demonstrated that although increased serum promoted the cloning ability of tumour 
cells in soft-agar, the addition of growth factors including EGF and insulin were able to 
support anchorage-independent growth when the serum concentration was reduced 
(Hamburger et al., 1983). These studies support my own hypothesis and suggest that 
although serum is required for tumour cell growth there are other independent factors in 
the environment that can support clonal ability.  
 
Chapter 4 also showed that DiD retaining dormant cells at day 14 had a higher 
clonogenic ability than their rapidly dividing counterparts. As mentioned, this not only 
adds further support to the hypothesis that dormant cells are not senescent cells but also 
indicates that the DiD retaining cells may represent a more resilient cell phenotype, able 
to survive under different conditions. This is supported by in vivo evidence in our 
laboratory, that this sub-population is more metastatic in xenograft models.  
 
In order to investigate what is mediating the switch to mitotic dormancy an 
investigation of the presence/levels of cell cycle regulators could be performed.  
P27Kip1 and P21 are both inhibitors of CDKs (cyclin-dependent kinases), which are 
required for normal progression through cell division. RT-qPCR and/or 
immunofluorescence could investigate the presence of P27Kip1 and P21, as well as 
other regulators of the cell cycle, in the DiD+ population to assess the role these factors 
play in dormancy.  
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7.1.3 Dormancy is characterised by changes in gene expression levels 
 
RT-qPCR (reverse transcriptase-quantitative PCR) was used to assess relative gene 
expression differences between DiD retaining dormant cells and DiD negative rapidly 
dividing cells. Initial studies using stand-alone TaqMan assays showed that the 
expression of CXCR4 was significantly increased in the dormant cell sub-population 
compared   to   rapidly   dividing   cells.   Using   the   Promega   Reliaprep™   kit   high   quality  
RNA was extracted from as little as 3x103, as measured by 2200 TapeStation, which 
allowed me to proceed with low density array card work using relatively low yields of 
cells obtained from FACS Aria sorting.  
 
LDA card 1 analysis showed that the PC-3NW1 dormant cell sub-population had a 
number of significantly altered gene expression values. CXCR4 was significantly up-
regulated in the DiD+ population compared to the DiD- cells, which confirmed the 
TaqMan result.  Markers of EMT including Fibronectin, Vitronectn and MMP2 and 3 
were also significantly increased in the dormant cell sub-population. Expression of a 
number of stem cell markers were also up-regulated in the dormant cell type, including 
CD24, ANAX2 and PSCA. PSCA has been shown to be highly expressed in prostate 
cancer compared to normal tissues and has been associated with tumor progression (Gu 
et al., 2000). However, traditional stem cells markers such as SOX2, Nanog and Oct4 
(TaqMan alias POU5F1) were not significantly up-regulated. This is in contrast to the 
studies published by Bapat and Kusumbe (2009), who found that slow-cycling PKH67 
retaining cells were characterised by an increase in expression of OCT4 and also 
Nanog. Interestingly, it was found that Nestin was one of the only genes that had 
reduced gene expression in the dormant sub-population whereas Bapat and Kusumbe 
found Nestin was increased in their dye retaining cells. This result is perhaps not 
surprising as the difference in Nestin expression may reflect inherent differences in the 
prostate cell lines used in my studies and the ovarian cell lines used by Bapat and 
Kusumbe.  
 
It has previously been proposed that a CSC sub-population is present within prostate 
cancers  with  the  expression  signature  CD44+/α2β1hi/CD133+  (Collins et al., 2005). It 
is hypothesised that this sub-population of cells have an increased self-renewal capacity 
and the ability to recapitulate the heterogeneity of the parental tumour. Gene expression 
Chapter 7: Discussion 
223 
 
analysis in Chapter 5 revealed that the DiD+ sub-population did not differentially 
express these markers (with the exception of alpha 2 integrin which was significantly 
up-regulated with a P value of 0.048). This result suggests that although the DiD+ 
dormant sub-population shares CSC-like characteristics such as increased clonogenic 
ability and expression of some prostate CSC markers, the DiD retaining population may 
be completely distinct from the previously proposed prostate CSC phenotype or a 
previously undefined subset of such a population. This result was perhaps not surprising 
as   the   CD44+/α2β1hi/CD133+   was   also   characterised   as   having   a   high   proliferative  
potential in vitro (Collins et al., 2005). However, differences in experimental 
approaches may explain this. The authors measured proliferation by colony formation in 
clonogenic assays in monolayer rather than growth curves or loss of cell membrane 
dyes, which is in agreement to the higher clonogenic ability of the DiD+ cells observed 
in Chapter 4. They also used combinations of adhesion assays and flow-cytometry 
analysis   of   antibodies   against   CD44,   CD133   and   α2,   β1   integrin   to   reveal   a  
CD44+/α2β1hi/CD133+   sub-population while here I used gene expression analysis 
using the LDA. Repeating the above flow-cytometry studies with the DiD retaining 
cells could clarify the relationship between dormant cells described here and prostate 
cancer stem cells, but it should be noted that expression of CD133 was beyond detection 
in my dormant cells therefore detection by flow-cytometry may not provide any 
additional information. Interestingly, studies by Guzman-Ramirez et al. (2009) found 
that cells isolated from prostate cancer patients that had a heightened ability to form 
prostaspheres (a measure of a stem cell-like phenotype) had a wide distribution of 
marker expression suggested both a stem cell like phenotype (CD44+ and other 
traditional markers such as OCT4) but also a basal like phenotype (CK5+/CK14+). The 
authors argue this suggests a heterogeneous cell composition and found that cells that 
had high self-renewal capacity (as measured by sphere formation) were both CD133+ 
and CD133-. It is therefore tempting to speculate that the dormant cells isolated in my 
studies may represent a fraction of the proposed prostate CSC sub-population that has 
lost CD133 and has an increased ability to form metastases in vivo. Considering the 
results in Guzman-Ramirez et al. it would be useful to asses the sphere forming ability 
of the dormant cells vs. the rapidly dividing bulk population in the three cell lines tested 
in my studies.  
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Following LDA card 1 analysis a second LDA card was designed (LDA card 2) with a 
more limited number of assays, which allowed the number of samples that could be 
investigated per card to be increased. The aim of this card was to assess whether key 
gene expression differences that were present in the PC-3NW1 DiD+ population, by 
LDA card 1 analysis, were also present in cells grown at clonal density in 1% FBS and 
cells that were initially considered to be rapidly dividing which then retained DiD after 
restaining.  
 
The most significant result of LDA card 2 experiments was that the gene expression 
profile of the PC-3NW1 dormant sub-population was not significantly different from 
cells  that  have  been  ‘forced’  into  dormancy  by  culture  in  1%  FBS  at  clonal  density.  This  
suggested that cells with a dormant phenotype share gene expression characteristics, 
regardless of how dormancy was acquired. This is potentially of value, since studying 
the drivers of dormancy and release of cells from this state could now be modelled 
using induced dormancy in these models. 
 
To investigate this further, as shown in Chapter 6, LDA card 2 was used to assess the 
gene expression levels of dormant cells in the LNCaP and C42B4 cell lines. It was 
found that the DiD retaining sub-population in the C42B4 cell line was not significantly 
different from the DiD retaining PC-3NW1 sub-population at the gene expression level 
across the assays tested. Although DiD+ LNCaP cells were significantly different to 
DiD+ PC-3NW1 cells, they were not significantly different from DiD+ C42B4 cells. 
Interestingly, the dormant cell sub-population in all three cell lines was characterised by 
a significant increase in the gene expression of CXCR4 compared to rapidly growing 
cells in the same populations. The level of CXCR4 expression in prostate cancer cell 
lines has previously been investigated by PCR. Mochizuki et al., (2004) found that 
CXCR4 was expressed at a high level in PC-3, LNCaP and DU-145 cells. However, 
Engl et al., (2006) found that CXCR4 expression in the LNCaP cell line was only 
moderate when compared to the DU-145 cell line. Engl et al. used end-point PCR 
whereas Mochizuki et al. used real-time PCR so this perhaps accounts for the variability 
in results. Although high CXCR4 expression in prostate cancer cell lines is not a new 
finding, to the best of my knowledge, the results demonstrated in Chapter 6 present a 
novel hypothesis that CXCR4 is differentially expressed in prostate cancer cell lines and 
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that a high CXCR4 sub-population exists within these cell lines that is characterised by 
a dormant phenotype.  
 
Significantly this result was also observed at the protein level by immunofluorescence. 
ImageJ analysis showed that DiD+ cells in all three prostate cancer cell lines had 
significantly higher positive staining for CXCR4 than their rapidly dividing DiD- 
counterparts. This result was perhaps not surprising as CXCR4 is hypothesised to not 
only induce HSC homing to the bone marrow, but also regulate HSC quiescence once in 
contact with the niche to maintain the HSC pool (Sugiyama et al., 2006). Using an 
induced CXCR4 knockout mouse model (MxCre-CXCR4flox/null ), the authors found 
evidence that CXCR4 null mice were more sensitive to drugs that target cycling HSCs 
(5-FluroUracil specifically). CXCR4 null mice also had a decreased fraction of KI-67- 
HSCs as measured by FACS Aria flow cytometry. CXCR4 presents an attractive 
candidate as a driver of dormancy in prostate cancer cell lines. In order to investigate 
this further conditional knockdown studies could be utilised to assess if when the 
CXCR4 gene is silenced, or removed, cells retain the ability to enter into the dormant 
state.  
 
There are numerous studies suggesting that CXCR4/CXL12 signalling promotes 
metastasis in prostate cancer. It would therefore be interesting to design experiments to 
define the drivers for CXCR4 increase in the dormant cells specifically and identify 
mechanisms to target this in these cells. As mentioned in Chapter 5 discussion, CXCR4 
is a target of the Hif1v transcription factor, which is translocated to the nucleus under 
hypoxic conditions (Ishikawa et al., 2009). Immunofluorescent analysis suggested that 
Hif1v nuclear translocation was increased in the DiD+ sub-population compared to 
DiD- cells. However, Hif1v is not the only transcription factor with the ability to bind 
to the CXCR4 promoter. The androgen regulated gene ERG has also been shown to act 
as an inducer of CXCR4 via the binding of ERG to specific ERG/Ets bindings sites in 
the CXCR4 promoter (Chinni et al., 2013). However, the gene expression level of ERG 
in the PC-3NW1 cell line was undetected, i.e. it had a Ct value of above 35, suggesting 
this affect would be minimal. It would be interesting to assess the epigenetic profile of 
the dormant cells as CXCR4 has been shown to be regulated by DNA methylation 
(Ramos et al., 2011). The authors used sodium bisulphite sequencing to determine the 
methylation status of CpG dinucleotides in the promoter region of the CXCR4 gene. By 
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using a combination of high and low CXCR4 expressing MDA cell lines (breast cancer 
cell lines), they found that low CXCR4 expression was linked to hypermethylation 
whereas high CXCR4 expression was linked to low methylation.  
 
Although CXCR4 may present a mechanism by which prostate cancer cells switch into 
dormancy, the final results chapter aimed to test whether high CXCR4 protein presence 
in primary prostate cancer samples was linked to metastasis. Work in our lab has shown 
that PC-3NW1 DiD+ cells formed more metastases in vivo compared to DiD- cells, 
identifying these cells in tissue microarrays may allow us to predict the presence of 
metastases. As the TNM stage was known, the amount of CXCR4 staining, after 
independent analysis by Dr. Colby Eaton and an independent and experienced 
pathologist (Professor Simon Cross), could be correlated to the disease status.  A further 
aim was to assess whether CXCR4 status correlated to other prognostic factors such as 
age and Gleason stage.  
 
7.1.4 Patient samples 
 
So far in the published literature, the value of CXCR4 as a prognostic indicator in 
prostate cancer has been conflicting and inconclusive. My work indicated that strong 
positive staining for CXCR4 was linked to a higher Gleason grade and Gleason score in 
patient samples. CXCR4 did not accurately correlate to tumour, lymph node, metastasis 
(TNM) status but was higher in patients with distant metastases than with lymph node 
metastasis. This data suggests that CXCR4 may contribute to the staging of patients 
with prostate cancer as more poorly differentiated cancers stained higher for CXCR4. 
CXCR4 could possibly be used in combination with other clinical parameters to decide 
if radical treatment is needed. 
 
As previously mentioned no follow-up clinical information was available to test 
whether patients with high CXCR4 staining but with low-grade tumours and no 
metastases at biopsy, progressed more frequently than patients in this group with low 
CXCR4. Similarly no survival data was available to test whether high CXCR4 was 
linked to poor survival. Interestingly of the studies discussed in Chapter 6 (Discussion 
6.4.1), that also measured the value of CXCR4 as a prognostic indicator, only Jung et al. 
(2011) stated a follow-up time (which was on average 36 months). These authors found 
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that CXCR4 was linked to the recurrence of tumours at the primary site and also to the 
development of distant metastases. It is hoped that the data provided in this thesis may 
be used to set up a clinical collaboration to test CXCR4 staining in a larger prostate 
cancer patient cohort with long-term clinical follow up. Such sample sets are currently 
not available but may be in the near future via UK collections (PROMPT).  CXCR4 has 
been associated with poor clinical outcome in triple-negative breast cancer as measured 
by reduced 5-year survival in patients with elevated CXCR4 staining (Yu et al., 2013). 
Building on this Yang et al. (2014) showed that silencing of CXCR4 in MDA-MB-231 
cells reversed EMT, increased apoptosis and reduced the incidence of lung metastases 
in xenograft models (Yang et al., 2014b). CXCR4 had also been indicated as a 
prognostic marker in ovarian cancer. A recent meta-analysis that compiled evidence 
from 7 published studies found that increased CXCR4 was associated with both poor 
overall survival and low progression free survival (Liu et al., 2014). These studies 
support further research into the investigation of CXCR4 as a prognostic indicator in 
prostate cancer on a larger scale to the experiments presented here. The experience in 
the Sheffield group suggest that there is also scope for developing better assays for 
CXCR4 (Eaton et al., 2010). 
 
7.2 Future work 
 
Although it was not possible to characterise the dormant sub-population in vivo i.e. DiD 
retaining cells in the bone marrow of mice after intracardiac injection due to insufficient 
cell numbers, it would be important to determine whether this sub-population represents 
the same dormant sub-population as that identified in vitro in my studies. The 
experiments in Chapter 5 need to be repeated with a much larger cohort of mice to 
increase the DiD+ cell yield for RNA extraction and so that the presence of proteins in 
sorted cells can be assessed in cytospun cells by immunofluorescence. Xenograft 
models in our group have been used to show that a small number of cells arrive in the 
bone marrow after injection (500-1,000 out of 1x105 cells injected) and that these cells 
can persist in a mitotically dormant state for up to 8 weeks. These studies also indicated 
that these cells are located close to osteoblast rich regions (Wang et al., 2014) and may 
therefore be held in a specific niche controlling dormancy. Future work should focus on 
defining this niche and the potential role it plays in tumour cell homing, attachment and 
dormancy. 
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Looking forward it would be important to extend the studies described in Chapter 4 to 
further define the role of the cell culture environment in maintaining dormancy. It is 
also important to determine the specific factors that trigger release of cells from 
dormancy. As mentioned this could involve knockdown studies to discover whether 
inhibition of CXCR4 prevented the dormant phenotype. As well as performing ELISAs 
to determine the components of the culture media in which dormant cells exist (as 
shown in Chapter 4, cells seeded at 1x105 cells per T25 flask and cultured for 21 days) 
compared to conditions where the dormant phenotype is not present or in which cells 
have been newly released from dormancy (Chapter 4, cells seeded at 5x103 cells per 
T25 flask and cultured for 21 days). Although it is generally suggested that 
CXCR4/CXCL12 signalling can regulate cell proliferation (Teicher and Fricker, 2010), 
Mochizuki et al., in their 2004 study found that although CXCL12 stimulated the 
migration of prostate cancer cells through a transwell chamber via the interaction with 
CXCR4, CXCL12 had no effect on the proliferation of cells as measured by MTT assay 
after incubation with increasing concentrations of the ligand.  
 
Although the experiments in Chapter 4 indicated that dormancy is not an intrinsic 
characteristic of a stem cell like sub-population, the acquisition of this state may still 
have a genetic basis. For example somatic cell fusion could underlie the dormant 
phenotype. Previous work has indicated that spontaneous fusion between prostate 
cancer cells leads to the development of a fused cell phenotype that has higher 
clongenic potential in anchorage independent conditions and an increased ability to 
form tumours in bone when injected into mouse xenograft models (Glen et al., 2011). It 
would therefore still be important to evaluate the dormant cell sub-population by 
karyotype analysis. In addition to this, with the availability of better technologies for 
large scale proteomic analysis, a more comprehensive evaluation of the dormant 
proteome would be valuable. The above approaches would refine understanding of 
tumour cell dormancy and potentially identify new markers for this phenotype.  The 
latter could reveal potential targets to dormancy, to either prevent its induction to allow 
therapy with traditional chemotherapeutics or prevent the release of dormancy and 
maintain low risk patient in a state of disease rest.  
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7.3 Conclusion 
 
This thesis has presented a novel hypothesis that suggests that within prostate cancer 
cell lines a phenotypically dormant sub-population is present which is defined by an 
increase in CXCR4. Further results suggest that dormancy is regulated by the 
environment and represents a unique sub-population that does not share the putative 
prostate CSC marker set. This work supports the further investigation of CXCR4 as a 
prognostic indicator in combination with existing clinical tests in prostate cancer 
patients.  
 
Further work is required to define the mechanisms that regulate cell entry and exit from 
the dormant phenotype, as well as the role of the bone niche in maintaining this state. It 
is hoped that a greater understanding of dormancy will aid the advancement of 
treatment for the prevention of overt, clinically relevant metastatic prostate cancer.  
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Appendix 1.1 
Gene Abbreviation 
aaaaaaaaaaaaaaaaaAb
breviation 
Gene Name 
ACPP 
 
Acid Phosphatase, Prostate 
 ACTA2 Actin, alpha 2 
ADAMTS1 
 
Metallopeptidase With Thrombospondin Type 1 Motif 
ADM2 Adrenomedullin 2 
AKT1 V-akt murine thymoma viral oncogene homolog 1 
ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 
ALPL Alkaline phosphatase 
ANGPT1 Angiopoietin 1 
ANXA2 Annexin A2 
AR Androgen receptor 
AXL AXL Receptor Tyrosine Kinase 
BGLAP Bone Gamma-Carboxyglutamate (Gla) Protein 
BMI1 B lymphoma Mo-MLV insertion region 1 homolog1 
BMP2 Bone Morphogenetic Protein 2 
BMP6 Bone Morphogenetic Protein 6 
BMP7 Bone Morphogenetic Protein 7 
CD24 Cluster of differentiation 24 
CD34 Cluster of differentiation 34 
CD38 Cluster of differentiation 38 
CD44 Cluster of differentiation 44 
CDH1 E-cadherin 
CDH2 N-Cadherin 
CDH7 Cadherin 7, Type 2 
CLDN4 Claudin 4 
COL1A1 Collagen, type I, alpha 1 
COX2-Mm Murine specific Mitochondrially Encoded Cytochrome C Oxidase II 
CXCL1 Chemokine (C-X-C Motif) Ligand 1 
CXCL12 Chemokine (C-X-C Motif) Ligand 12 
CXCL16 Chemokine (C-X-C Motif) Ligand 16 
CXCR4 Chemokine (C-X-C Motif) Receptor 4 
CXCR6 Chemokine (C-X-C Motif) Receptor 6 
CXCR7 Chemokine (C-X-C Motif) Receptor 7 
DKK1 Dickkopf WNT Signaling Pathway Inhibitor 1 
DSP Desmoplakin 
ERG 
 
V-Ets Avian Erythroblastosis Virus E26 Oncogene Homolog 
ESR1 Estrogen Receptor 1 
ESR2 Estrogen Receptor 2 
FGF2 Fibroblast growth factor 2 
FGF8 Fibroblast growth factor 8 
FN1 Fibronectin 
FST Follistatin 
 
 
 
GAPDH-Mm Murine specific Glyceraldehyde-3-Phosphate Dehydrogenase 
GAS6 Growth arrest-specific 6 
ITGA2 Integrin, Alpha 2 
ITGA4 Integrin, Alpha 4 
ITGB1 Integrin, Beta 1 
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JAG1 Jagged 1 
KIT 
 
V-Kit Hardy-Zuckerman 4 Feline Sarcoma Viral Oncogene 
Homolog  KLK3 Kallikrein-Related Peptidase 3 
KRT18 Keratin 18 
KRT5 Keratin 5 
KRT8 Keratin 8 
LDHA Lactate dehydrogenase A 
LDHB Lactate dehydrogenase B 
MATN2 Matrilin 2 
MCAM Melanoma cell adhesion molecule (CD146) 
MMP2 Matrix metalloproteinase-2 
MMP3 Matrix metalloproteinase-3 
MUC1 Mucin 1 
NANOG Nanog Homeobox 
NES Nestin 
NOG Noggin 
NOTCH1 NOTCH1 
NR3C1 
 
Nuclear Receptor Subfamily 3, Group C, Member 1 (NR3C1) 
OCLN Occludin 
PGR Progesterone recepto 
POU5F1 POU Class 5 Homeobox 1(OCT4) 
PROM1 Prominin 1(CD133) 
PSCA Prostate stem cell antigen 
PTEN Phosphatase and tensin homolog 
RHOB Ras Homolog Family Member B 
RUNX2 Runt-Related Transcription Factor 2 
S100A4 Fibroblast-Specific Protein-1 
SDC1 Syndecan 1 
SHH Sonic hedgehog 
SOX2 SRY (Sex Determining Region Y)-Box 2 
SPARC Osteonectin 
SPP1 Osteopontin 
TEK Tyrosine Kinase, Endothelial 
TERT Telomerase reverse transcriptase 
TGFB1 Transforming Growth Factor, Beta 1 
TGFBR1 
 
Transforming Growth Factor, Beta Receptor 1 
TJP1 Tight Junction Protein 1 
TMPRSS2-ERG Transmembrane Protease, Serine 2 fusion gene with ERG 
TMPRSS2-ERGfusion TMPRSS2 Transmembrane Protease, Serine 2 
TNC Tenascin C 
TNFRSF11A 
 
Tumor Necrosis Factor Receptor Superfamily, Member 11a, NFKB 
Activator(RANK) TNFRSF11B Osteoprotegerin 
TNFSF11 Tumor Necrosis Factor (Ligand) Superfamily, Member 11(RANKL) 
TP63 Tumour Protein P63 
VIM Vimentin 
VTN Vitronectin 
 
 246 
 
Appendix 1.2 
Gene 
Abbreviation  
ΔCT  DiD- ΔCT  DiD+ P value 
ACPP 
 
9.94 ± 0.16 9.90 ± 0.41 0.875 
ACTA2 15.85 ± 0.47 15.40 ± 0.22 0.209 
ADAMTS1 
 
10.50 ± 0.43 9.61 ± 0.44 0.068 
ADM2 12.64 ± 0.24 12.27 ± 0.20 0.112 
AKT1 6.02 ± 0.10 5.85 ± 0.07 0.091 
ALDH7A1 8.17 ± 0.25 8.69 ± 0.50 0.186 
ALPL 17.70 ± 0.53 19.76 ± 0.53 0.626 
ANGPT1 15.21733 ± 0.29 15.36 ± 0.22 0.528 
ANXA2 3.87 ± 0.19 3.27 ± 0.11 0.010 
AR 17.00 ± 0.64 16.59 ± 0.42 0.403 
AXL 10.87 ± 0.40 10.15 ± 0.65 0.176 
BGLAP 17.08 ± 0.45 17.37 ± 0.69 0.652 
BMI1 5.06 ± 0.39 4.66 ± 0.27 0.223 
BMP2 8.33 ± 0.53 7.53 ± 0.77 0.215 
BMP6 7.62 ± 0.47 7.96 ± 0.44 0.421 
BMP7 15.13 ± 0.27 14.00 ± 0.53 0.030 
CD24 4.04 ± 0.15 3.13 ± 0.26 0.007 
CD34 UD UD UD 
CD38 13.79 ± 0.38 13.88 ± 0.45 0.810 
CD44 5.12 ± 0.29 4.66 ± 0.30 0.125 
CDH1 6.29 ± 0.28 5.95 ± 0.50 0.359 
CDH2 6.53 ± 0.19 6.33 ± 0.12 0.213 
CDH7 11.48 ± 0.38 11.34 ± 0.10 0.560 
CLDN4 6.99 ± 0.11 6.77 ± 0.49 0.480 
COL1A1 16.51 ± 0.96 14.15 ± 0.61 0.023 
COX2-Mm UD UD UD 
CXCL1 14.25 ± 0.29 11.00 ± 0.34 0.0002 
CXCL12 17.99 ± 0.65 21.53 ± 0.45 0.865 
CXCL16 8.80 ± 0.47 8.94 ± 0.46 0.742 
CXCR4 9.35 ± 0.72 7.58 ± 0.71 0.038 
CXCR6 UD UD UD 
CXCR7 12.27 ± 0.27 11.60 ± 0.56 0.138 
DKK1 3.93 ± 0.46 2.97 ± 0.41 0.055 
DSP 10.47 ± 0.27 9.95 ± 0.58 0.231 
ERG 
 
UD UD UD 
ESR1 18.14 
 
17.23 ± 0.19 0.020 
ESR2 14.56 ± 0.46 14.71 ± 0.43 0.726 
FGF2 10.79 ± 0.12 9.96 ± 0.45 0.037 
FGF8 16.00 ± 1.19 16.03 ± 0.93 0.983 
FN1 9.98 ± 0.19 7.01 ± 0.44 0.0004 
FST 9.39 ± 0.47 7.21 ± 0.19 0.0017 
Gapdh-Mm UD UD UD 
GAS6 UD UD UD 
ITGA2 6.91 ± 0.25 5.99 ± 0.45 0.048 
ITGA4 UD UD UD 
ITGB1 4.46 ± 0.65 3.83 ± 0.44 0.233 
JAG1 7.83 ± 0.05 7.26 ± 0.10 0.0010 
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KIT 
 
UD UD UD 
 
 
   KLK3 UD UD UD 
KRT18 11.06 ± 0.23 11.11 ± 0.22 0.819 
KRT5 UD UD UD 
KRT8 16.91 ± 0.57 16.44 ± 0.59 0.368 
LDHA 3.22 ± 0.30 2.88 ± 0.38 0.288 
LDHB 4.04 ± 0.09 5.01 ± 0.39 0.014 
MATN2 10.81 ± 0.18 9.09 ± 0.14 0.0001 
MCAM 10.76 ± 0.14 12.21 ± 0.004 0.00007 
MMP2 17.63 ± 0.19 16.29 ± 0.35 0.0044 
MMP3 17.91 ± 0.10 13.39 ± 0.48 0.00009 
MUC1 12.47 ± 0.24 11.93 ± 0.49 0.160 
NANOG 12.02 ± 1.42 11.93 ± 0.41 0.914 
NES 8.31 ± 0.25 9.47 ± 0.41 0.013 
NOG 11.04 ± 0.30 11.09 ± 0.87 0.936 
NOTCH1 8.57 ± 0.35 8.99 ± 0.50 0.310 
NR3C1 
 
13.15 ± 0.33 12.50 ± 0.40 0.093 
OCLN 8.05 ± 0.05 8.15 ± 0.14 0.333 
PGR 17.89 ± 0.74 18.60 ± 0.51 0.802 
POU5F1 11.59 ± 1.17 11.94 ± 0.49 0.650 
PROM1 UD UD UD 
PSCA 18.17 ± 0.19 15.58 ± 0.37 0.0004 
PTEN UD UD UD 
RHOB 8.61 ± 0.20 8.93 ± 0.50 0.375 
RUNX2 11.12 ± 0.65 11.29 ± 0.21 0.703 
S100A4 7.46 ± 0.11 7.51 ± 0.62 0.899 
SDC1 7.42 ± 0.39 7.24 ± 0.32 0.560 
SHH 18.07 ± 0.50 17.93 ± 0.29 0.142 
SOX2 12.47 ± 0.48 12.57 ± 0.38 0.801 
SPARC 5.80 ± 0.37 5.68 ± 0.47 0.750 
SPP1 UD UD UD 
TEK 17.12 ± 0.39 16.19 ± 0.63 0.096 
TERT 12.36 ± 0.50 13.07 ± 0.19 0.083 
TGFB1 5.51 ± 0.80 5.69 ± 0.09 0.770 
TGFBR1 
 
8.00 ± 0.02 8.15 ± 0.55 0.052 
TJP1 8.09 ± 0.27 8.01 ± 0.09 0.773 
TMPRSS2-ERG UD UD UD 
TMPRSS2 15.59 ± 0.64 13.74 ± 0.30 0.010 
TNC 9.05 ± 0.26 7.76 ± 0.37 0.007 
TNFRSF11A 
 
12.62 ± 0.39 13.54± 0.67 0.111 
TNFRSF11B 13.98 ± 0.27 14.00 ± 0.56 0.963 
TNFSF11 UD UD UD 
TP63 9.49 ± 4.39 12.37 ± 0.12 0.321 
VIM 1.73 ± 0.71 1.70 ± 0.54 0.937 
VTN 18.23 ± 0.30 16.58 ± 0.94 0.043 
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Appendix 1.3 
Gene Abbreviation 
aaaaaaaaaaaaaaaaaAbbr
eviation 
Gene Name 
CD34 Cluster of differentiation 34 
COL1A1 Collagen, type I, alpha 1 
CXCL1 Chemokine (C-X-C Motif) Ligand 1 
 CXCL12 Chemokine (C-X-C Motif) Ligand 12 
 CXCR4 Chemokine (C-X-C Motif) Receptor 4 
DKK1 Dickkopf WNT Signaling Pathway Inhibitor 1 
FN1 Fibronectin 
FST Follistatin 
 
 
 
HIF1A Hypoxia-inducible factor 1 alpha 
MATN2 
 
Matrilin 2 
MCAM Melanoma cell adhesion molecule (CD146) 
MMP2 Matrix metalloproteinase-2 
MMP3 Matrix metalloproteinase-3 
NES Nestin 
Prostate stem cell antigen 
 
POSTN erios in 
PSCA Prostate stem cell antigen 
 
 
 
 
SHH Sonic Hedgehog 
SOSTDC1 Sclerostin Domain Containing 1 
TEK Tyrosine Kinase, Endothelial 
Tenascin C 
 
TNC 
 
Tenascin C 
 
TP63 Tumor Protein P63 
VTN Vitronectin
 
 
